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ABSTRACT 
 
X-CHROMOSOME INACTIVATION IN FEMALE PREDISPOSITION TO 
AUTOIMMUNITY 
 
Elif UZ 
PhD in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Tayfun Özçelik 
May 2008, 135 Pages 
 
The high female preponderance is thought to be important in identifying the 
etiological factors. Sex hormones, pregnancy related microchimerism, and 
environmental factors are investigated as likely candidates. Disturbed X-
chromosome inactivation (XCI) is another candidate, which may contribute to the 
break-down of self-tolerance. In this study, we tested the hypothesis that “loss of 
mosaicism” for X-linked gene expression may contribute to autoimmune disease 
etiology. Therefore, XCI status of healthy individuals and patients diagnosed with 
scleroderma (SSc), autoimmune thyroiditis (AITDs), Sjogren’s syndrome 
(SICCA), and juvenile idiopathic arthritis (JIA) in the Turkish population were 
analyzed by genotyping the methylation status of a CAG polymorphism in the 
androgen receptor (AR) gene. Extremely skewed XCI was observed in a significant 
proportion of SSc (OR: 38.9; P<0.0001), AITDs (OR: 9.6; P<0.0001), and JIA 
(OR: 4.4; P=0.0022). Further genotyping of AITDs in Tunisian and SSc in the US 
population supported the initial observations (OR: 3.8; P=0.0046; OR: 3.8; 
P<0.0001) respectively. Analysis of rheumatoid arthritis (RA) in the Tunisian 
population suggests that extremely skewed XCI (OR: 6.7; P<0.0001) could be 
involved in disease pathogenesis. Moreover, pre-eclampsia, a disease in which 
autoimmunity may be important, skewed XCI was observed (OR; 11.7; P=0.0005). 
However, in SICCA random patterns of XCI was observed suggesting that extreme 
skewing is not a common feature of all female prevalent autoimmune disorders. In 
conclusion, our results suggest that extremely skewed XCI may be important 
factor in autoimmune disease pathogenesis.  
 
Keywords: autoimmune diseases, X-chromosome inactivation, female 
predisposition, HUMARA assay. 
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ÖZET 
 
X-KROMOZOMU İNAKTİVASYONU VE OTOİMMÜN HASTALIK 
İLİŞKİSİ 
 
Elif UZ 
Doktora Tezi, Moleküler Biyoloji ve Genetik  
Tez Danışmanı: Prof. Dr. Tayfun Özçelik 
Mayıs 2008, 135 Sayfa 
 
Otoimmün hastalıklar dünya çapında en sık rastlanan hastalık gruplarından biridir. 
Hastalıklara göre değişmekle birlikte kadınlarda daha sık rastlanmaktadır. Nedeni 
tam olarak bilinmemekle birlikte cinsiyet hormonları, hamileliğe bağlı olarak 
gelişen mikrokimerizm ve çevresel faktörler kadınlarda sık görülme ile ilişkili 
olabilir. X-kromozomu inaktivasyonu (XCI) sapması önemli bir etyolojik faktör 
olabilir. Bu çalışmada XCI’na bağlı mozaik yapının bozulmasının otoimmün 
hastalık etiolojisinde rol alabileceği hipotezi test edilmiştir. Bu nedenle Türk 
populasyonunda skleroderma (SSc), otoimmün tiroiditis (AITDs), Sjogren 
sendromu (SICCA) ve juvenil idiopatik artrit (JIA) hastaları ve sağlıklı bireyler 
genotiplenmiştir. Androjen reseptör (AR) genindeki CAG polimorfizminin 
metillenme durumu incelenerek XCI statüsü belirlenmiştir. XCI’da aşırı sapma 
SSc (OR: 38.9; P<0.0001), AITDs (OR: 9.6; P<0.0001), ve JIA (OR: 4.4; 
P=0.0022) hastalarında görülmüştür. Buna ek olarak Tunus populasyonunda 
AITDs (OR: 3.8; P=0.0046)  ve Amerikan populasyonunda SSc (OR: 3.8; 
P<0.0001) hastalarının genotiplenmesi ile bulgularımız desteklemiştir. Tunus 
populasyonunda romatoid artrit (RA) hastaları üzerinde yapılan inceleme 
sonucunda XCI’nun bu hastalıkta da aşırı saptığını göstermiştir (OR: 6.7; 
P<0.0001). Otoimmünitenin, hastalık etyolojisinde etkin olduğu düşünülen pre-
eklampsi hastalarında da XCI sapması gözlenmiştir (OR: 11.7; P=0.0005). SICCA 
grubunda yürütülen incelemelerde ise XCI oranlarının kontrol grubu ile benzer 
olduğu saptanmıştır. Bu gözlem XCI oranlarının sapmasının tüm otoimmün 
hastalıklarda görülmediğini ortaya koymuştur. Sonuçlarımız XCI ile otoimmün 
hastalık gelişimi arasında bir ilişki olabileceği görüşünü desteklemektedir. 
 
Anahtar kelimeler: otoimmün hastalıklar, X-inaktivasyonu, kadınlarda sık 
görülme, HUMARA 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Immune system 
 
The human body faces millions of pathogens and foreign invaders every day. Our 
immune system detects and eliminates antigens and pathogens by differentiating self 
antigens from foreigns. Immune system recognizes these foreigners by two 
mechanisms: Innate immune system and adaptive immune system. The former 
defends the host organism from infection by other organism in a non-specific 
manner. Innate immune system specifically recognizes antigenic structures of 
microbes via pattern recognition receptors. It is known that innate immune system is 
present both in animals and plants (Litman et al. 2005). In addition, the recognition 
is highly conserved during evolution among invertebrates and vertebrates (Klein 
1999; Medzhitov&Janeway 2000). However, the specialized cells of adaptive 
immune system eliminate pathogen in a specific manner. Those cells (termed as T- 
and B cells) are equipped with receptors that provide the immune system with the 
ability to recognize and remember specific pathogens. This system is called as 
“adaptive”, because a small number of products of genes are capable to recognize, 
eliminate and remember a vast number of different antigen receptors. The cells of 
this system achieve this process via somatic hypermutation and V(D)J 
recombination.  
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1.2 Self tolerance and autoimmunity 
 
Immune system is body’s defense system against “foreign” invaders. This system is 
programmed so that it can recognize and attack to the bacteria, viruses, antigens and 
proteins. Interestingly, immune system does its function with the ability of 
discriminating between self-and nonself antigens. Normal individuals are tolerant of 
their own antigens and this phenomenon is called self tolerance. It is the 
fundamental property of the immune system. Immunologic tolerance was 
recognized in the 1950s through a set of experiments performed by Peter Medawar 
and colleagues. In these studies, they observed that adult mouse of one type of 
strains rejected a skin graft from an allogeneic mouse of different strain. These two 
mice differ from each other at the major histocompatibility complex (MHC). They 
further continued the experiments by injecting the lymphocytes of mice of different 
strain, but this time during neonatal life. Interestingly, the injected cells were not 
rejected this time because the neonate became immunotolerant. After the neonate 
became an immunocompetent adult, skin grafts from all mouse strains whose MHC 
was different than of the strain whose lymphocytes were injected at neonatal stage 
were rejected (Medavar 1957). These experiments lead us to accept the concept that 
early exposure of developing lymphocytes to foreign antigens induces tolerance. A 
great effort has been dedicated to explain the mechanisms and to find a therapeutic 
improvements for inducing tolerance to prevent the rejection of organ allografts and 
xenografts. Moreover, understanding the basis of tolerance induction is important in 
treatment of autoimmune and allergic diseases. In mature lymphocytes, the 
mechanism of tolerance to foreign antigens is similar in many ways to those of self-
tolerance. Differentiation between self-nonself proteins is called as “self tolerance”. 
Self tolerance is divided into two classes: (1) central tolerance, in which immature 
lymphocytes recognize self antigens in generative lymphoid organs (bone marrow 
and thymus), and (2) peripheral tolerance in which mature lymphocytes were 
encountered to self antigens in peripheral lymphoid organs (spleen, lymph nodes). 
Central tolerance occurs in the generative lymphoid organs because the only 
antigens present in these organs at high titer are the self antigens. Normally foreign 
antigens that enter into the body should be already attacked by the peripheral 
lymphoid organs, therefore during generation of lymphocytes in the thymus or bone 
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marrow they normally encounter only self antigens. In this process, which is called 
as “negative selection”, lymphocyte clones that recognize self antigens with high 
affinity are eliminated. Peripheral tolerance is observed in peripheral tissues after 
the mature lymphoids leave the generative organs. When lymphocytes recognize 
antigens with a low level of costimulators in peripheral tissues, peripheral tolerance 
is induced. This type of unresponsiveness is necessary against self antigens that are 
expressed in peripheral tissues but not in generative lymphoid organs.  
 
Tolerance against self antigens is provided by means of three types of mechanisms: 
(1) apoptotic cell death, also called as only “deletion”. This process is used mainly 
in central tolerance, (2) anergy; functional inactivation of lymphocytes without cell 
death, and (3) suppression of lymphocyte activation and effector function of 
lymphocytes. In peripheral tolerance, all of the three types of mechanisms are used. 
If those self-reactive lymphocytes that escape from tolerance cannot be eliminated, 
autoimmune disorders may develop (Goodnow et al.2005).  
 
 
1.3 Autoimmune diseases 
 
Autoimmune diseases are known to affect approximately 5 percent of the population 
in US and Europe (Sinha et al. 1990; Jacobson et al. 1997; Eaton et al. 2007). 
Clinicians classify autoimmune disorders as systemic and organ specific. In organ 
specific autoimmune diseases one organ is affected, whereas in systemic 
autoimmune disorders multiple organs or systems may be affected. Some of the 
examples of these two types of autoimmune diseases are indicated in Table 1.1 
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Table 1.1 Examples of systemic and organ specific autoimmune diseases. 
 
Type Name of Disorder Affected Organ(s) 
Systemic Rheumatoid arthritis Joints, skin, less commonly lung 
SLE Skin, joints, kidneys, heart, brain, 
red blood cells 
Scleroderma Skin, intestine, lung 
Sjogren’s syndrome Salivary glands, tear glands, joints 
Organ 
specific 
Type I diabetes mellitus Pancreas islets 
Hashimoto’s thyroiditis, Grave’s 
disease 
Thyroid 
Celiac disease, Crohn’s disease GI tract 
Primary biliary cirrhosis Liver 
 
 
 
Genetic susceptibilities, environmental factors, and infectious agents may trigger 
autoimmune reactions. Epidemiological studies show that genetic susceptibility 
have a role in the formation of autoimmune disorders.   
In simple diseases, the causative gene determines the disease state. However, like in 
autoimmune disorders, more than one gene may have role in the formation of 
complex diseases. There are only a few of the genetic traits that are associated with 
autoimmune disorders. AIRE, CTLA4, FOXP3, and PTPN22 are the genes that are 
known to be involved in the formation of autoimmunity in Homo sapiens 
(Rioux&Abbas 2005). 
 
AIRE (autoimmune regulator) gene encodes a 545-amino acid protein, responsible 
for the thymic expression of some antigens. Those antigens have high expression 
level in different peripheral tissues. Mutation in AIRE results in autoimmune 
polyendocrine syndrome (APS-1) (OMIM #240300) (Nagamine et al 1997; Björses 
et al. 2000). The autoimmune attacks are observed against multiple organs.  
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FOXP3 (forkhead box P3) gene encodes a transcription factor that belongs to the 
forkhead/winged-helix family. It was shown by Brunkow et al. that a frameshift 
mutation in Foxp3 gene results in a protein lacking the forkhead domain in mice 
(scurfy mice). These mice are characterized by overproliferation of CD4+CD8- cells, 
increased level of cytokines and multiorgan infiltration. In addition to the mouse 
model, a human disease known as IPEX (Immunodysregulation, 
Polyendocrinopathy, and Enteropathy, X-Linked Syndrome; OMIM #304790) has 
been shown to be caused by mutation in FOXP3 gene (Benett et al. 2001; Wildin et 
al. 2001) 
 
CTLA 4 (cytotoxic T lymphocyte antigen 4) protein, also known as CD152 is a 
member of immunoglobulin superfamily and expressed in activated T cells. CTLA 4 
protein is an inhibitory receptor and binds to B7-1 and B7-2 on antigen presenting 
cells. It was reported by Ueda et al in 2003, that CTLA-4 gene is associated with 
autoimmune diseases including Grave’s disease, autoimmune hypothyroidism, and 
type 1 diabetes mellitus. 
 
PTPN22 (protein tyrosine phosphtatase, non-receptor type 22) is also known as Lyp. 
The gene that codes for PTPN22 is located on chromosome 1 (1p13.3-p13.1). 
PTPN22 protein is involved in T-cell activation (Cohen et al. 1999). It is reported 
that R620W polymorphism on PTPN22 increases the susceptibility in various 
autoimmune disorders including type I diabetes (Bottini et al. 2004), rheumatoid 
arthritis (Begovich et al. 2004), SLE (Kyogoku et al. 2004), and Grave’s disease 
(Velaga et al. 2004). 
 
In simple diseases, the causative gene is deterministic in disease state. 
Consequently, genome wide linkage studies demonstrate sharing of alleles between 
affected members of families, and are used to identify the causal genetic variant. 
However, the case in complex diseases is more complicated. Disease state is 
determined via interactions of multiple genotypes together with the environmental 
factors. Autoimmune disorders are a group of complex diseases. Even though a 
number of causative alleles are associated with certain autoimmune disorders, 
environmental factors are thought to have impact on disease susceptibility. 
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Molecular mimicry is one of the environmental factors. It is mainly based on the 
similarities between foreign and self antigens that are sufficient to produce an 
immune response. The mechanism remains puzzling. Bacteria, viruses, xenobiotics 
and chemicals are candidates for the initiation of autoimmune disorders by 
molecular mimicry. One example is in primary biliary cirrhosis (PBC). E2 
component of human pyruvate dehydrogenase complex (PDC-E2) is the major 
autoantigen in PBC. It was proposed that exposure to a microorganism that express 
PDC similar to human PDC-E2 could act as a trigger of autoimmune reaction in 
PBC. Novosphingobium aromaticivorans was reported to posses a PDC-E2 like 
protein with high degree of homology to human PDC-E2. Exposure to this organism 
has been reported to a predisposing factor in PBC (Kaplan 2004).  
 
Viral and bacterial infections are the other type of environmental factors. Local 
immune responses that recruit leukocytes into the tissues may be induced by 
infections of particular tissues by viruses or bacteria. This recruitment may result in 
the expression of costimulators on tissue APCs and finally in breakdown of self 
tolerance (Abbas&Lichtmann 2003).  
 
 
 
1.4 Sex differences in autoimmune disorders 
 
The high female:male prevalence is known to be associated in most autoimmune 
disorders. This ratio ranges from 2:1 in multiple sclerosis to 10:1 in autoimmune 
thyroid diseases (AITDs) (Chitnis 2000, Hernandez-Molina 2007). Some of the sex 
ratio according to the disease types is displayed on Table.1.2 
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Table 1.2 Gender prevalence ratios for selected autoimmune disorders (Whitacre 
2001, Gleicher&Barad 2007, Hernandez-Molina et al. 2007). 
 
Disease Female:Male ratio 
Autoimmune thyroid diseases   10:1-50:1 
Primary biliary cirrhosis   9:1 
Sjogren’s syndrome   9:1 
Systemic lupus erythamosus   8:1-9:1 
Scleroderma   3:1-4:1 
Rheumatoid arthritis   3:1 
Multiple sclerosis   2:1 
Myasthenia gravis   2:1 
Type I Diabetes mellitus   1:1-2:1 
 
 
Females produce higher immunoglobulin levels than age-matched males in response 
to infection or immunization. Moreover, it was noted that women have higher 
absolute number of CD+4 lymphocytes compared to men. The tendency towards 
autoimmunity in females can be ascribed at first glance to hormonal differences. 
Hormones are distinctive chemicals between two sexes. It was shown that the 
acquired immune system of females differs from that of males. Estrogen stimulates 
immunologic reactions driven by CD4+ TH2 cells and B cells. However androgens 
perform this reaction through enhancement of CD4+ TH1 and CD8+ cells (Whitacre 
et al. 1999, Beagley & Gockel 2003). In multiple sclerosis and rheumatoid arthritis, 
where female predominance has been observed, disease activity decreases during 
pregnancy, especially in the third trimester, where estrogen and progesterone levels 
are the highest (Nelson&Ostensen 1997, Confavreux et al 1998). In contrast, disease 
activity worsens or remains unchanged in SLE during pregnancy. Another important 
difference between two sexes is the pregnancy. Maternal cells remained in the blood 
of fetus or vice versa are called microchimerism. Presence of fetal cells is detected 
in the blood of a mother years after delivery (Bianchi et al. 1996). This may be 
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evidence that fetal cells are not effectively eliminated from maternal blood. But even 
microchimerism alone cannot explain the female preponderance in autoimmune 
diseases because there are many patients that give no birth. Moreover, the pediatric 
forms of certain autoimmune disorders cannot explain the female predominance due 
to hormones or microchimerism. X-chromosome inactivation is a biological 
regulation, which is observed only in females, and this may explain the female 
preponderance of autoimmune diseases. 
 
 
1.5 Kast and Stewart Hypothesis 
 
In 1977, Richard Kast offered an explanation for the high female/male ratio in many 
autoimmune diseases for the first time. In his publication, Kast listed autoimmune 
diseases with high female preponderance. He noticed that besides the 
environmental, hormonal and microchimerism effects, a novel mechanism other 
than classical patterns of inheritance may have a role in female predisposition to 
certain autoimmune diseases. One such mechanism is the disturbance in X-
chromosome inactivation process. He hypothesized that any disturbance in female 
X-heterochromatinisation might have the potential to influence of the occurrence of 
autoimmune disorders with high incidence in women. Later in 1998, Jeffrey Stewart 
developed this hypothesis. In his publication, where he sets the similar hypothesis in 
systemic lupus erythematosus (SLE), Stewart argued that differences in the self-
antigen presentation profiles to the immune system due to XCI mosaicism may be 
one of the factors that lie behind the female preponderance of the disease. Two 
different cell classes, differing in a subset of transcribed genes are present in females 
due to the XCI process. One cell population presents X-encoded genes inherited 
from the father, whereas the other half of the cell population transcribes those X-
encoded genes inherited from mother. This hypothesis is the art of this study. Even 
though there are exceptions to this rule (escape from XCI), the self antigen proteins 
expressed from X-chromosome differ. Negative selection occurs in the thymus and 
mediated by antigen presenting cells (APCs), particularly the dendritic cells. If a T 
cell is autoreactive to an X-encoded antigen, and is tolarized only by one type of 
dendritic cell due to extremely skewed X chromosome inactivation pattern, that 
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autorective cell escape from negative selection and enter the circulation. In this case 
T cells may maturate and enter periphery without having been negatively selected to 
antigens that are encoded from predominantly inactive X chromosome. This 
situation is illustrated in Figure 1.1. 
 
 
 
 
 
 
Figure 1.1 Skewed XCI and its consequences on tolerance induction in the thymus (Chitnis et al. 
2000). 
 
 
 
XCI patterns were examined in the blood cells of female patients with systemic 
lupus erythematosus, juvenile diabetes, multiple sclerosis, and juvenile rheumatoid 
arthritis. However no significant difference in XCI patterns between subjects and 
controls was observed (Chitnis et al. 2000). There may be two possible explanation: 
first the number of subjects and controls are relatively small, and second, there was 
only one control group for comparing XCI results of both adult and juvenile onset of 
autoimmune diseases. Subsequently, a case-control study on female twins 
10 
 
discordant for AITDs and healthy female twins was conducted in Danish population. 
The frequency of skewed XCI in AITDs twins was found to be higher than in the 
control group (Brix et al. 2005). In 2007, Miozzo et al. performed a similar study in 
primary biliary cirrhosis patients and difference in XCI patterns in mononuclear 
cells of patients and controls was not statistically significant (Miozzo et al. 2007). 
Moreover, X-chromosome monosomy has been manifested a common mechanism 
for autoimmune diseases (Invernizzi et al. 2005)  
 
Previous studies with AR assay have reported that skewed XCI ratio increase with 
the age (Busque et al.1996, Sharp et al. 2000). These observations suggest that 
skewed XCI can be acquired with age. The extremely skewed XCI incidence was 
1.9% in neonates, 4.5% in young women (28-32 years old), and 22.7% in old 
women (>60 years old) (Busque et al. 1996). Similar increase in the incidence of 
skewed XCI was observed with age. In 2000, Sharp et al. performed a similar study 
and observed an increase in the incidence of both skewed and extremely skewed 
XCI in women more than 60 years old. 
 
 
 
 
1.6 X- Chromosome inactivation 
 
 
1.6.1. Dosage compensation 
 
Sex determination is evolved in different ways among species. Sex was determined 
in response to environmental stimuli in reptiles (Western&Sinclair 1999). However 
in majority of species sex determination is based on chromosome-based pathways. 
Chromosome-based pathways differ between species. Presence of a Y chromosome 
is sufficient in mammals do develop a male organism. However, in flies and worms, 
the ratio of the number of X chromosome per haploid autosome set is necessary for 
determining sex. Therefore, XX becomes female, and XY or XO becomes male in 
flies and worms respectively (Bridges 1921, Madl&Herman 1979). In mammals, 
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presence of Y chromosome leads to the formation of male organism due to the 
presence of sex determining region Y (SRY). In addition to SRY, Y chromosome 
harbours not more than 50 genes, whereas X chromosome encodes for 
approximately 1500 genes (Lahn et al. 2001, Ross et al. 2005). Due to the gene 
content differences between the two chromosomes and sex determination pathway, 
dose difference of X chromosome gene product levels arise between the two sexes. 
Dosage compensation mechanisms based on chromosome-wide regulation. They 
were developed to compensate for the dose differences. Strategies of dosage 
compensation evolved in several different ways (Figure 1.2). Flies increase the 
expression level of X chromosome twofold (Park&Kuroda 2001), while worms 
halved the transcription levels of each of X chromosomes (Meyer&Casson 1986, 
Blackwell&Walker 2002). Transcriptional silencing of one of the two X 
chromosome occurs in female cells of mammals (Lyon 1961).  
 
 
 
 
Figure 1.2 Strategies of dosage compensation. In Drosophila melanogaster, male (XY) X-linked 
expression increases twofold. In Caenorhabditis elegans, hermaphrodite (XX) transcription from 
each of the two X chromosomes decreases twofold. In mammals, one of the two X chromosomes in 
females is inactivated (Huynh&Lee 2005). 
 
 
 
1.6.2. Mechanism of X-Chromosome inactivation  
 
In mammals, dosage compensation for X-encoded gene products between females 
and males is achieved by silencing of the two X-chromosomes in female cells and 
first hypothesized by Lyon in 1961. The inactivation takes place during early 
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development. In female eutherians, paternal and maternal X chromosomes were 
randomly affected from X-Chromosome inactivation (XCI) process. This inactive 
state gives rise to female adults that are mosaic for two cell types expressing one of 
the X chromosomes and stably inherited. Inactive X chromosome is observed as 
‘Barr body’ during interphase under microscope (Barr 1949). 
 
Recent experiments show that XCI occurs as early as the four cell stage of the 
embryo but is variable and leaky and does not become fixed until after implantation 
but before differentiation of ES cells (Huynh&Lee 2003, Okamoto et al 2004). 
There are two consequences of X dosage compensation in humans: (1) only one X 
chromosome functions in all cells of both sexes, irrespective of the number of X 
chromosomes; and (2) females are cellular mosaics. Those mechanisms are observed 
in eutherians. The mosaic pattern is not observed in marsupials. They inactivate only 
paternal X (VandeBerg et al. 1987). One of the interesting finding is the pattern 
observed in mice. Even though the XCI pattern is random in fetus, only paternal X 
is inactivated in extra embryonic tissues (Takagi&Sasaki 1975, Cooper 1971).  
 
How does XCI work? Scientists have dealed with this question for decades. Even 
though the detailed mechanisms for all steps are not known entirely, it is well 
established that four steps are crucial: counting, selection, silencing and 
maintenance. For X inactivation to occur cells must posses at least two XCI center 
(XIC). This locus is located in Xq13 in humans and has syntheny with murine and 
mouse. Studies on mouse models reported that Xic regulates counting, selection and 
silencing. The first step begins with the determination of the number of X 
chromosomes per cell (counting). Only a single X chromosome per diploid 
autosome set will remain active and the remaining extra copies being inactivated. 
Xic is involved in selection process. The choice of either paternal or maternal X 
chromosome for subsequent inactivation is random. Recent studies in mice showed 
that three non-coding loci are necessary for the XCI process. These are Xist, Tsix, 
and Xite. They are located within Xic (Brown et al. 1992). These three elements act 
in cis during inactivation. From these elements, Xist is necessary for cis inactivation 
of X chromosome (Clemson et al. 1996). Experiments showed us that if Xist is 
deleted, X chromosome cannot be inactivated in mice. Those data show us that Xist 
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is primarily necessary for inactivation. Even though the exact mechanism is not 
known entirely, a non-coding RNA transcribed from Xist coats the future inactive X 
chromosome. In order to test the crucial role of Xist in inactivation, Lee and 
colleagues (Lee et al. 1996) transfected it onto an autosomal chromosome in mouse 
embryonic stem cells at a critical time and observed that it inactivated the autosome. 
How does Xist alone determine inactivation of a chromosome? Recent studies show 
that Xist alone is not involved in inactivation. An antisense strand, called Tsix 
encodes also a non-coding RNA that is complementary to Xist. Tsix is transcribed 
from the active X. Due to this feature of Tsix, Xist is inactivated in the subsequent 
active X chromosome (Lee et al. 1999). Any targeted deletion/insertion that 
abolishes Tsix transcription, results in Xist RNA accumulation. This demonstrates 
that Tsix has a repressive effect on Xist. However, it is still not clear whether Tsix 
transcript, or the act of transcription, or both, that are involved in inactivation 
process (Nesterova et al. 2003). Tsix expression is regulated by bipartite enhancer, 
including Xite and DXPas34.Tsix and Xite mediate together counting and choice of 
XCI. After determination, they regulate Xist expression (Xu et al. 2006). DXPas34 
is a polymorphic minisatellite region and has been shown to enhance Tsix 
expression (Stavropoulos et al. 2005). The regulating elements and their interaction 
in mouse X-chromosome are illustrated in Figure 1.3.  
 
Whatever the mechanism is, Xist has a primary role in coating and inactivating the 
whole X chromosome except pseudo autosomal regions (PAR). Those regions 
contain genes that have homologous pair in Y chromosome and have a role in X-Y 
pairing during mitosis. Not all genes that escape inactivation have Y homologs. One 
of the most striking features of PARs is that they are localized at the two distal parts 
of an X chromosome, PAR1 in Xp and PAR2 in Xq. Carrel et al. presented a 
comprehensive XCI profile of the human X chromosome in 2005. They achieve this 
in a fibroblast-based test system with human-rodent hybridoma cells. About 15% of 
total X-linked genes to be analyzed escape inactivation to some degree. 
Interestingly, the location of the genes that escape inactivation differs. The 
molecular mechanism and profile of how and which of those genes escape 
inactivation is currently unknown. Failure of spreading of silencing by Xist may 
involve in escape, or any reactivation of those genes may cause escaping. Even 
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though Ke & Collins in 2003 displayed in their research that CpG islands seem to be 
less abundant at the 5’ end of genes escaping inactivation, these genes are seem to 
be the ones in Carrel’s study showing variable inactivation patterns. 
 
          
 
 
Figure 1.3 The illustrative scheme of known genes and regulatory elements in the Xic region on 
mouse X-chromosome. The Tsix gene initiated 16 kb downstream of Xist is transcribed as antisense 
of Xist and negatively regulate its transcription together with Xite and DXPas34 (Morey&Bickmore 
2006 
 
 
 
 
 
 
1.7. Autoimmune disorders that were selected for this study 
 
In this study, autoimmune diseases with high female preponderance were selected. 
Disorders both from systemic and organ specific autoimmune diseases were 
included. Scleroderma, Sjogren’s syndrome, rheumatoid arthritis and juvenile 
idiopathic arthritis were selected as systemic autoimmune disorders. Type I diabetes 
mellitus and autoimmune thyroiditis were included as organ specific diseases.  
 
 
1.7.1. Scleroderma (SSc) 
 
The name scleroderma was derived from the Greek word "skleros", which means 
hard. "Derm" means skin. “Systemic sclerosis” is also used in nomenclature. It is a 
chronic autoimmune disorder of unknown etiology characterized with severe and 
progressive cutaneous and visceral fibrosis, pronounced alterations in the 
microvasculature, and numerous cellular and humoral immunological abnormalities. 
Thickening, hardening, or tightening of the skin, blood vessels and internal organs 
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are the major symptoms observed in systemic sclerosis. Clinical forms of 
scleroderma are heterogeneous ranging from limited to diffuse types. Limited 
cutaneous scleroderma involves limited skin fibrosis with minimal systemic 
alterations. In diffuse cutaneous scleroderma severe internal organ diseases are 
observed together with diffuse skin lesions, which can rapidly progress to hardening 
after an early inflammatory phase (LeRoy et al. 1988). The pathologic changes in 
scleroderma are observed in three steps: 1) accumulation of collagen and other 
connective tissue components in the extracellular matrix, which causes severe tissue 
fibrosis; 2) chronic inflammatory process characterized by infiltration of 
mononuclear cells, mostly of T cell lineage; 3) development of microvascular forms 
resulting in intimal proliferation, narrowing and thrombosis of the vessel lumen. 
Progression of vascular and fibrotic changes with a decrease in the inflammatory 
components leads to end-stage fibrosis and atrophy of the affected organs 
(Jimenez&Derk 2004).   
 
The prevalence of scleroderma may vary by ethnic background and the geographical 
region. However an estimate of mean prevalence around 150 cases per million in 
Europe (Le Guern et al. 2004, Alamanos et al. 2005) and about 250 cases per 
million in US (Mayes et al. 2003) has been reported. Japan has the lowest 
prevalence with 20-50 cases per million (Tamaki et al. 1991). Systemic sclerosis is 
known to be at least three times more common in women than in men and two times 
more common in Blacks than in Whites (Laing et al, 1997).  
 
The possible cause(s) of scleroderma has remained elusive despite numerous 
studies. It has been proposed that many chemical and physical agents may be 
involved in the pathogenesis. Infectious agents are one of the possible causes of 
scleroderma since the autoantibodies that are produced in SSc are thought to be the 
result of a response caused by molecular mimicry (Oldstone 1987). Self antigens 
that contain epitopes structurally similar to viral or bacterial proteins induce 
formation of autoantibodies due to the molecular mimicry. Other than molecular 
mimicry, retrovirus (Jimenez et al. 1995), cytomegalovirus (Pandey&LeRoy 1998) 
and parovirus (Magro et al. 2004) etiologies have been suggested. Viral infections 
may trigger initially autoimmune reaction or they may have a role in the 
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maintenance of the chronicity of the autoimmune process. Environmental agents 
have also been associated with the pathogenesis of scleroderma. Aromatic 
hydrocarbons, such as toluene, xylene, vinyl chloride, benzene and silica have been 
shown to relate to SSc (Haustein&Herrmann 1994, Garabrant et al 2003). The 
contribution of genetic factors have also been considered in the development of 
scleroderma because;  (1) there are cases with a family history, (2) differences exist 
in prevalence and clinical manifestation among different ethnic groups, and (3) there 
is increased prevalence of certain HLA and MHC alleles among the disease classes 
with different types. They differ also among different ethnic groups (Derk&Jimenez 
2003). Even though the concordance of SSc among monozygotic twins is 4.2% and 
dizygotic twins 5.9%, the presence of specific autoantibodies is higher (Feghali-
Bostwick et al. 2003). Moreover, certain HLA classes II antigens-mostly HLA-DQ 
types- have associations in SSc susceptibility (Arnett 1995). In 1997, Artlett and 
colleagues analyzed the inheritance pattern of HLA class I and II type haplotypes in 
the families of 37 SSc patients and 42 control individuals. They found that 70% of 
SSc patients but only 21% of controls had HLA class II alleles compatible with 
either their offspring or mother. Based on these observations, they proposed that 
there are clinical similarities between systemic sclerosis and graft-versus-host-
disease (GVHD) induced by the presence of persisting fetal cells.  The hypothesis of 
involvement of fetal microchimerism in scleroderma was first proposed by 
Black&Stevens (1989) based on the pathological similarities between SSc and 
GVHD. Subsequently, Bianchi et al. reported presence of male fetal cells in a 
normal woman 27 years after the birth of her son and published certain evidence of 
involvement of fetal cells in the pathogenesis of scleroderma. Allogeneic fetal and 
maternal cells can cross the placenta during pregnancy and may persist in the blood 
and/or tissues. It has been proposed that these cells may become activated upon 
stimulation by an environmental effect. The identification of Y-chromosome 
specific sequences in the blood and tissues of female SSc patients that give birth to a 
male offspring strengthen the hypothesis of presence of a relationship between 
microchimerism and scleroderma (Artlett et al. 1998). At the same time, Nelson and 
colleagues (1998) found similar results by investigating involvement of 
microchimerism in the pathogenesis of scleroderma. Using quantitative PCR 
specific for Y-chromosome specific sequences, they compare presence of fetal cells 
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between SSc patients and control women. Fetal DNA was found significantly more 
in the blood of women with SSc. Moreover, women with scleroderma had given 
birth to an HLA class II compatible child more often than controls. All these results 
support the possibility of relationship between SSc and microchimerism.  
 
 
 
1.7.2. Sjogren’s Syndrome (SICCA) 
 
Sjogren’s syndrome is an autoimmune disorder of unknown etiology. The main 
manifestations of this syndrome include keratoconjunctuvitis sicca (dry eye), 
xerostomia (dry mouth) and other extraglandular abnormalities. Lymphocytes that 
infiltrate to lacrimal and salivary glands cause drying of eyes and mouth. Sjogren’s 
syndrome is primarily classified into two categories: primary and secondary SICCA. 
Primary Sjogren’s syndrome is defined as the lack of presence of another type of 
connective tissue disease (rheumatoid arthritis, SLE, or SSc) associated with gland 
inflammation. Secondary Sjogren’s syndrome progresses in the presence of another 
type of connective tissue disease (Venables 2004).  
 
The classification of Sjogren’s syndrome has some difficulties due to lack of single 
disease-specific diagnostic criteria. Recently modified European classification 
criteria are the most functional one (Vitali et al. 2002) with new revisions and 
exclusions.  
 
One of the major feature of Sjogren’s syndrome is its high prevalence among 
women rather than in men (women:men ratio is 9:1). The epidemiological data 
about SICCA is very poor due to the ambiguity in classification criteria. It is known 
that it occurs worldwide and in all ages. A recent epidemiological study about 
prevalence of SICCA was reported that primary Sjogren’s syndrome affects 0.4-3.1 
million adults (Helmick et al. 2008). 
 
Familial clustering of SICCA has been reported in several publications (Reveille et 
al 1984, Boling et al. 1983, Moriuchi et al. 1986). However, the lack of large twin 
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studies does no permit determination of concordance rate in primary Sjogren’s 
syndrome. Only a few case reports have been published describing twins in primary 
SICCA (Scofield et al. 1997, Bolstad et al. 2000). Interestingly, familiar clustering 
of different autoimmune diseases and co-association of more than one type of 
autoimmune disorders in the family members has frequently been reported. In 
addition, presence of other autoimmune diseases in the relatives of Sjogren’s 
syndrome probands has been widely reported (Foster et al. 1993, Tanaka et al. 2001, 
Anaya et al. 2006). 
 
Sjogren’s syndrome is considered as a complex disease with autoimmune 
manifestations. Susceptibility to the disease may vary from environmental factors to 
the viruses and genetic contributions. Since the MHC genes are the best documented 
genetic risk factors for the development of autoimmune disorders, they have been 
analyzed detailed in Sjogren’s syndrome. Even though patients from different ethnic 
origins exhibit different HLA types, most specifically HLA-DR and DQ alleles are 
associated with SICCA. This HLA-mediated risk seems more strongly linked to the 
anti-SS-A/Ro antibody rather than the disease itself.  A stronger correlation between 
anti Ro/SSA autoantibodies and HLA-DR3/DR2 has been reported recently (Arnett 
et al. 1989, Bolstad et al. 2001). Other than HLA genes, polymorphisms o the 
promoter of IL-10 ha been recently reported in Finnish and Italian population 
(Hulkkonen et al. 2001, Font et al. 2002).  
 
Among the environmental factors, viruses are the most prominent candidates 
because salivary glands are a site of latent infection by them. HIV, hepatitis C virus 
and T-leukemia retrovirus-I (HTLV-I) have been reported as the strongest 
candidates in the pathogenesis of Sjogren’s syndrome (Kordossis et al. 1998, 
Haddad et al. 1992, Terada et al. 1994).  
 
 
 
 
 
 
19 
 
1.7.3. Rheumatoid Arthritis (RA)  
 
Rheumatoid arthritis is a chronic inflammatory autoimmune disease characterized 
by the presence of autoantibodies, like rheumatoid factor (RF), anti-cyclic 
citrullinated peptide (CCP), and anti-keratin antibodies (AKA). It leads to 
destruction of joints causing pain, swelling and stiffness. These criteria are 
developed by the American Rheumatology Association in 1988 (Arnett et al. 1988). 
The clinical symptoms are results of cascade of multicellular changes including 
infiltration of lymphocytes and granulocytes into the articular cartilage, proliferation 
of synovial fibroblasts and macrophages and neovascularization of the synovial 
lining surrounding the joints. Subsequently, many cellular components including 
macrophages, dendritic cells, fibroblast-like synoviocytes, mast cells, eosinophills, 
neutrophills, T cells and B cells are recruited in the joints.  
 
Epidemiologic studies indicated that RA occurs worldwide and affects about 1% of 
the population in US and UK (Alamanos&Drosos 2005, Symmons et al 2002). A 
less prevalence has been reported in African population (Adebajo&Davis 1994). 
Disease occurs at any age but onset of disease increases in the elderly people with a 
female preponderance of 2.5 fold (Lee&Weinblatt 2001).  
 
Genetic and environmental factors are suggested to play a role in the etiology of RA. 
Smoking is the most reported risk factor for RA (Silman et al. 1996, Harrison 2002).  
The genetic contribution in the susceptibility of RA in Finnish and UK patients was 
reported between 53% and 65% (MacGregor et al .2000). Monozygotic twins have 
concordance rate around 15%, whereas dizygotic twin rates fall around 3.5% in 
Europe and Australia (Aho et al. 1986, Bellamy et al. 1992, Silman et al. 1993).  
 
Among the genetic factors, HLA locus was the first candidate region for RA due to 
the polymorphic immunological role of their products.  Association of RA and 
HLA-DRB1 was first established in 1978 by Stastny. This particular locus account 
for nearly half of the genetic component of susceptibility to the disease and 
confirmed in different populations (Gregersen et al. 1987, Wordsworth&Bell 1991). 
In a recent study, candidate gene association was analyzed in 2370 RA patients and 
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1757 controls from the North American Rheumatoid Arthritis Consortium 
(NARAC) and Swedish Epidemiological Investigation of Rheumatoid Arthritis 
(EIRA) cohorts. Strong association between RA and PTPN22, CTLA4, and PADI4 
was documented (Plenge et al. 2005).  
 
 
 
1.7.4. Juvenile Idiopathic Arthritis (JIA) 
 
Juvenile idiopathic arthritis is a childhood onset autoimmune disease with unknown 
etiology. It is characterized by arthritis observed in the patients with less than 16 
years old and persistent for at least 6 weeks. The term juvenile idiopathic arthritis 
(JIA) was first proposed in 1995 and then revised in 1997 (Fink 1995, Petty et al. 
1998) instead of the term used by European League Against Rheumatism (EULAR) 
as juvenile chronic arthritis (JCA) (Wood 1978) and by American College of 
Rheumatology (ACR) as juvenile rheumatoid arthritis (JRA) (Brewer et al. 1977). 
The International League against Rheumatism (ILAR) classifies JIA and overcome 
disagreements between the two criteria sets (Petty et al. 2004). The general 
categorization of JIA is based on the number of joints involved and the presence of 
systemic symptoms: 
1. Oligoarticular JIA: It is the only form of JIA that is not present in adults. 
This type of arthritis affects up to four joints. Affected joints are usually the 
large types (particularly lower limbs), notably the knee. Symmetric joint 
involvement is observed in less than one third of the cases (Al-Matar et al. 
2002, Guillaume et al. 2000). Oligoarticular JIA is divided in two 
subcategories: (a) Persistent oligoarthritis in which no more than four joints 
were affected throughout the disease course, (b) extended oligoarthritis 
which affects a cumulative total of five or more joints after the first 6 
months.  
2. Polyarticular JIA: This form of JIA affects five or more joints, most 
commonly metacarpophalangeal joints and wrists and is subdivided in two 
major categories according to the presence of rheumatoid factor: RF(+) and 
RF(-). Both large and small joints are affected and symmetric joint 
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involvement is highly observed. The adult equivalent form of polyarticular 
JIA is the rheumatoid arthritis (Johnson 2006).  
3. Systemic JIA: This form of JIA includes children affected from arthritis with 
systemic features. Systemic JIA is characterized by spiking fever which 
occurs daily for at least 2 weeks together with evanescent rash, 
lymphadeonopathy, hepato/splenomegaly or serotosis. It clinically resembles 
adult onset Still’s disease and most patients later develop a polyarticular 
form with involvement of both large and small joints (Hofer&Southwood 
2002). 
4. Psoriotic JIA: Psoriosis together with arthritis is observed at least with two 
of the following symptoms: (i) dactylitis, (ii) nail pitting or onycholysis, (iii) 
family history of psoriasis in a first degree relative (Stoll et al. 2006).  
5. Enthesitis related JIA: Enthesitis is the inflammation at the insertion of 
tendons into bones. This subgroup of JIA is characterized by arthritis 
together with enthesitis and at least two of the following features: (i) 
sacroiliac joint tenderness and/or inflammatory spinal pain, (ii) acute anterior 
uveitis (iii) presence of HLAB27 or presence of familial history HLAB27 
positive disease. This type of JIA mainly affects boys after the age of 8 years 
(Davidson 2000).   
6. Other JIA: This group of the disease is composed of the children that do not 
meet any criteria above.  
 
JIA is one of the most common childhood rheumatic diseases. The incidance of JIA 
changes between 7 and 21 per 100,000 in US and Europe (Peterson et al. 1996, 
Kaipiainen-Seppänen&Savolainen 1996, von Koskull et al. 2001, Berntson et al. 
2003). It was reported that cumulatively more females than males are affected by 
JIA (male:female ratio is 1/2 or 1/3). However this unequal distribution varies with 
disease subtype. Female predominance is observed in the oligo-and polyarticular 
subgroup, whereas male predominance in enthesitis related JIA (Borchers et al. 
2006). 
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A wide variety of autoantibodies has been detected however rheumatoid factor (RF) 
(Minden et al. 2000), and antinuclear antibodies (ANA) (Berntson et al. 2003, Flato 
et al.  1998, Serra et al. 1999) are routinely used in the serological diagnosis of the 
patients. JIA rarely manifests familial occurrence, therefore family studies are 
uncommon or based on small numbers. Another parameter for genetic contribution 
is twin studies. In a study performed among Finnish monozygotic twins with JIA, 
the λs was calculated near to 20 (Savolainen et al. 2000). A different study from US 
indicated λs as 15, a value similar to type I diabetes mellitus (Moroldo et al. 1997). 
HLA-B27 was first and most strongly associated genetic risk factor in older and 
male JIA patients (Rachelefsky et al. 1974). A study that was performed on 521 
British JIA patients and 537 matched controls displayed that aarious subgroups of 
JIA were reported to associate with distinct HLA profiles. (Thomson et al 2002).  
Studies about non-MHC loci reported polymorphisms on TNF, IL-10, interferon 
regulatory factor 1 (IRF-1), and macrophage migration inhibitory factor (MIF) that 
display strong associations with JIA (Date et al. 1999, Zeggini et al. 2002, Crawley 
et al. 1999, Vencovsky et al. 2001, Meazza et al. 2002).  
 
 
 
1.7.5. Autoimmune Thyroid Diseases (AITDs) 
 
Autoimmune thyroid diseases are a combination of a group of immunological 
responses, which target the thyroid gland. Although classical AITDs include mainly 
Grave’s disease (GD) and Hashimoto’s thyroiditis (HT), postpartum thyroiditis 
(PPT), atrophic autoimmune thyroid diseases, and thyroid associated 
ophthalmopathy (TAO) were counted as minor variants of AITDs. However, in this 
study, only HT and GD were included in the context of AITDs. Both GD and HT 
involve infiltration of the thyroid by B and T cells, giving reaction against thyroid 
antigens. The reaction causes production of thyroid autoantibodies, subsequently 
causing hypothyroidism in HT and hyperthyroidism in GD. Hypothyroidism in HT 
is associated with thyroid peroxidase and thyroglobulin autoantibodies. 
Hyperthyroidism in GD is associated with thyroid-stimulating hormone receptor 
autoantibodies (McLachlan et al. 2007).  
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AITDs are one of the most common autoimmune disorders and affects women more 
than men. The prevalence of hyperthyroidism is 2.5% in females and 0.6 % in males 
and the prevalence of hypothyroidism is 4.8% in females and 0.9 in males in a large 
study of north European population (Bjoro et al. 2000). Another recent study 
performed among US population reported prevalence of hyperthyroidism was found 
0.5% and hypothyroidism 3.7% (Aoki et al. 2007). Even though many 
environmental factors, like iodine intake, may affect the prevalence, virtually all 
studies report the increased hypothyroidism in women with advancing age (Canaris 
et al. 2000). 
 
The etiology of AITDs has not been fully understood, but there are numerous 
studies supporting the effects of genetic factors. The most powerful method to 
decide the presence of genetic predisposition to complex diseases is twin studies. 
Two main studies that search large twin populations with GD gave information 
about the concordance rates. First study is from Denmark by Brix et al. (2001) and 
reported that the concordance rate was 35% in monozygotic (MZ) twins and 3% in 
dizygotic (DZ) twins. Moreover, they suggested that genetic factors are responsible 
for 79% of the susceptibility to develop GD. The same group found that the 
frequency of skewed XCI in female twins with AITDs was 34%, which was higher 
than the prevalence in the corresponding control populations (Brix et al. 2005). 
Another study from California confirmed the results of the Danish group. The 
concordance rate among US population was found 17% in MZ twins, whereas 1.9% 
in DZ twins (Ringold et al. 2002).  
 
Brix and colleagues (2000) performed a similar study in Danish HT twin population 
and statistically significant results were reported. Concordance rate was found 55% 
and 0% in MZ and DZ twins respectively. In addition, the concordance rates for 
thyroid autoantibodies were found to be higher in MZ twins compared to DZ twins. 
Several methods exist to determine whether complex disease susceptibility is 
influenced by genetic factors. One of them is calculating λs (siblings ratio), which is 
a quantitative measure of genetic contribution to the disease if the value of the ratio 
is greater than 5. In AITDs case, the λs was calculated 16.9 for AITDs, 11.6 for GD, 
and 28.0 for HT. This study was performed on 155 patients (Villanueva et al. 2003). 
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Several scientists have reported the familial occurrence of AITDs from different 
geographical regions. In 1967, Hall&Stanbury reported a family whom 33% of 
siblings of patients with GD or HT developed AITDs. Later, in 2001, the largest 
family whose members exhibit AITDs together with other types of autoimmune 
disorders (The Akr Family) was reported by Maalej et al. This family has more than 
200 members. More than 60 individuals were affected with AITDs.  Subsequently, a 
Chinese-American family with 8 members affected from AITDs over 3 generations 
was reported (Villanueva et al. 2002).  
 
The genes that are thought to be involved in the pathogenesis of AITDs can be 
categorized in two; those that are involved in immune system regulation and those 
involved in thyroid physiology.  Among the immune related genes, the human 
leukocyte antigen genes on MHC region are the first candidates because they are 
highly polymorphic and contain many genes that have role in immune responses. An 
association between HLA-DR3 and GD has been conferred as a risk factor 
(Ban&Tomer 2003). Among the HLA types, the strongest association in the 
pathogenesis of HT has been shown on HLA-DR4 (Tandon et al 1991, Jenkins et al. 
1992) and HLA-DQw (Badenhoop et al. 1990, Wu et al. 1994). Another important 
immune system regulation molecule is the cytotoxic T lymphocyte antigen-4 
(CTLA-4), which down regulates T cell activation by competing for the binding of 
B7 to CD28. A considerable high number of studies have been carried out and 
numerous results support the association between AITDs and CTLA-4 
(Jacobson&Tomer 2007).  
 
 
 
1.7.6. Type I Diabetes Mellitus (T1D) 
 
Diabetes mellitus is a group of disorder of multiple etiology characterized by 
chronic hyperglycemia together with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin action, secretion or both. The first 
agreement about diagnostic criteria and classification system in diabetes mellitus 
was achieved in 1980 by World Health Organization (WHO 1980) and then revised 
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in 1985 (WHO 1985). The report in 1980 categorized the disease into two major 
classes: IDDM (insulin dependent diabetes mellitus) or Type I, and NIDDM (non-
insulin dependent diabetes mellitus) or Type II. In 1985, according to the revised 
categorization, 4 types of the disease classes were accepted: Type I, Type II, 
gestational diabetes mellitus, and other types. 
 
Briefly, Type I diabetes occurs as a result of destruction of pancreatic islet beta 
cells. Due to the loss of beta cell function, insulin cannot be produced. Type II 
includes the form of diabetes which results from defect(s) in insulin secretion. In 
this type, the mass of pancreatic beta cells and their functions are preserved to some 
extent. Gestational diabetes mellitus occurs for the first time during pregnancy and 
the symptoms disappear after delivery or birth. In the other type of diabetes, the 
disease occurs either as a result of specific mutations in the genes related to the 
mechanisms of insulin action or as a manifestation of various pathologic conditions. 
Type I diabetes occurs as a result of autoimmune destruction of insulin-producing 
beta cells in pancreas by CD4+ and CD8+ T cells and macrophages infiltrating the 
islets. Disease progression causes insulin deficiency and if not treated may result in 
coma and death. T1D has been classified as an organ-specific autoimmune disease 
with unclear etiology. Autoantigens that are mainly detected in T1D patients are 
proinsulin, glutamic acid decarboxylase (GAD65 and 67), and the protein thyrosine 
phosphatase (IA2) (Lieberman&DiLorenzo 2003). Even though the female:male 
ratio is not more than one in T1D patients, there are subgroups of the disease that 
exhibit high female preponderance. Thyroid antibodies were present in 
approximately 15-30% of T1D patients and about half of these patients progress to 
clinical AITDs (Golden et al. 2005).  
 
Type I diabetes accounts about 10% of all cases of diabetes. It was reported that 
T1D occurs most commonly in Europe and North America. There are differences 
between the incidence rates and the geographical variation. One of the lowest 
incidence rate is observed in China (0.57 cases per 100,000 population in China 
whereas 18-20 cases per 100,000 in UK and 48 cases per 100,000 in Finnland) 
(Karvonen et al. 2000, DIAMOND project group 2006). 
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The family history of patients with T1D is not common; however there is clear 
genetic predisposition for the disease with first degree relatives having a lifetime 
risk of developing T1D of 6.0 vs 0.4% in the general population (Harjutsalo et al 
2006). In addition, the twin studies reported that the concordance rate in MZ twins is 
approximately 50% (Kyvik et al. 1995, Redondo et al. 1999). 
 
Susceptibility is inherited largely in the HLA region. The HLA locus is thought to 
play a role about 50% of the genetic susceptibility. Among them, HLA-DR and 
HLA-DQ subtypes predominantly are suggested to have a role in genetic 
susceptibility. In fact, the HLA locus on chromosome 6 was the first locus shown to 
be associated with the disease (Nerup et al. 1974). Moreover this region is 
considered to contribute about half of the familial basis of type I diabetes (Todd 
1995). Candidate gene studies reported another non-MHC gene, insulin on 
chromosome 2q as risk factors contributing 10 % of susceptibility to T1D (Bell et 
al. 1984). CTLA-4 and a variant of PTPN22 are two other most powerful candidate 
genes that are reported to have association with T1D (Ueda et al. 2003, Bottini et al. 
2004).  
 
 
 
1.8. Pre-eclampsia (PEE) 
 
Previous reports indicated that sera from patients diagnosed with pre-eclampsia 
include greater amounts of Th1-type cytokines. Although the etiology and 
patophysiology of pre-eclampsia remain unsolved, association with poor 
placentation, endothelial dysfunction and excessive inflammation was revealed 
(Saito&Sakai 2003). Since autoimmune components were suggested to be involved 
in pre-eclampsia, it was selected for investigating the role of XCI in the etiology of 
the disease. Pre-eclampsia is characterized by hypertension (more than 140/90 
mmHg) and proteinuria (more than 0.3 g/L) in previously normotensive non-
proteinuric pregnant women. PEE is the leading cause of maternal and fetal 
mortality and morbidity. It occurs in 3-7% of pregnancies and about 8,370,000 cases 
per year have been estimated over the world (Sibai et al. 1993). The presence of 
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placenta is necessary for appearance of symptoms, because delivery of fetus and 
placenta causes disappearance of them. Besides hypertension and proteinuria, 
edema, visual disturbances, headache and vomiting can be observed in patients as 
clinical features. If those symptoms become more severe, like elevated liver 
enzymes, hemolysis, and thrombocytopenia, the syndrome is called as HELLP 
(hemolytic anemia, elevated liver enzymes, and low platelet count) and was 
observed in 5-8% of pre-eclamptic women (Noris et al. 2005). 
 
The etiology of pre-eclampsia is still not completely clear, however genetic, 
immunologic and environmental factors (oxidative stress) are suggested to play an 
important role in the pathogenesis. There are several publications that indicate 
genetic factors predisposing to PEE. In familial cases of pre-eclampsia, linkage 
studies indicated different candidate loci on different regions. Arngrimsson et al. 
performed a genome-wide scan and found a susceptibility locus on 2p13 in Iceland 
population (1999). Subsequently in 2001 by Lachmeijer et al. and then in 2004 by 
Oudejans et al. two candidate loci on 12q and 10q22 were reported in Dutch 
population. Lastly, a study in Finnish population indicated 2p13 locus as a candidate 
region (Laasanen et al. 2003).  
 
Immune mechanisms are suggested to be involved in the patogenesis of PEE. It was 
reported that angiotensin receptor (AT1) agonistic antibodies were raised in the 
blood of pre-eclamptic women whereas they were rarely observed in normotensive 
pregnant women. These autoantibodies have the capability of activating the 
angiotensin AT1 receptor and support the classification of PEE as a pregnancy-
specific autoimmune disorder (Wallukat et al. 1999, Xia et al. 2002). 
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1.9. AIM OF THE STUDY 
 
Autoimmune diseases affect 5-8 percent of the population. An important 
characteristic of this group of diseases is the female predominance in certain 
autoimmune disorders. Even though the exact mechanisms that cause this unequal 
distribution between sexes are not entirely known, environmental factors, pregnancy 
related microchimerism, and sex hormones are likely candidates. Disturbed XCI is 
another candidate mechanism in the contribution of breakdown of self-tolerance. In 
this study, the hypothesis that ‘loss of mosaicism’ in the female cells may have a 
potential role in the pathogenesis of female predominant autoimmune diseases was 
tested. Methylation status of CAG repeat polymorphism of androgen receptor (AR) 
gene was genotyped to determine XCI status of patients and controls. Patients 
diagnosed with scleroderma (n=70), autoimmune thyroiditis (n=110), Sjogren’s 
syndrome (n=78), juvenile idiopathic arthritis (n=81) and pediatric scleroderma 
patients (n=13) and their age matched controls (n=160 for adult and n=183 for 
pediatric samples) in the Turkish population were genotyped. Moreover, XCI status 
of autoimmune thyroiditis (n=145) and rheumatoid arthritis (n=106) patients and 
controls (n=97) in the Tunisian population and scleroderma patients (n=125) in the 
US population were genotyped. Independently, patients diagnosed with pre-
eclampsia (n=67) in which autoimmunity may be an important component, were 
genotyped for AR gene polymorphism.  
Subaim 1: Microchimerism was documented to associate with scleroderma, 
therefore the relationship between microchimerism and skewed XCI was 
investigated in Turkish and US scleroderma patients.  
Subaim 2: In order to investigate the parental origin of inactive X-chromosome, US 
scleroderma patient (n=19) and their mothers were genotyped for AR gene 
polymorphism. 
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CHAPTER 2 
 
 
MATERIALS AND METHOD 
 
 
 
2.1. ADULT SAMPLES 
 
2.1.1. Turkish control samples 
 
Caucasian females comprised of 160 Turkish healthy unrelated volunteers were 
involved as controls in our studies. The mean age at analysis was 46±10.0 
(mean±SD) for Turkish controls. There was no clinical evidence or family history of 
autoimmune disease and inflammatory joint disease. The results of XCI profile of 
this group were involved in comparison of XCI pattern of patients with Turkish 
scleroderma, Turkish AITDs, US scleroderma, and Turkish Sjogren’s syndrome. 
Turkish control women were involved in determination of XCI psttern of Tunisian 
patients together with Tunisian control group.  
 
2.1.2. Turkish scleroderma patients 
 
Caucasian women (n=70) diagnosed with scleroderma and healthy control women 
(n=160) with no history of autoimmune disease or cancer were included in this 
study. All patients fulfilled the American College of rheumatology diagnostic 
criteria for scleroderma (Subcommittee for Scleroderma Criteria of the American 
Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980). 
The ethics review boards at the participating institutions approved the study 
protocol. Informed consent was obtained from all subjects.The mean (±SD) ages 
were 49 (±14) years for SSc patients and 46 (±10) years in controls. The duration of 
symptoms (Raynaud’s phenomenon, puffy hands, esophagitis, or dyspnea) was 10 
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(±7) years among the SSc patients and the mean age at diagnosis was 39 (±12) 
years. Among 70 patients, five had the limited cutaneous form of disease, and sixty 
five patients had diffuse disease. XCI pattern was determined in the cells of blood 
obtained from patients and control women. In order to test whether the same skewed 
pattern in XCI was observed in the cells from different tissue types, samples from 
skin biopsy, buccal wash and hair specimens were requested from the patients 
whose XCI pattern in blood cells was more than 80%.  
 
 
2.1.3. US scleroderma patients 
 
DNA samples were obtained from 125 scleroderma patients and 160 control women.  
Clinical characteristics of the patients have been published elsewhere (Loubiere et 
al. 2005). The ethics review boards at the participating institutions approved the 
study protocol. Informed consent was obtained from all subjects. The maternal and 
fetal microchimerism status of the patients was available. In order to determine the 
paternal origin of the inactive X chromosome, from 19 patient-mother pair, whose 
DNA samples were enough in quantity for the analysis, were included in this study.  
 
 
2.1.4. Turkish autoimmune thyroid diseases patients 
 
In this study, 110 Caucasian women diagnosed with AITDs (81 were diagnosed 
with HT and 29 with GD), and 160 healthy female controls with no history of 
autoimmune disease and cancer were included. All the patients were selected 
randomly. The mean ages were 44.8±14.1 years for AITDs (46±14.2 years in the 
Hashimoto patients, and 40.6±13.2 years in the Graves’ patients), and 46±10 for 
controls (standard deviations were displayed in parantheses). The duration of the 
symptoms was 5.7±7.4 years among the AITDs patients (5.7±7 years in the 
Hashimoto patients and 6±8.5 years in the Graves’ patients). The mean age of 
diagnosis was 39±12 years. All clinical investigations described in this study were 
conducted in accordance with the guidelines in the Declaration of Helsinki 
(http://www.wma.net). The ethics review board of the participating institutions 
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approved the study protocol. Informed consent was obtained from all subjects. In 
order to test whether the same skewed pattern in XCI is observed in the cells from 
different tissue types, samples from thyroid biopsy, buccal wash and hair specimens 
were requested from the patients whose XCI pattern in blood cells was more than 
80%. 
 
 
2.1.5. Turkish Sjogren’s  syndrome patients 
 
Caucasian women diagnosed with Sjogren’s syndrome (n=78) and 160 healthy 
Caucasian female were included and genotyped to determine the XCI patterns. The 
ethics review board of the participating institutions approved study protocol.  
 
 
2.1.6. Combined group of Turkish and Tunisan control samples 
 
Caucasian females comprised of 97 Tunisian and 160 Turkish healthy unrelated 
volunteers served as controls in our studies. The mean age at analysis was 43.5±15.3 
(mean±SD) years for the Tunisian and 46±10.0 (mean±SD) for Turkish controls. 
There was no clinical evidence or family history of autoimmune disease and 
inflammatory joint disease.  
 
 
2.1.7. Tunisian Akr family 
 
Akr family is a large family with more than 400 members. The importance of 
examining this family is that 76 members over 3 generations were diagnosed with 
AITDs. 242 members from this family were sampled.  40 of them diagnosed with 
GD, 13 with HT, and 23 with PIM, and 166 unaffected. The ratio of female to male 
is 1 in GD, 3.3 in HT, and 4.2 in PIM patients. The age of patients at the onset of 
disease ranged between 12 and 58 years. The mean age was 35 years. 44 women 
members from this family were included in this study. Among these 44 individuals, 
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20 were diagnosed with AITDs and 24 were healthy women. Clinical characteristics 
of the members of Akr family have been reported by Maalej et al. (2001, 2008). 
 
 
2.1.8. Tunisian autoimmune thyroid diseases patients 
 
Caucasian women diagnosed with AITDs (n=145) were included in this study. 
Among those patients, 58 were diagnosed with Grave’s disease (GD), 40 with 
Hashimoto’s thyroiditis (HT), and 47 with primary idiopathic myxodema (PIM). 
The mean age was 46.5±14.5 (mean ±SD) years for AITDs patients (57.2±13.1 
years in PIM patients, 43.3±13.2 years in the Hashimoto patients and 44.6±14 years 
in Graves’ patients). The duration of the symptoms was 7.5±4.6 years for the AITDs 
patients (6.5±5 years in PIM patients, 7.2±4 years in Graves’ patients, and 7.7±4.6 
years in the Hashimoto patients). The mean age of diagnosis was 37.9±15.1 years. 
Presence of biochemical hyperthyroidism by a decrease of TSH, an increase of T4 
levels and positive TSH receptor antibody, in association with diffuse goiter or the 
presence of exophthalmos was the diagnostic criteria for GD. For the diagnosis of 
HT, presence of thyroid hormone replaced primary hypothyroidism, defined as a 
TSH level above the upper limits associated with or without positive titters of 
thyroid autoantibodies (anti-thyroglobulin and/or anti-thyroid peroxydase) and a 
palpable goiter were the criteria. PIM was diagnosed by the presence of 
hypothyroidism requiring T3 or T4 replacement. Patients with PIM have an atrophic 
gland. 
 
 
2.1.9. Tunisian rheumatoid arthritis patients 
 
Caucasian women affected with RA (n=106) were enrolled in this study. All patients 
fulfilled the 1987 American College of Rheumatology criteria for RA (Arnett et al. 
1988). All clinical data were reviewed by a rheumatologist university fellow. The 
mean age was 47.6±13.4 (mean ±SD) years. The duration of the symptoms was 
15±8.9 years. The mean age of diagnostic was 40.3±12 years. Among 106 RA 
patients, 65 were rheumatoid factor (RF) positive (61.3%), 70 were anti-cyclic 
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citrullinated peptides (anti CCP) positive (66%), 15 presented nodules (14.1%), and 
70 presented with erosive disease (66%). Presence of another auto-immune diseases 
(Sjögren’s syndrome, Type I diabetes, Thyroid auto-immune diseases) were 
observed in 15 patients. 
 
 
2.1.10. Turkish pre-eclampsia patients 
 
Caucasian women (n=67) diagnosed with preeclampsia, and 130 apparently healthy 
Caucasian female controls were included in this study. The control group women 
were selected from the individuals of Turkish control group so that the age of 
subjects was matched with the healthy women. For this reason the number of control 
group of pre-eclampsia patients is 130. The ethics review board of the participating 
institutions approved study protocol. Pregnancy history, age, and disease 
information accompanied by informed consent was obtained from all subjects. In the 
control group (124/130) women gave birth to at least one child. None of the control 
women had a history of pregnancy loss, autoimmune disease or cancer. In the 
patient group all women had singleton deliveries. The birth registry at the Etlik 
Maternity and Women’s Health Teaching Hospital in Ankara was used to contact 
the pre-eclamptic cases. The mean ages were 29.8 ± 5.7 years (mean ± SD; range = 
21– 42 years old) for the cases, and 31.6 ± 5.6 (range = 21– 47 years old) for the 
controls. Development of hypertension and proteinuria within 7 days of each other 
after the twentieth week of gestation in women was defined as pre-eclampsia. 
Hypertension was defined as diastolic blood pressure of at least 90 mm Hg that 
occurs on at least two occasions, 4-168 h apart. If the blood pressure was more than 
140 mm Hg, the condition was defined as severe hypertension. Proteinuria was 
defined as urinary protein excretion of more than 300 mg in 24 h. In the presence of 
severe hypertension and proteinuria, HELLP syndrome (haemolysis, elevated liver 
enzymes, low platelets) or eclampsia, pre-eclampsia was considered severe. The 
patients with a previous history of chronic hypertension, renal disease or diabetes 
mellitus were excluded. In order to test whether the same skewed pattern in XCI is 
observed in the cells from different tissue types, samples from buccal wash 
specimens were requested from the patients with various degree of XCI.  
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2.2. PEDIATRIC SAMPLES 
 
 
2.2.1. Turkish pediatric control samples 
 
Helathy children with no autoimmune disorders or cancer (n=92) and newborn 
babies (n=91) were included in this study as the control group of pediatric 
autoimmune diseases. The ethics review board of the participating institutions 
approved study protocol. 
 
 
2.2.2. Turkish juvenile idiopathic arthritis patients 
 
Eighty one Caucasian children diagnosed with JIA were included in this study. All 
patients fulfilled the American College of rheumatology diagnostic criteria for 
juvenile idiopathic arthritis (Petty et al. 1998). The mean age of the patients at the 
onset of disease was 5.6±3.8 (mean±SD) years for JIA. Among 81 JIA patients, 21 
were diagnosed with polyarthritis, 3 were with extended oligoarthritis, and 57 were 
with oligoarthritis JIA. The ethics review board of the participating institutions 
approved study protocol. 
 
 
2.2.3. Turkish pediatric scleroderma patients 
 
Thirteen children diagnosed with pediatric scleroderma were included in this study. 
The ethics review board of the participating institutions approved study protocol.  
 
 
2.2.4. British cell line samples of type I diabetes mellitus (TPO+&TPO-) patients 
and BBC1958 control individuals 
 
Type I diabetes mellitus was selected as an organ specific pediatric onset 
autoimmune disease. For this reason collaboration with Dr John Todd from 
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Cambridge University was proposed. However the samples from patients and 
controls have been preserved as established cell lines.  453 DNA samples of cell 
lines of T1D (TPO-) patients and 354 DNA samples of cell lines of T1D (TPO+) 
patients were involved in this study. 466 DNA samples of cell lines of BBC 1958 
cohort were involved in this study. Clinical characteristics about the patients and 
controls have been reported elsewhere (Wellcome Trust Case Control Consortium; 
Australo-Anglo-American Spondylitis Consortium (TASC) 2007). 
 
 
 
2.3. DNA ISOLATION  
 
2.3.1. DNA isolation from venous blood 
 
DNA from venous blood was isolated by using MN Nucleospin Blood Kit 
(Germany) according to the protocol of the manufacturer. In this protocol, 200µL 
venous blood was mixed with 25µL proteinase K and 200µL B3 solution of the kit. 
This solution was incubated at 70°C for 15 min. During the incubation period, the 
solution was vortexed minimum two times. Since B3 solution lyses the cells, mixing 
by vortexing enhance disruption of membrane of the cells. At the end of this 
incubation procedure, 210µL (96-100%) ethanol was added and vortexed. The lysate 
was loaded into the column provided in the kit package and centrifuged at 13,000 
rpm for 1 min. During this step genomic DNA was attached to the column resin.  
The flow-through was discarded and 500µL of buffer BW was added into the 
column. These columns were centrifuged at 13,000 rpm for 1 min and the collecting 
tube with flow-through was discarded. The column was placed in a new collecting 
tube and 600 µL of buffer B5 was added. Both BW and B5 buffers are used to wash 
the cloumn and discard the residual parts and salts. The tube was centrifuged at 
13,000 rpm for 1 min and the flow-through was discarded. Buffer B5 contain 
ethanol. In order to remove residual ethanol on the membrane of column, it was 
centrifuged one more time at 13,000 rpm for 1 min. The tube with flow-through was 
discarded and the column was placed in a 1.5 mL eppendorf tube. 100µL of pre-
heated (at 70°C) elution buffer was added on the membrane of the column and 
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incubated at room temperature for 1 min. The tube was centrifuged at 13,000 rpm 
for 1 min. Genomic DNA atached on the membrane of the column was eluted into 
the eppendorf tube. The column was discarded and the DNA samples were 
preserved at 4°C. The quantity of DNA samples were measured using 
spectrophotometry or nanodrop. 5µL of DNA sample was diluted in 95µL ddH2O 
and the mixture was loaded into the column of spectrophotometry apparatus. The 
integrity of DNA samples were controlled by using 1% agarose gel electrophoresis. 
Runs were performed at 120 Volt for 30 min. 
 
 
  2.3.2. DNA isolation from buccal wash specimen 
 
Buccal wash (25 mL in H2O) from patients were centrifuged at 2000 rpm for 10 
min. The supernatant was discarded and the procedure in section 2.3.1 was 
performed for further DNA isolation. 
 
 
2.3.3. DNA isolation from hair specimen 
 
Chelex resin was used to isolate DNA from hair specimen (Walsh et al. 1991). 
Rooted hair was cut (approximately 0.5 cm) and washed with deionized water. The 
hair was incubated in 200 µL 5% Chelex (BioRad, CA, USA) at 56°C overnight. 
The mixture is then mixed and boiled for 8 min. After boiling the tubes were 
centrifuged at 13000 rpm for 3 min. The hair and chelex resin were accumulated in 
the pellet. 10 µL from the supernatant was taken and used as a template for 
restriction digestion reaction.  
 
 
2.3.4. DNA isolation from skin biopsy specimen 
 
Skin biopsy specimen was mechanicaly disrupted via a blade in the plate and then 
put into an eppendorf. The particules were washed in 1XPBS and then vortexed. 
The vortexed specimen was washed with 1XPBS and put into a new eppendorf. 25 
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µL proteinase K and 200 µL of Buffer3 of DNA Isolation Kit were put on the 
mixture. The tubes were incubated at 70°C for 15 min and the kit protocol in section 
2.3.1 was procedured.  
 
 
2.3.5. DNA isolation from thyroid biopsy specimen 
 
The thyroid biopsy specimen was put into an eppendorf and 200µL of 1XPBS was 
added. The specimen was homogenized. 65µL of proteinase K and 200µL of B3 
Buffer of the kit were added and incubated at 70°C overnight and the kit protocol in 
section 2.3.1 was procedured.  
 
 
 
2.4. HUMARA ASSAY 
 
The inactivation of one of the X chromosomes starts with accumulation of 
noncoding RNA of XIST. Next step is chromatin changes such as histone 
modification and methylation of DNA in the 5’ region of the genes 
(Heard&Disteche 2006). Methylation at the deoxycytosine residues in CpG 
dinucleotides was especially noted in this process (Wolf et al.1984, Keith et al. 
1986). Hpa II and Hha I are two restriction enzymes both of which contain CpG 
dinucleotides in their recognition sites and do not have the capability of cutting the 
DNA if the target site is methylated.  The genes that contain Hpa II or Hha I sites in 
their 5’ region can be analyzed to determine their methylation status, however the 
two alleles originating from two parents should be different from each other. Highly 
polymorphic CAG repeats in the first exon of androgen receptor (AR) gene was 
genotyped to asses the XCI pattern first by Allen et al. in 1992. Human AR gene was 
prefered in this assay because it has been shown to be highly affected by 
inactivation (Meyer et al. 1975). In this assay, highly polymorphic CAG repeats 
flanked by restriction sites of both methylation specific enzymes were amplified by 
PCR. By this way, methylation patterns of maternally and paternally derived X 
chromosomes can be identified. In this study, Hpa II was used for digestion of 
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DNA. Oligonucleotide primers were designed to flank both the methylation-
sensitive restriction-enzyme sites and the CAG repeat simultaneously (Figure 2.1). 
Only the region on inactive X chromosome between the primer sets can be amplified 
because Hpa II digestion is failed due to methylated CpG dinucleotides. 
 
 
2.4.1. Restriction enzyme digestion 
 
The protocol that was described first by Allen et al. was used in HUMARA assay. 
Two sets of reactions were prepared for each subject in restriction digestion 
protocol. Both sets contain 150-250 ng genomic DNA, 1X reaction buffer (33mM 
Tris-acetate (pH 7.9), 10 mM magnesium acetate, 66 mM potasium acetate, 0.1 
mg/mL BSA), and 2 Units of RsaI (a restriction enzyme with sites outside the PCR 
product, which is not sensitive to methylation and thus digests active and inactive X 
alleles equally). RsaI was used to improve the PCR and to mae the DNA more 
accessible. The only difference between these two sets is the presence of 
methylation sensitive restriction enzyme HpaII in the tube labeled as “digested (D)” 
(8 Units per 20 µL reaction). The tubes that do not contain HpaII were labeled as 
“undigested (U)” Both reaction sets were completed to a final volume of 20 µL with 
deionized water. Restriction digestion rection tubes were incubated at 37°C 
overnight. Restriction digestion products were incubated at 70°C for 15 min in order 
to inactivate the enzymes. One control male sample that was cytogenetically verified 
as 46, XY was involved in this tudy as a control for complete digestion. 
 
 
2.4.2. Polymerase chain reaction (PCR) 
 
For each sample, two PCR were performed. The only difference between these two 
rection was the template. Tubes were labeled as “U” if the template was the 
restriction digestion product of undigested reaction (without HpaII), and labeled as 
“D” if the template is the product of digested reaction. PCRs were carried out in a 
total of 25 µL volume. Restriction digestion products were amplified with 10 pmol 
of each primers, 0.12 mM of each dNTPs, 1X Taq polymerase buffer (750 mM Tris-
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HCl (pH 8.8 at 25°C), 200 mM (NH4)2SO4, 0.1% (v/v) Tween 20), 1.0 mM MgCl2, 
and 1 Unit Taq polymerase. The sequence of primers were as follows: RS6 
(forward) 5’-GTC CAA GAC CTA CCG AGG AG-3’ and RS7 (reverse) 5’-CCA 
GGA CCA GGT AGC CTG TG-3’. In order to amplify the desired region on AR 
locus, 94°C 5 min initial denaturation step was followed by 30 cycles of 94°C 30 
sec, 58°C 30 sec, 72°C 30 sec. amplification step. Final extension was performed at 
72°C 5 min. The sequence of polymorphic region on AR gene is illustrated in Figure 
2.2. Amplicons were controlled in 1.5% Agarose Gel. The gel was prepared by 
adding agarose in 1X TAE and 1 µL of ethidium bromide (10mg/mL). Runs were 
performed in 1X TAE at 120 V for 20 min. 
Polymerase chain reactions of the SSc, AITDs and Control samples were performed 
via radioactively labeled nucleotides. The reaction contents were the same as 
explained above, except 0.1 µCi of α-33P-dCTP (NEN, Boston, MA) per reaction 
was added. PCR conditions were the same with the cold reaction. 
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gaggccggcccggtgggggcgggacccgactcgcaaactgttgcatttgctctccacctcccagcgc
cccctccgagatcccggggagccagcttgctgggagagcgggacggtccggagcaagcccagaggca
gaggaggcgacagagggaaaaagggccgagctagccgctccagtgctgtacaggagccgaagggacg
caccacgccagccccagcccggctccagcgacagccaacgcctcttgcagcgcggcggcttcgaagc
cgccgcccggagctgccctttcctcttcggtgaagtttttaaaagctgctaaagactcggaggaagc
aaggaaagtgcctggtaggactgacggctgcctttgtcctcctcctctccaccccgcctccccccac
cctgccttccccccctcccccgtcttctctcccgcagctgcctcagtcggctactctcagccaaccc
ccctcaccacccttctccccacccgcccccccgcccccgtcggcccagcgctgccagcccgagtttg
cagagaggtaactccctttggctgcgagcgggcgagctagctgcacattgcaaagaaggctcttagg
agccaggcgactggggagcggcttcagcactgcagccacgacccgcctggttaggctgcacgcggag
agaaccctctgttttcccccactctctctccacctcctcctgccttccccaccccgagtgcggagcc
agagatcaaaagatgaaaaggcagtcaggtcttcagtagccaaaaaacaaaacaaacaaaaacaaaa
aagccgaaataaaagaaaaagataataactcagttcttatttgcacctacttcagtggacactgaat
ttggaaggtggaggattttgtttttttcttttaagatctgggcatcttttgaatctacccttcaagt
attaagagacagactgtgagcctagcagggcagatcttgtccaccgtgtgtcttcttctgcacgaga
ctttgaggctgtcagagcgctttttgcgtggttgctcccgcaagtttccttctctggagcttcccgc
aggtgggcagctagctgcagcgactaccgcatcatcacagcctgttgaactcttctgagcaagagaa
ggggaggcggggtaagggaagtaggtggaagattcagccaagctcaaggATGGAAGTGCAGTTAGGG
CTGGGAAGGGTCTACCCTCGGCCGCCGTCCAAGACCTACCGAGGAGCTTTCCAGAATCTGTTCCAGA
GCGTGCGCGAAGTGATCCAGAACCCGGGCCCCAGGCACCCAGAGGCCGCGAGCGCAGCACCTCCCGG
CGCCAGTTTGCTGCTGCTGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG
CAGCAGCAGCAGCAGCAGCAAGAGACTAGCCCCAGGCAGCAGCAGCAGCAGCAGGGTGAGGATGGTT
CTCCCCAAGCCCATCGTAGAGGCCCCACAGGCTACCTGGTCCTGGATGAGGAACAGCAACCTTCACA
GCCGCAGTCGGCCCTGGAGTGCCACCCCGAGAGAGGTTGCGTCCCAGAGCCTGGAGCCGCCGTGGCC
GCCAGCAAGGGGCTGCCGCAGCAGCTGCCAGCACCTCCGGACGAGGATGACTCAGCTGCCCCATCCA
CGTTGTCCCTGCTGGGCCCCACTTTCCCCGGCTTAAGCAGCTGCTCCGCTGACCTTAAAGACATCCT
GAGCGAGGCCAGCACCATGCAACTCCTTCAGCAACAGCAGCAGGAAGCAGTATCCGAAGGCAGCAGC
AGCGGGAGAGCGAGGGAGGCCTCGGGGGCTCCCACTTCCTCCAAGGACAATTACTTAGGGGGCACTT
CGACCATTTCTGACAACGCCAAGGAGTTGTGTAAGGCAGTGTCGGTGTCCATGGGCCTGGGTGTGGA
GGCGTTGGAGCATCTGAGTCCAGGGGAACAGCTTCGGGGGGATTGCATGTACGCCCCACTTTTGGGA
GTTCCACCCGCTGTGCGTCCCACTCCTTGTGCCCCATTGGCCGAATGCAAAGGTTCTCTGCTAGACG
ACAGCGCAGGCAAGAGCACTGAAGATACTGCTGAGTATTCCCCTTTCAAGGGAGGTTACACCAAAGG
GCTAGAAGGCGAGAGCCTAGGCTGCTCTGGCAGCGCTGCAGCAGGGAGCTCCGGGACACTTGAACTG
CCGTCTACCCTGTCTCTCTACAAGTCCGGAGCACTGGACGAGGCAGCTGCGTACCAGAGTCGCGACT
ACTACAACTTTCCACTGGCTCTGGCCGGACCGCCGCCCCCTCCGCCGCCTCCCCATCCCCACGCTCG
CATCAAGCTGGAGAACCCGCTGGACTACGGCAGCGCCTGGGCGGCTGCGGCGGCGCAGTGCCGCTAT
GGGGACCTGGCGAGCCTGCATGGCGCGGGTGCAGCGGGACCCGGTTCTGGGTCACCCTCAGCCGCCG
CTTCCTCATCCTGGCACACTCTCTTCACAGCCGAAGA 
 
Figure 2.1 The sequence of intron1 and exon1 of AR gene downloaded from 
http://www.ensembl.org . Underlined sequences are primers. Sequences that highlighted with dark 
gray are restriction sites of Hpa II, light gray are restriction sites of Rsa I, and italic sequences are 
polymorphic CAG repeat sites 
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2.4.3. Polyacrylamide gel electrophoresis (PAGE) 
 
Radioactively labeled PCR products were separated on 8% denaturing PAGE. 
Acrylamide:bisacrylamide solution (29:1) was mixed with 10XTAE and 8M urea 
was dissolved in this solution. TEMED and 10% Ammonium persulfate were added 
for polymerization. 5 µL of stop solution (95% formamide, 20 mM EDTA, 0.05% 
bromophenol blue, 0.05% xylene cyanol) was added into PCR products and 
denatured at 94°C for 5 min. and then put immediately on ice. 4µL from the 
denatured products were loaded and the gel was run at 60W for 4 hours. The gel was 
dried and autoradiographed on medical film CP-BU (Agfa, Mortsel, Belgium). Each 
hot product was confirmed on 4% MetaPhor agarose gel electrophoresis (FMC 
Bioproducts, Rockland, ME). 
Cold PCR products were resolved by using 8% PAGE. In order to prepare PAGE, 
30% acrylamide:bisacrylamide solution (29:1) was mixed with 10X TAE, 10 % 
Ammonium persulfate (APS), and TEMED.  10 µL from each sample was loaded 
and each gel was run at 15W for 2-4 hours according to the length of the gel. The 
gels were stained with EtBr for 10 min and destained in ddH2O for 5 min. 
Densitometric analysis of the bands were performed twice for each sample using the 
MultiAnalyst version 1.1 software. A corrected ratio (CrR) was calculated by 
dividing the ratio of the predigested sample (upper/lower allele) by the ratio of the 
non-predigested sample for normalization of the ratios that were obtained from the 
densitometric analyses. The use of CrR compensates for preferential amplification 
of the shorter allele when the number of PCR cycles increases (Delforge et al. 
1995). A skewed population is defined as a cell population with greater than 80% 
expression of one of the AR alleles. This corresponds to CrR values of <0.25 or >4. 
 
2.4.4. Statistical analyses 
 
The results from case and control groups were compared by χ2 test withYate’s 
Correction and Fisher’s Exact Test. In addition, odd’s ratio value for control and 
case groups were performed in 95% confidence interval. 
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2.5. Y CHROMOSOME STUDY 
 
Microchimerism was reported to be associated with scleroderma; therefore fetal 
microchimerism in the blood of women with scleroderma was analyzed. In this 
study Y chromosome specific sequences were analyzed by PCR described elsewhere 
(Kogan et al. 1987; Patri et al. 1994). The total volume of reactions was 15µL. 
Approximately, 60-100 ng of DNA was amplified with 6.0 pmol of each primers, 
0.2 mM of each dNTPs, 1X Taq polymerase buffer (750 mM Tris-HCl (pH 8.8 at 
25°C), 200 mM (NH4)2SO4, 0.1% (v/v) Tween 20), 1.0 mM MgCl2, 10% DMSO 
(dimethyl sufoxide) and 1 Unit Taq polymerase. The sequence of primers were:                
Y1(F): 5’-5'-TCCACTTTATTCCAGGCCTGTCC-3'; and  
Y2(R): 5'-TTGAATGGAATGGGAACGAATGG-3'  
 
 
2.6. HAPLOTYPE ANALYSIS OF AITDs FAMILY 
 
2.6.1. PCR 
 
It is determined that, the mother and the sister of the patient 04-445, whose XCI 
ratio was above 90%, were diagnosed with AITDs. Peripheral blood from all the 
members of the family (including the parents, affected and non-affected siblings) 
were obtained and DNA isolations were performed as indicated in section 2.3.1. In 
order to screen the X chromosome, Human MapPairs Version 10 was purchased 
from Research Genetics (currently available by Invitrogen, CA, USA) (Table 2.1). 
PCRs were performed in a total of 25 µL volume. 90-150 ng of DNA was amplified 
with 10 pmol of each primers, 0.6 mM of each dNTPs, 1X Taq polymerase buffer 
(750 mM Tris-HCl (pH 8.8 at 25°C), 200 mM (NH4)2SO4, 0.1% (v/v) Tween 20), 
1.5 mM MgCl2, 10% DMSO (dimethyl sufoxide) and 1 Unit Taq polymerase. PCR 
conditions were as follows: 94°C 5 min initial denaturation step was followed by 30 
cycles of 94°C 30 sec, 55°C 30 sec, 72°C 30 sec. amplification step. Final extension 
was performed at 72°C 5 min.  
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2.6.2. Denaturing PAGE and silver staining 
 
PCR products were separated on 6% denaturing-PAGE. The gel was prepared by 
mixing 25 gr urea, 10 mL acrylamide:bisacrylamide solution (38:2), 6mL TAE 
(10X), 300 µL APS (10%) and TEMED. Total volume of the gel was 60 mL. 
Amplicons were denatured at 95°C for 5 mins and put immediately on ice. 5 µL of 
stop solution was mixed with the PCR products and approximately 4 µL was loaded 
on the gel. The gel was run at 60W for 2-3 hours according to the size of the 
amplicons.  
Silver staining was performed according to the modifications of Bassam et al. First, 
the gel was incubated in fixation solution (10% glacial acetic acid) for 15 mins. 
Then it was washed with ddH2O and shaked in AgNO3 solution (0.1% AgNO3, 2.5 
mL formaldehyde (37%)) for 20 mins. Then the gel was incubated by shaking in 
developing solution (3% NaCO3, 1.5 mL formaldehyde (37%), 0.02% sodium 
thiosulfate) until the bands become visible. The gel was immediately put into 
fixation solution.  
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Table 2.1 Primers used in X-chromosome screening for haplotype analysis. 
CODE FORWARD (5’3’) REVERSE (5’3’) AMPLICON 
SIZE (bp) 
DXY218 GTCCTATGATTCATGATTG GGCTGAGCTTCCTACAGCA 164 
DXS1071 CCCAGATCGCNCCATT ATGGCTCTGAGGCGGG 234-254 
DXS9895 TTGGGTGGGGACACAGAG CCTGGCTCAAGGAATTACAA 140 
DXS8051 ACCAGAAATGAGCGATTATTG TTTTTGAACTAAGAACCTGGAG 145 
DXS8022 CTGTCACAGAAGTCCCATTTTA GGAAACTAATGCAGCATGTC 160 
DXS987 GTTGAGATAATGAGGCCAGT ACNTTAAAAGCCTGGTTCTTCTAAA 206-244 
DXS9902 TGGAGTCTCTGGGTGAAGAG CAGGAGTATGGGATCACCAG 182 
DXS8036 ATACAAACTGCCCCACTTCC CTCTGGNTCCTGTCCTGG 125-135 
DXS8019 TTCATTAAAAGCCGTCTTTG TGTTGAGTTTCCTCACAGC 156 
DXS999 GCTAACAACCTAGACTTCAACC CAGTTTCACAATCTCTGCC 260-276 
DXS7163 GACCATTATATNCGACTAACTTTTA AGCTTTGGTGCAGTTTTTG 240-254 
DXS6795 TGTCTGCTAATGAATGATTTGG CCATCCCCTAAACCTCTCAT 284 
DXS9896 CCAGCCTGGCTGTTAGAGTA ATATTCTTATATTCCATATGGCACA 195 
DXS8014 GGCAAAGTTGTCAGAGGC CAAATGGCTTGTTCCAGTT 265-283 
DXS6810 ACAGAAAACCTTTTGGGACC CCCAGCCCTGAATATTATCA 209 
GATA144D04 AGCCAGAAGGAGGAGGATTA ATCTTTCTGTACTTGCAGTGAGG 241 
DXS7132 AGCCCATTTTCATAATAAATCC AATCAGTGCTTTCTGTACTATTGG 284 
DXS6800 GTGGGACCTTGTGATTGTGT CTGGCTGACACTTAGGGAAA 206 
DXS6799 ATGAATTCAGAATTATCCTCATACC GAACCAACCTGCTTTTCTGA 252 
DXS9893 TGTCACGTTTACCCTGGAAC TATTCTTCTATCCAACCAACAGC 111 
GATA172D05 TAGTGGTGATGGTTGCACAG ATAATTGAAAGCCCGGATTC  
GATA165B12 TATGTATCATCAATCATCTATCCG TTAAAATCATTTTCACTGTGTATGC 133 
DXS8078 TGCATCCCCATAGTAATTGGT CAAATGGCAGGATTTCCC 202 
GATA31E08 AGGGGAGAAGGCTAGAATGA CAGCTGACAGAGCACAGAGA 248 
DXS998 CAGCAATTTTTCAAAGGC AGATCATTCATATAACCTCAAAAGA 113-119 
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2.7. CHEMICALS, REAGENTS AND ENZYMES 
 
2.7.1. Enzymes 
 
All the restriction digestion enzymes and Thermus aquaticus polymerase enzymes 
were purchased from MBI Fermentas (Amherst, NY, USA). 
 
 
2.7.2. Thermal Cyclers 
 
For PCR reactions, the thermal cycler The GeneAmp System 9600 and 2400 
(Perkin-Elmer, USA) were used. 
 
 
2.7.3. Standard solutions and buffers 
 
1X TAE (Tris-acetic acid-EDTA):  40mM Tris-acetate,  
2 nM EDTA, pH 8.0 
 
Ethidium bromide:     10mg/ml in water (stock solution) 
30 ng/ml (working solution) 
 
Agarose gel loading buffer (6X):   15% ficoll 
0.05% bromophenol 
0.05% xylene cyanol 
 
Acrylamide:bisacrylamide (30%):   29.5 gr acrylamide 
0.44 gr bisacrylamide 
100 ml with ddH2O 
 
Phosphate buffered saline (10XPBS): per liter: 80 g NaCl, 2 g KCl, 14.4 g 
Na2HPO4, 2.4 g KH2PO4, pH: 7.4  
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2.7.4. Chemicals and reagents 
 
Table 2.2 List of chemicals and reagents used in this study 
 
Reagent or Chemical Company 
Agarose Basica LE, EU 
Acetic acid Sigma, St Lois, MO, USA 
Acrylamide Sigma, St Lois, MO, USA 
Ammonium persulfate Carlo Elba, Milano, Italy 
Bisacrylamide Sigma, St Lois, MO, USA 
Bromophenol blue Sigma, St Lois, MO, USA 
Chelex 100 BioRad, CA, USA 
dNTPs MBI Fermentas, Amherst, NY, USA 
DMSO Sigma, St Lois, MO, USA 
Nucleospin® Blood Kit Macherey-Nagel Duren, Germany 
EDTA Carlo Elba, Milano, Italy 
Ethanol Merck, Frankfurt, Germany 
Ethidium bromide Sigma, St Lois, MO, USA 
Formaldehyde Sigma, St Lois, MO, USA 
MetaPhor FMC Bioproducts, Rockland, ME 
pUC Mix 8 (DNA size marker) MBI Fermentas, Amherst, NY, USA 
TEMED Sigma, St Lois, MO, USA 
Tris-Base Bio-Rad, CA, USA 
Urea Sigma, St Lois, MO, USA 
 
 
2.7.5. Oligonucleotides 
 
Primers were purchased from Iontek (Istanbul, Turkey). Only the primers that were 
used for haplotype analysis, Human MapPairs Version 10 was purchased from 
Research Genetics (currently available by Invitrogen, CA, USA) 
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CHAPTER 3 
 
 
RESULTS 
 
 
3.1. ADULT SAMPLES 
 
Only the samples whose alleles were adequately resolved were labeled as 
‘informative’. Extremely skewed XCI was described as the inactivation of one allele 
more than 90%. If one of the alleles was preferentially inactivated more than 80%, 
the XCI pattern was named as ‘skewed’.  
 
 
3.1.1. PCR-based X inactivation study of peripheral blood of Turkish control 
samples 
 
Among 160 controls, 124 were informative at AR locus. This number represents 
77.5% of the control population. 10 of 124 informative control cases displayed 
skewed XCI (8.1%). Only 3 of 124 informative control women display extremely 
skewed XCI pattern (2.4%). It was well documented that extremely skewed XCI is a 
rare event in various group of control females (Busque et al. 1996, Sharp et al. 
2000, Amos-Landgraf et al. 2006). Our results are consistent with these previous 
reports. 
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3.1.2.1 PCR-based X inactivation study of peripheral blood of Turkish scleroderma 
patients 
 
XCI status was informative in 55 of 70 SSc patients (78.6%). Among informative 
patients, skewed XCI was observed in 35 of the 55 informative patients (63.6%), 
while in 10 of 124 control women (8.1%). Extremely skewed XCI ratio was 
observed in 27 of 55 informative patients (49.1%) and in 3 of 124 control women 
(2.4%) (P<0.0001 for both patterns). Odds ratio for skewed pattern of XCI was 
calculated as 20.0 with 95% confidence interval (CI) between 8.5 and 46.6. 
Considering only the extremely skewed pattern, the odds ratio was calculated as 
38.9 (95% CI= 11.0-137.3). A representative gel image is displayed on Figure 3.1. 
Since the data for SSc patients is bimodal, the distribution of XCI profiles according 
to age was plotted (Figure 3.2). A shift toward the skewed range in older patients 
and controls was not observed.  
 
 
 
               
 
Figure 3.1 Gel image of XCI patterns of 3 scleroderma patients. Polymerase chain reaction products 
from the androgen receptor methylation assay demonstrate extremely skewed X chromosome 
inactivation patterns in samples. For each sample, DNA was either undigested (-) or digested (+) with 
the methylation-sensitive restriction enzyme Hpa II. Marker (M; pUC mix 8 [331-bp and 242-bp]) 
fragments are visible.  
 
 
 
 
 
 
             M     03-880            03-962            03-900            m     
Hpa II                 -       +            -         +            -          +        
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Figure 3.2 Distribution of X inactivation patterns according to age in scleroderma patients and 
control subjects. 
 
 
 
 
 
 
3.1.2.2 PCR-based X inactivation study of skin biopsy, buccal mucosa, and hair 
follicle samples of Turkish scleroderma patients 
 
From the patients whose XCI pattern of blood cells was above 90%, skin biopsy, 
buccal wash and hair samples were obtained in order to compare the XCI patterns of 
affected tissue and various tissue types from different embryonic cell lineages. Skin 
biopsy samples were obtained from the site of clinically detectable cutaneous 
changes in 5 patients (03-894, 03-899, 03-956, 03-963, and 03-1101). Buccal 
mucosa and hair follicle specimens were also collected from the same patients, 
excluding the patients 03-963. The skin biopsy, buccal mucosa, and hair follicle 
samples revealed random XCI pattern in all patients analyzed. The only exception 
was the XCI profile of buccal mucosa of 03-894 (Table 3.1). The gel image of blood 
and skin biopsy samples were represented in Figure 3.3. 
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Table 3.1 Blood, skin biopsy, buccal mucosa, and hair follicle XCI patterns of five 
Turkish SSc patients 
 
Sample 03-894 03-899 03-956 03-963 03-1101 
Blood 98:2 96:4 95:5 95:5 95:5 
Skin biopsy 51:49 53:47 51:49 65:35 55:45 
Buccal mucosa 95:5 71:29 57:43 - 65:35 
Hair follicle 68:32 55:45 61:39 - 54:46 
 
 
 
 
 
 
 
                            
Figure 3.3. Skewed X chromosome inactivation in samples. Polymerase chain reaction products of 
undigested ( ) (lane 1) and Hpa II–digested (+) DNA from blood (lane 2) and skin biopsy samples 
(lane3) of patients 03-894, 03-899, and 03-1101 are shown. 
 
 
 
 
3.1.2.3 Pregnancy history and Y chromosome analysis 
 
Clinical characteristics of the informative patients were displayed on Table 3.2. 
Since microchimerism in the blood of scleroderma patients was reported, Y 
chromosome sequences were investigated in the blood of scleroderma patients and 
control subjects. This analysis was performed in all patients without prior 
knowledge of the pregnancy history of the individuals. Among 39 patients who were 
                1                  2       3 
    HpaII          -                  +       + 
03-894 
 
03-899 
 
03-1101 
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known to have at least one son Y chromosome specific DNA was detected in 16 
patients (41%). No history of pregnancy was in 23 patients. In the control group 31 
women were known to have at least one son and the Y chromosome specific 
sequence was detected only 2 of them (6.5%) (P=0.0026). The results of Y 
chromosome specific sequence analysis were summarized in Table 3.3. Difference 
in persistence of fetal DNA in peripheral blood of patients and control group is 
statistically significant and consistent with the previous reports (Nelson et al. 1998, 
Artlett et al. 1998). However, distribution of Y chromosome specific DNA was not 
significantly different between the women with skewed and random XCI 
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Table 3.2 Clinical characteristics of Turkish SSc patients with skewed XCI. 
No Code DOB YDO PH Sex and birth year of children 
>90% skewing 
1 03-894 1945  1989  G0, P0 - 
2 03-963 1938  1998  G0, P0 - 
3  03-879  1966  1991  G0, P0 - 
4  03-1123 1950  1990  G0, P0  - 
5 03-951  1986  2003  G0, P0  - 
6  03-881  1971  1990  G0, P0  - 
7 03-892  1965  1993  G0, P0  - 
8  03-1112  1963  1997  GII, PI  F 1998 
9  03-899  1953  1998  GI, PI  F 1977 
10 03-948  1959  1989  GII, PII  M 1971, M 1975 
11 03-954  1965  2000  GII, PII  M 1998, F 1999 
12 03-886  1960  1994  GII, PII  M 1986, F 1989 
13 03-1120  1950  1983  GII, PII  M 1970, F 1973 
14 03-890  1956  1989  GII, PII  M 1989, F 1992 
15 03-895  1941  1984  GIV, PII  M 1959, F 1969 
16 03-880  1967  2002  GII, PII  F 1987, M 1990 
17 03-888  1952  1996  GII, PII  M 1973, F 1977 
18  03-962  1946  1993  GIII, PIII  F 1968, F 1970, M 1973 
19 03-878  1945  2000  GIII, PIII  F 1968, F 1971, M 1977 
20 03-893  1936  1984  GIX, PIV  F 1953, M 1954, F 1956, M 1962 
21 03-1110  1932  1993  GVI, PIV  F 1952, F 1954, M 1962, M 1964 
22 03-956  1956  2001  GV, PIV  F 1973, F 1975, M 1977, M 1980 
23 03-953  1941  1995  GIV, PIV  M 1967, M 1969, F 1974, F 1976 
24  03-884  1938  1994  GVI, PIV  M 1965, M 1969, F 1973, F 1975 
25 03-900  1940  1984  GVII, PV  M 1955, F 1960, F 1962, M 1966, M 1974 
26 03-1101  1941  1993  GV, PV  F 1957, F 1959, M 1963, M 1968, M 1969 
27 03-952  1938  1984  GVI, PV  M 1960, M 1964, F 1969, F 1971, F 1973 
80–90% skewing 
1 03-877  1954  1999  GII, P0  - 
2  03-1104  1956  1983  G0, P0  - 
3  03-949  1975  2000  G0, P0  - 
4 03-1128  1983  2002  G0, P0  - 
5 03-943  1942  1999  GII, PII  M 1965, M 1969 
6  03-950  1936  1982  GIV, PIV  M 1953; M 1955, M 1964, F 1969 
7 03-1122  1949  1993  GVIII, PV  M 1966, F 1968, M 1970, M 1978, F 1982 
8 03-885  1933  1993  GVII, PVII  F 1960, F 1961, F 1963, F 1964, F 1966, M 1968, M 1971 
60-69% skewing 
1 03-1113 1965 1994 GVI, PV M 1990, F 1991, M 1992, F 1996, M 1998 
2 03-1126 1951 1993 G0, P0 - 
3 03-958 1976 1993 G0, P0 - 
4 03-957 1970 1991 G0. P0 - 
5 03-1111 1952 1991 G2, P2 M 1980, M 1983 
50-59% skewing 
1 03-1114 1967 1995 G3, P3 M 1996, F 2000, M 2001  
2 03-1132 1977 1993 G1, P1 F 2002 
3 03-947 1961 1988 G0, P0 - 
4 03-1115 1961 1989 G3, P2 M 1986, F 1991 
5 03-1118 1966 2000 G5, P4 F 1980, M 1985, F 1989, M 1995  
6 03-1131 1929 1999 G0, P0 - 
7 03-944 1945 1987 G7, P6 M 1963, M 1969, M 1972, F ? 
8 03-955 1947 1996 G3, P2 M 1969, F 1973 
9 03-887 1946 1989 G2, P2 M 1965, M 1969 
10 03-1103 1940 1993 G2, P2 M 1961, F 1966 
11 03-945 1979 2003 G1, P0 M 2000 
12 03-898 1967 1998 G0, P0 - 
13 03-1117 1956 2001 G1, P1 F 1990 
14 03-1125 1940 1978 G2, P2 M 1962, F 1965 
15 03-1127 1967 2000 G0, P0 - 
DOB: Date of Birth, YDO: Year of Disease Onset, PH: Pregnancy History, G:Gravida, P: Para, F: 
female, M: male.  
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Table 3.3 Distribution of Y chromosome sequences in Turkish SSc patients and 
controls who gave birth to male children 
 
Gorup Positive no (%) Negative no (%) Total no 
SSc patients 16 (41.0) 23  (59.0) 39 
   Skewed XCI 9   (40.9) 13  (59.1) 22 
   Random XCI 4   (36.4) 7    (63.6) 11 
Control females 2   (6.5) 29  (93.6) 31 
   Skewed XCI 1   (25.0) 3    (75.0) 4 
   Random XCI 1   (4.16) 23  (95.8) 24 
 
 
 
 
3.1.3.1. PCR-based X inactivation study of peripheral blood of US scleroderma 
patients 
 
Among 125 Scleroderma patients, 94 were informative (75.2%). Extremely skewed 
ratio was observed in 17 of 94 informative patients (18.1%). When these results 
were compared with Turkish control group, the ratio was 2.4% (only 3 samples in 
124 informative controls). One of the representative gel images is depicted in Figure 
3.4.  
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Figure 3.4 Gel image of XCI patterns of 6 US scleroderma patients. Polymerase chain reaction 
products from the androgen receptor methylation assay demonstrate X chromosome inactivation 
patterns in samples SAP13A (allele ratio:78%:22%), SAP30A (not informative), SAP44A 
(52%:48%), SAP61A (100%:0%), SAP75A (not informative), and SAP121A (88%12%). For each 
sample, DNA was either undigested (-) or digested (+) with the methylation-sensitive restriction 
enzyme Hpa II. Marker (M; pUC mix 8 [only 242-bp]) fragment is visible.  
 
 
 
These results are statistically significant, since P<0.0001 and odds ratio=8.9 (95%CI 
is between 2.5 and 30.6). If skewed XCI pattern was taken into account, the skewing 
ratio was observed in 32 of 94 informative patients, yet only in 10 of 124 
informative control (34.0% and 8.1% respectively) (P<0.0001) (odds ratio=5.9, CI 
95%=2.7-12.8). These results were consistent with the results of Turkish 
scleroderma patients. XCI patterns of US and Turkish patients and their combined 
results were indicated in Table 3.4. 
 
 
 
Table 3.4 Proportions of scleroderma patients and controls with skewed XCI. 
 
 No. (%) observed with skewing 
 US SSc patients TR SSc patients Combined Control 
Degree of skewing 
(%) 
(n=94) (n=55) (n=149) (n=124) 
+90 17 (18.1%) 27 (49.1%) 44 (29.5%) 3 (2.4%) 
80-89 15 (16.0%)   8 (14.5%) 23 (15.4%) 7 (5.6%) 
70-79 15 (16.0%) 0 (0.0%) 15 (10.1%) 22 (17.7%) 
60-69 24 (25.5%) 5 (9.1%) 29 (19.5%) 29 (23.4%) 
50-59 23 (24.5%) 15 (27.3%) 38 (25.5%) 63 (50.8%) 
For comparison by χ2, P<0.0001(both >80% skewing and >90% skewing) 
 
 
             M   SAP13A     SAP30A    SAP44A    SAP61A   SAP75A     SAP121A  
Hpa II             -       +        -      +        -       +       -      +         -      +         -       + 
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3.1.3.2. PCR-based X inactivation study of peripheral blood of US scleroderma 
patient-mother pairs 
 
To determine the parental origin of inactive X chromosome, 19 patients with skewed 
XCI profile for whom maternal DNA was available were analyzed. 10 in 19 patient-
mother pairs were informative for the AR gene polymorphism. In the remaining 9 
pair both the patients and their mothers were heterozygous for the AR gene 
polymorphism however no difference between allele sizes was observed. By this 
way it was not possible to determine the parental origin of inactive X chromosome. 
In 10 informative mother-daughter pairs, the inactive X chromosome was maternal 
origin in 8 patients and paternal origin in 2 patients (P=0.055). This result is on the 
border of statistical significance. Unfortunately the number of available samples 
from patient-mother pairs is small. XCI pattern was skewed in 3 mothers of patients 
(Table 3.5). Interestingly, the same allele was skewed in both the mothers and 
daughters. One of these mothers had been diagnosed with temporal arteritis, which 
is an autoimmune condition. 
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Table 3.5 Parental origin of the inactive X chromosome in SSc 
patients with skewed XCI 
 
Sample Degree of skewing Parental origin of the 
inactive X chromosome 
Patient 1  95 Maternal 
Mother 1  95  
   
Patient 2  95 Maternal 
Mother 2 95  
   
Patient 3 86 Maternal 
Mother 3 88  
   
Patient 4 100 Maternal 
Mother 4 Not informative  
   
Patient 5 90 Maternal 
Mother 5 Not informative  
   
Patient 6 90 Maternal 
Mother 6 Not informative  
   
Patient 7 85 Maternal 
Mother 7 67  
   
Patient 8 85 Maternal 
Mother 8 58  
   
Patient 9 85 Paternal 
Mother 9 70  
   
Patient 10 80 Paternal 
Mother 10 70  
 
 
 
3.1.3.3. Evaluation of skewed XCI for correlation with microchimerism 
 
Pregnancy-related microchimerism has been reported in scleroderma (Artlett et al. 
1998, Nelson et al.1998). Therefore US patients for whom microchimerism data was 
available were investigated for correlation of skewed XCI with fetal and maternal 
microchimerism.  Among the patients with skewed XCI pattern, 12 patients were 
tested for maternal microchimerism (MMc), 14 patients were tested for fetal 
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microchimerism (FMc). Positive MMc was observed in 7 of the 12 skewed patients 
(58.3%), and positive FMc was observed in 8 of the 14 skewed patients (57.1%) 
(Table 3.6). Same analyses were performed for patients with random XCI pattern. 
Among 15 patients, 10 of them were positive for MMc (66.7%), and 14 of 25 
patients were positive for FMc (56.0%) (P=1.0). Neither maternal nor fetal 
microchimerism was found to be correlated with skewed XCI pattern. 
 
 
 
Table 3.6 Proportion of maternal (MMc) and fetal (FMc) microchimerism in US 
SSc patients 
    MMc                                                          FMc 
Skewed 
(>80 %) 
 
12 tested 58.3% 
positive for 
MMc 
Skewed 
(>80 %) 
14 tested 57.1% 
positive for 
FMc 
 
7 positive  
 
8 positive  
 
5 negative  
 
6 negative  
Random 
(<80 %) 
15 tested 66.7% 
positive for 
MMc 
Random 
(<80 %) 
25 tested 56.0% 
positive for 
FMc 
 
10 positive  
 
14 positive  
 5 negative  
 
11 negative   
 
 
 
 
3.1.4.1. PCR-based X inactivation study of peripheral blood of Turkish autoimmune 
thyroid diseases patients 
 
XCI results were informative in 83 of the 110 AITDs patients (75.5%). Skewed XCI 
was observed in 28 of 83 informative patients (33.80%). Extremely skewed XCI 
was found in 16 of 83 informative patients (19.3%). When the results of AITDs 
patients were compared with the results of Turkish control group, a significant 
difference was observed (P<0.0001 for both type of patterns) (Table 3.7). Odds ratio 
is 5.8 (95% CI=2.6-12.8) for skewed XCI and 9.6 (95%CI=2.7-34.3) for extremely 
skewed XCI. When the XCI profiles of patients diagnosed with Hashimoto’s and 
Grave’s diseases- were analyzed independently, the difference in XCI patterns 
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between patients and controls was still statistically significant. In 23 of 67 
informative Hashimoto’s patients (34.3%; P<0.0001) and 5 of 16 informative 
Graves’ patients (31.3%; P=0.0167) skewed XCI was observed. The data in Turkish 
AITDs patients is bimodal, therefore a distribution of the XCI profiles according to 
age was plotted. However, a shift towards the skewed range in older patients and 
controls was not observed (Figure 3.5). 
 
 
 
Table 3.7 Proportion of Turkish AITDs patients and controls with skewed XCI 
 
Degree of 
skewing (%) 
No. (%) observed with skewing 
AITDs patients Control 
(n=83) (n=124) 
+90 16 (19.3%)                 3  (2.4%) 
80-89 12 (14.5%) 7  (5.6%) 
70-79 6  (7.22%) 22 (17.8%) 
60-69 16 (19.3%) 29 (23.4%) 
50-59 33 (39.8%) 63 (50.8%) 
For comparison by χ2, P<0.0001(both >80% skewing and >90% skewing) 
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Figure 3.5 Distribution of X-inactivation patterns according to age in AITDs patients and control 
subjects. 
 
 
 
3.1.4.2. PCR-based X inactivation study of thyroid biopsy, buccal mucosa, and hair 
follicle samples of Turkish autoimmune thyroid diseases patients 
 
In order to analyze the XCI profile of affected tissue, thyroid biopsy specimen in 
this case, and other tissue types, DNA from buccal mucosa, thyroid biopsy, and hair 
follicle were obtained from five patients (04-121, 04-198, 04-214, 04-221, and 04-
225). These patients were randomly selected. Their blood XCI profile displayed 
skewed XCI (Figure 3.6). Five patients displayed skewing in the same direction for 
thyroid biopsy and buccal mucosa. The skewing was less marked in the thyroid than 
in blood and buccal mucosa cells. Hair follicles showed random XCI pattern in all 
patients that were analyzed (Table 3.8).  
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Figure 3.6 X- inactivation analysis of androgen receptor locus in five AITDs patients. PCR products 
of undigested (-) and Hpa II digested (+) DNA from peripheral blood, thyroid biopsy, buccal mucosa, 
and hair follicle samples were depicted.  
 
 
 
 
 
 
 
 
 
 
                  M      Blood                Thy. biopsy     Buccal             Hair               m       
Hpa II                      -            +          -          +           -           +         -          +        
 
04-121 
 
 
 
 
 
04-198 
 
 
 
 
 
04-214 
 
 
 
 
 
04-221 
 
 
 
 
 
04-225 
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Table 3.8 Blood, thyroid biopsy, buccal mucosa, and hair follicle XCI patterns of 
five Turkish AITDs patients 
 
Sample 04-121 04-198 04-214 04-221 04-225 
Blood 94:6 91:9 84:16 92:8 91:9 
Thyroid 72:28 79:21 76:24 74:26 64:36 
Buccal 86:14 97:3 87:13 89:11 82:18 
Hair 60:40 50:50 (-) 59:41 52:48 
 
 
 
3.1.4.3. Pregnancy history and pedigree analysis 
 
Characteristics of informative AITDs patients were displayed in Table 3.9. Only the 
patients with a complete pregnancy and family history were included. There were 
two features that differ in the pedigrees of AITDs patients with skewed and random 
XCI. The first one was recurrent spontaneous abortion (RSA) which is defined as 
three or more pregnancy losses. It was reported that RSA has been associated with 
skewed XCI (Sangha et al. 1999, Pegoraro et al. 1997). In 4 of 25 (16%) AITDs 
patients with skewed XCI, RSA was occurred, whereas a history of RSA was 
negative for both AITDs patients with random XCI and control women (P=0.0199). 
The etiology of RSA in AITDs is still unknown, however two-four fold of increase 
in the miscarriages were reported in the first trimester of pregnancy of women with 
thyroid antibodies (Stagnaro-Green&Glinoer 2004, Prummel&Wiersinga 2004). The 
second feature was the positive family history which was present in 12 of the 25 
(48%) probands with skewed XCI and in 10 of 39 (25.6%) patients with random 
XCI. In order to extent the XCI study in the family members contact was set up with 
all of the 12 probands. Initially, a positive response was received from 3 families, 
however only the blood samples from the family members of two probands could be 
obtained (04-445; proband of family 1 and 04-298; proband of family 2).   In both 
families, only the affected individuals displayed skewed XCI patterns and the 
nonaffected members display random XCI pattern. In family 1, the inactive X 
chromosome is of maternal origin. In family 2, the XCI pattern of the affected sister 
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of proband 04-298 was skewed however; her mother was not informative for the AR 
polymorphism and the inactive X chromosome was of paternal origin. Therefore, 
only the members of family 1 were investigated for haplotype analysis. 
 
 
 
 
Table 3.9 Clinical characteristics and XCI status of Turkish AITD patients 
 
No Patient SOD DOB OOD PH S&BDOC FH 
+90% skewing 
1 04-136 GD 1975 2004 G0, P0, A0  -  - 
2 04-127 HT 1975 2003 G0, P0, A0  -  - 
3 04-138 HT 1962 1980 G7, P0, A7  - 2 sisters 
4 04-298 HT 1979 2003 G1, P1, A0 F03 Mother, 1 sister 
5 04-445 HT 1961 2000 G1, P1, A0 F88 Mother, 1 sister 
6 04-198 HT 1935 2004 G2, P2, A0 M68, M72  - 
7 04-221 HT 1958 2000 G4, P2, A2 M91, F94 2 sisters 
8 04-250 HT 1967 1996 G7, P2, A5 M89, M93 1 son 
9 04-226 HT 1963 2004 G3, P3, A0 M83, F88, M98 1 sister 
10 04-233 GD 1967 1990 G4, P3, A1 M88, F94, M01  - 
11 04-121 HT 1957 1988 G7, P4, A3 F78, M83, F91, F94  - 
12 04-205 HT 1927 2003 G6, P5, A1 M47, M50, F52, F53, M55  - 
13 04-225 HT 1936 1975 G6, P6, A0 F56, F58, F60, F62, M64, M66 1 daughter 
80-89% skewing 
14 04-132 HT 1960 2002 G0, P0, A0  - Mother, 1 sister 
15 04-223 HT 1956 1988 G0, P0, A0  - Mother, 1 sister 
16 04-105 GD 1978 1999 G5, P1, A4 M98  - 
17 04-131 HT 1944 2002 G3, P2, A0 M69, M71  - 
18 04-120 HT 1956 1994 G3, P3, A0 F75, M77, F78  - 
19 04-107 HT 1948 1998 G4, P3, A1 F70, F72, F76  - 
20 04-98 HT 1956 2000 G8, P3, A1 F79, F81, F87 2 daughters 
21 04-218 HT 1941 1991 G4, P3, A1 M61, F63, F67  - 
22 04-108 HT 1952 1999 G5, P3, A2 F77, F78, M83  - 
23 04-208 HT 1960 1999 G5, P3, A0 F83, F85, M88 Mother  
24 04-110 GD 1960 1998 G4, P4, A0 M80, M83, M85, F96  - 
25 04-214 HT 1921 1999 G9, P8, A1 F44, M45, F47, F48, M54, F56, F58, M60 1 daughter 
70-79% skewing 
26 04-203 HT 1961 2004 G3, P1, A0 M82  - 
27 04-230 HT 1951 1999 G2, P2, A0 M77, M86 1 son 
28 04-213 HT 1947 1998 G7, P3, A0 F67, M68, M71  - 
29 04-228 HT 1953 2001 G3, P3, A0 M71, M73, M82  - 
30 04-137 HT 1932 1981 G5, P4, A0 F50, F53, M55, F59  - 
60-69% skewing 
31 04-206 GD 1946 1964 G1, P0, A1  -  - 
32 04-92 HT 1971 1998 G3, P1, A0 F96 Mother  
33 04-240 HT 1975 2003 G2, P1, A0 M00  - 
34 04-139 HT 1959 2002 G1, P1, A0 M97  - 
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35 04-257 HT 1973 2004 G3, P2, A1 M95, M01  - 
36 04-112 HT 1952 1999 G2, P2, A0 F72, F77 Mother  
37 04-220 GD 1955 1998 G3, P2, A0 M74, M78  - 
38 04-103 HT 1962 1986 G6, P2, A1 F82, M92  - 
39 04-251 HT 1941 1984 G5, P3, A2 M60, M63, M65 2 sisters 
40 04-99 HT 1961 1997 G6, P3, A2 F81, F85, F87 Mother, 1 sister 
41 04-224 GD 1950 2001 G6, P5, A1 M69, M72, F73, M75, F78  - 
50-59% skewing 
42 04-96 HT 1939 1996 G0, P0, A0  -  - 
43 04-242 HT 1960 1999 G0, P0, A0  -  - 
44 04-129 HT 1982 1998 G0, P0, A0  - Mother  
45 04-196 HT 1956 1999 G6, P1, A0 F93  - 
46 04-231 HT 1964 2003 G1, P1, A0 M93  - 
47 04-201 GD 1971 2001 G2, P1, A1 F93 Mother  
48 04-95 HT 1975 2004 G3, P2, A0 F98, M00  - 
49 04-239 HT 1951 2003 G3, P2, A0 M68, M75  - 
50 04-246 HT 1961 1996 G2, P2, A0 M78, F81  - 
51 04-200 HT 1954 1992 G5, P2, A0 M73, M75 3 sisters 
52 04-237 HT 1970 2004 G2, P2, A0 M93, F97  - 
53 04-102 HT 1964 2003 G3, P2, A1 F95, F87  - 
54 04-204 HT 1949 2002 G4, P2 A0 F71, M73  - 
55 04-93 GD 1960 2003 G2, P2, A0 M91, F94  - 
56 04-116 GD 1960 2003 G4, P2, A0 F86, M89 1 brother 
57 04-197 HT 1961 1976 G6, P3, A2 M82, M84, M98  - 
58 04-229 HT 1938 1980 G3, P3, A0 M61, M63, F65 1 sister 
59 04-255 HT 1974 1993 G3, P3, A0 F92, M96, F01  - 
60 04-212 GD 1958 2002 G4, P3, A0 M76, F80, M84  - 
61 04-238 HT 1939 2002 G6, P4, A0 M61, M65, F67, M72  - 
62 04-117 HT 1944 2004 G6, P4, A0 M60, M64, F66, F67  - 
63 04-211 GD 1950 2002 G6, P6, A0 F66, F67, F72, M84, M85, M86  - 
64 04-243 GD 1937 1994 G12, P7, A1 M57, M59, F60, F62, M65, M67, F68  - 
 
SOD: state of disease, DOB: date of birth, OOD: onset of disease, PH: pregnancy history, S&BDOC: 
sex and birth date of children, FH: family history, HT: Hashimoto’s thyroiditis, GD: Grave’s disease, 
G: gravida, P: para; A: abortion, M: male, F: female 
 
 
 
3.1.4.4. Haplotype analysis  
 
Haplotype analysis was performed in the members of family 1 by using 
polymorphic X-chromosomal markers to determine possible segregation between 
the disease and marker alleles because XCI segregated as a heritable trait associated 
with AITDs in two generations. The image of haplotype structure was displayed in 
Figure 3.7. The size of the family was not large enough to prove linkage yet it still 
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provided valuable information about the exclusion area on X chromosome. A 
minimal critical region on X chromosome might be associated with AITDs. Xp11-
q13 (GATA144DO4, DXS7132, and AR) and Xp22 DNA markers (DXS8022, 
DXS987, and DX9902) showed concordance among the affected individuals and 
discordance among the nonaffected individuals indicating positive segregation 
between the disease and marker alleles. Unfortunately, Formal acceptance of linkage 
to any loci could not be achieved mainly due to the small size of the family 
(Abecasis. et al. 2002).   
The genes located on the mininmal critical regions were listed. BioMart tool 
(http://www.ensembl.org) was used to list the candidate genes. Only the known 
protein coding genes were included in this analysis. In the region between the 
markers DXS8051 and DXS8036 on Xp22 48 known protein coding genes were 
listed.  183 genes were listed in the region between the marker DXS8014 and the AR 
gene on Xp11-q13. Among these candidate genes listed the ones that code proteins 
with antigenic property were searched. A variety number of genes that encode 
proteins that belong to cancer-testis antigen (XAGE, GAGE, SSX) and melanoma 
antigen (MAGE) family were present on only Xp11-q13 region. The MAGE gene 
encoded proteins are members of cancer-testis antigen group. They are reported to 
be potential targets for tumor immunotherapy (Scanlan et al. 2004). Interestingly, 
Forkhead Box P3 (FOXP3) a member of forkhead/winged-helix family of 
transcriptional regulators. A frameshift mutation in Foxp3 gene results failure of 
coding the protein lacking the forkhead domain. Brunkow et al. (2001) reported that 
defective Foxp3 was present in ‘scurfy’ (sf) mice and this gene is essential for 
normal immune homeostatis. Marson et al. (2007) reported that many of the target 
proteins of FOXP3 suppress the activation of target genes on T cell stimulation. 
Suppression of target genes of FOXP3 was reported for the normal function of 
regulatory T cells since the overexpression of these target genes were to be 
documented to be associated with autoimmune diseases. An arg397-to-trp mutation 
in the FOXP3 gene was to be reported to be the cause of immunodysregulation, 
polyendocrinopathy, and enteropathy, X-linked (IPEX) syndrome (Wildin et al. 
2001). 
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Figure 3.7 Haplotype structure of AITDs Family. Patient 04-445 was arbitrarily selected to construct 
the haplotype. Maternally inherited haplotype was highlighted with solid black bar. Haplotypes of the 
remaining sibs were compared with the reference individual (04-445), and shared portions were also 
marked with solid bars. Noninformativeness in the crossover regions were demonstrated with thin 
bars. The regions between the DNA markers DXS8051 and DXS8036 as well as DXS8014 and AR 
regions on Xp22 and Xp11-q13 regions, respectively, were not excluded since positive segregation 
between the disease and marker alleles was observed. 
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3.1.5. PCR-based X inactivation study of peripheral blood of Tunisian autoimmune 
thyroid diseases patients 
 
Informative XCI pattern was observed in 100 of 145 AITDs patients (69.0%).  
Extremely skewed XCI was observed in 14 of 100 informative patients (14.0%). 
The same pattern was observed in 4 of 46 informative Tunisian controls (8.7%). 
Since the number of informative control individuals was not enough (n=46), the 
Turkish and Tunisian control samples were combined and XCI results of Tunisian 
patients were compared with this combined group (n=170). Extremely skewed XCI 
was observed in 7 of the 170 (4.1%) informative controls in combined cohort 
(P=0.0046, odds ratio=3.8 with 95%CI between 1.5 and 9.8). Skewed XCI was 
present in 26 of 100 informative patients (26.0%) while in 19 of 170 informative 
controls (11.2%). These results were statistically significant (P=0.0022; OR:2.8, 
95%CI=1.5-5.4), and were concordant with XCI results of Turkish AITDs patients. 
Representative gel image of XCI pattern of Tunisian AITDs patients was displayed 
in Figure 3.8. 
 
 
       
       
      
 
Figure 3.8 Gel image of XCI patterns of 6 Tunisian AITDs patients. Polymerase chain reaction 
products from the androgen receptor methylation assay demonstrate X chromosome inactivation 
patterns in samples AITDs 8 (allele ratio: not informative), AITDs 15 (not informative), AITDs 16 
(78%:22%), AITDs 17 (68%:32%), AITDs 18 (not informative), and AITDs 20 (90%10%). For each 
sample, DNA was either undigested (-) or digested (+) with the methylation-sensitive restriction 
enzyme Hpa II. Marker (M; pUC mix 8 [331-bp and 242-bp]) fragment is visible.  
 
 
 
 
             M     AITDs 8          AITDs 15      AITDs 16      AITDs 17       AITDs 18        AITDs 20     0    
Hpa II              -          +          -         +          -         +          -         +          -          +          -          + 
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Tunisian AITDs patients were categorized according to their clinical phenotype. 
Among 100 informative AITDs patients, 46 were positive and 54 were negative for 
thyroid autoantibody status. Skewed XCI in those patients (elevated anti-
thyroglobulin and/or anti-thyroid peroxydase) was 39.1% (18 of 46) (P=0.01). The 
frequency of extremely skewed XCI was 21.7% (10 of 46) (P=0.03). When the 
patients who were negative for thyroid autoantibodies in their blood were 
considered, the skewed XCI pattern was observed in 8 of 54 informative subjects 
(14.8%, P=0.48) and extremely skewed XCI was observed in 4 of 54 informative 
patients (P=0.3). These results indicated that in the subgroup of patients who had 
elevated anti-thyroglobulin and/or anti-thyroid peroxydase in their blood skewed 
there might be association between the disease and XCI. The results of skewed XCI 
in AITDs patients, and control subjects are summarized in Table 3.10 according to 
the autoantibodies they contain in serum. Subdividing according to the clinical 
phenotype of AITDs patients with positive autoantibodies revealed that the 
frequency of skewed XCI was 38.8% (7 of 18) in GD, 40% (4 of 10) in PIM and 
38.8% (7 of 18) in HT. These results were not significantly different from the 
female controls (P=0.05, P=0.09 and P=0.05) respectively.  
 
 
 
Table 3.10 Correlation of XCI patterns and thyroid autoantibodies in Tunisian 
AITDs patients 
 
Degree of 
skewing 
(%) 
No. (%) observed with skewed 
Autoantibodies (+) 
(n = 46) 
Autoantibodies (-)  
(n = 54) 
Control females 
(n=170) 
90+ 10 (21.7) 4 (7.4) 7 (4.1) 
80-89 8 (17.4) 4 (7.4) 12 (7.1) 
70-79 9 (19.5) 14 (25.9) 29 (17.1) 
60-69 8 (17.4) 14 (25.9) 36 (21.2) 
50-59 11 (24) 18 (33.4) 86 (50.6) 
      For comparison by χ2, P = 0.01 (>80% skewing); P = 0.03 (>90% skewing) (Autoantibodies+) 
   P = 0.48 (>80% skewing); P = 0.3 (>90% skewing) (Autoantibodies+) 
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3.1.6. PCR-based X inactivation study of peripheral blood of Tunisian rheumatoid 
arthritis patients 
 
 
Informative XCI was observed in 76 of the 106 RA patients (71.7%). Skewed XCI 
was observed in 26 of the 76 informative patients (34.2%) whereas the same pattern 
was observed in 19 of 170 controls (11.2%). More importantly, extremely skewed 
XCI was present in 17 of the 76 patients (22.4%) while only in 7 of the 170 controls 
(4.1%) (P<0.001 for both skewed and extremely skewed patterns). The results of 
XCI patterns of RA patients and controls were summarized in Table 3.11. These 
results are statistically significant since odds ratio is 6.7 (95%CI=2.7-17.0) for 
extremely skewed XCI and 4.1 (95%CI=2.1-8.1) for skewed XCI patterns. A 
representative gel image of XCI pattern of Tunisian RA patients was displayed in 
Figure 3.9. Age alone is unlikely to influence the strikingly bimodal data in Tunisian 
RA patients (Figure 3.10). We did not observe a shift towards the skewed range in 
older patients and controls. 
 
 
 
         
     
 
    
 
Figure 3.9 Gel image of XCI patterns of 7 Tunisian RA patients. Polymerase chain reaction products 
from the androgen receptor methylation assay demonstrate X chromosome inactivation patterns in 
samples RA51 (allele ratio: 80%:20%), RA53, RA55, RA60 (not informative), RA62 (69%:31%), 
RA63 (100%:0%), RA64 (80%:20%). For each sample, DNA was either undigested (-) or digested 
(+) with the methylation-sensitive restriction enzyme Hpa II. Marker (M; pUC mix 8 [only 242-bp]) 
fragment is visible.  
 
 
 
             M     RA51           RA53           RA55           RA60           RA62           RA63          RA64         0      
Hpa II              -        +         -         +         -        +        -         +        -         +        -        +        -         + 
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Figure 3.10 Distribution of X-inactivation patterns according to age in Tunisian RA patients and 
control subjects. 
 
 
 
Table 3.11 Proportion of Tunisian RA patients and controls with skewed XCI 
 
 
Degree of skewing (%) 
No. (%) observed with skewed 
Rheumatoid arthritis  
(n = 76) 
Control females  
(n = 170) 
90+ 17 (22.4) 7 (4.1) 
80-89 9 (11.8) 12 (7.1) 
70-79 11 (14.5) 29 (17.1) 
60-69 28 (36.8) 36 (21.2) 
50-59 11 (14.5) 86 (50.6) 
         For comparison by χ2, P<0.0001(both >80% skewing and >90% skewing) 
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3.1.7. PCR-based X inactivation study of peripheral blood of members of Tunisian 
Akr family 
 
Informative XCI was observed in 28 of 44 members of Akr Family (63.6%). 
Interestingly, in none of the members of Akr Family extremely skewed XCI was 
observed. The pedigree of subfamilies of Akr Family was represented in Appendix. 
A representative PAGE image is displayed on Figure 3.11. The skewed XCI was 
observed only in 3 members of the 28 informative subjects (10.7%) and in 19 of 170 
controls (11.2%) (P=1.0). This value is not statistically significant. Among the 44 
women members of Akr Family, 20 were diagnosed with AITDs. When only the 
patients were considered, 11 of 20 subjects were informative. Segregation between 
the disease and skeweded XCI pattern was not observed in the members of this 
family. Skewed XCI profile was observed only in one of the 11 informative patients.  
The summary of the results of XCI patterns in Akr Family can be found in Table 
3.12. 
 
 
 
 
 
        
 
Figure 3.11 Gel image of XCI patterns of 6 members of Tunisian Akr Family. Polymerase chain 
reaction products from the androgen receptor methylation assay demonstrate X chromosome 
inactivation patterns in samples D10 (allele ratio: not informative), TD35 (55%:45%), TD31 
(56%:44%), D48 (71%:29%), TD2 (70%:30%), and TD1 (73%:27%). For each sample, DNA was 
either undigested (-) or digested (+) with the methylation-sensitive restriction enzyme Hpa II. Marker 
(M; pUC mix 8 [331-bp and 242-bp]) fragment is visible. 
 
 
 
 
 
 
             M    D10                TD35            TD31            D48              TD2              TD1             0            
Hpa II              -          +        -         +          -        +         -         +         -         +         -         + 
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Table 3.12 Proportion of Tunisian Akr Family members and controls with skewed 
XCI 
 
 
Degree of skewing (%) 
No. (%) observed with skewed 
Akr Family   
(n = 28) 
Control females  
(n = 170) 
90+            0  (0.0) 7 (4.1) 
80-89 3  (10.7) 12 (7.1) 
70-79 12 (42.9) 29 (17.1) 
60-69 5  (17.9) 36 (21.2) 
50-59 8  (28.6) 86 (50.6) 
         For comparison by χ2, P=1.0 (both >80% skewing and >90% skewing) 
 
 
3.1.8. PCR-based X inactivation study of peripheral blood of Turkish Sjogren’s 
syndrome patients 
 
Informative XCI was observed in 51 of 78 SICCA patients (65.4%). Among 51 
informative patients, extremely skewed XCI was detected only in 3 patients (5.9%). 
This percentage is very close to the percentage of control women with extremely 
skewed XCI pattern (3 in 124; 2.4%) (P=0.4). Skewed XCI was observed in 8 of 51 
informative SICCA patients (15.7%) and in 10 of 124 informative control women 
(8.1%) (P=0.2 and odds ratio=2.1 with 95% CI: 0.8-5.7). The gel image of 
representative SICCA samples is exhibited on Figure 3.12. The XCI patterns of 
SICCA samples and control women were summarized in Table 3.13. Skewed XCI in 
blood cells of SICCA patients were not different than of control group. This result 
displayed that other than XCI may have role in the pathogenesis of Sjogren’s 
syndrome. Environmental factors like molecular mimicry or viruses may have role 
in initiation of failure in self tolerance since lack of association was reported in 
primary biliary cirrhosis (Miozzo et al. 2007). 
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Figure 3.12 Gel image of XCI patterns of 4 SICCA patients. Polymerase chain reaction products 
from the androgen receptor methylation assay demonstrate X chromosome inactivation patterns in 
samples 04-472 (allele ratio: 84%:16%), 04-479 (70%:30%), 04-482, and 04-484 (not informative). 
For each sample, DNA was either undigested (-) or digested (+) with the methylation-sensitive 
restriction enzyme Hpa II. Marker (M; pUC mix 8 [331-bp and 242-bp]) fragment is visible. 
 
 
 
 
Table 3.13 Proportion of SICCA patients and controls with skewed XCI 
 
 
Degree of skewing (%) 
No. (%) observed with skewed 
SICCA patients 
(n = 51) 
Control 
(n=124) 
90+ 3   (5.9) 3   (2.4) 
80-89 5   (9.9) 7   (5.6) 
70-79 14  (27.5) 22 (17.8) 
60-69  9   (17.7) 29 (23.4) 
50-59 20 (39.2) 63  (50.8) 
         For comparison by χ2, P = 0.2 (>80% skewing); P = 0.4 (>90% skewing)  
 
 
 
3.1.9.1. PCR-based X inactivation study of peripheral blood of Turkish Pre-
eclampsia patients 
 
Informative XCI pattern was observed in 46 of 67 pre-eclampsia patients (68.7%). 
Control group (n=130) for pre-eclampsia patients are chosen among the Turkish 
Control cohort so that the mean ages were almost the same for patient and control. 
Among 130 healthy control women, informative XCI status was observed in 86 
cases (66.2%). Extremely skewed XCI was observed in 21.7% of informative 
patients (10 in 46), whereas this ratio was observed only in 2 of 86 informative 
             M          04-472                  04-479                  04-482                 04-484               05    
Hpa II                     -            +             -             +            -             +             -            + 
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healthy women (2.3%, P=0.0005). The odds ratio was calculated as 11.7 
(95%CI:2.4-56.0). Skewed XCI was observed in 16 of 46 informative patients 
(34.8%) whereas in 8 of 86 informative controls (9.3%, P=0.0006) (Table 3.14). The 
odds ratio was calculated as 5.2 (95%CI:2.0-13.4). Aging is highly unlikely to be 
involved because of the relatively young ages of the patients. A shift towards the 
skewed range in older patients and controls was not observed (Figure 3.13). A gel 
image that display PEE patients with skewed XCI pattern can be observed in Figure 
3.14.  
 
 
 
               
 
Figure 3.13 Distribution of X-chromosome inactivation patterns according to age in pre-eclampsia 
patients and control subjects 
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Figure 3.14 Gel image of XCI patterns of 5 PEE patients. Polymerase chain reaction products from 
the androgen receptor methylation assay demonstrate X chromosome inactivation patterns in samples 
04-298 (allele ratio: 98%:2%), 04-176 (91%:9%), 04-182 (100%:0%), 04-376 (83%:17%), and 04-
284 (76%:34%). For each sample, DNA was either undigested (-) or digested (+) with the 
methylation-sensitive restriction enzyme Hpa II. Marker (M; pUC mix 8 [331-bp and 242-bp]) 
fragment is visible. 
 
 
 
 
 
Table 3.14 Proportion of PEE patients and controls with skewed XCI 
 
 
Degree of skewing (%) 
No. (%) observed with skewed 
PEE patients 
(n = 46) 
Control females  
(n = 86) 
90+ 10 (21.7) 2 (2.3) 
80-89 6   (13.0) 6 (7.0) 
70-79 6   (13.0) 15 (17.4) 
60-69 13 (28.3) 20 (23.3) 
50-59 11 (23.9) 43 (50.0) 
         For comparison by χ2, P = 0.0006 (>80% skewing); P = 0.0005 (>90% skewing)  
 
 
 
 
 
 
 
 
               M    04-298           04-176             04-182              04-376               04-284        m            
Hpa II                -        +           -          +          -           +           -           +           -          +    
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3.1.9.2. PCR-based X inactivation study of buccal mucosa specimen of Turkish   
pre-eclampsia patients 
 
 
In order to analyze the XCI pattern of mesodermal tissue (in this case blood) with 
the other tissue type, buccal mucosa (ectodemal origin) was obtained from 7 patients 
randomly. The XCI patterns of buccal mucosa cells were very close to blood cells. 
The results were displayed in Table 3.15.  
 
 
Table 3.15    Blood and buccal mucosa XCI patterns of seven PEE patients 
 
Sample 04-176 04-182 04-190 04-298 04-192 04-284 04-289 
Blood 91:9 93:7 90:10 98:2 83:17 71:29 70:30 
Buccal 90:10 90:10 90:10 100:0 80:20 69:31 66:34 
 
 
 
 
 
 
3.1.9.3. Pregnancy history 
 
The clinical characteristics of informative patients were displayed in Table 3.16. The 
differences in the pregnancy details between women with extremely skewed and 
random pattern were important because a common background for pre-eclampsia 
and recurrent spontaneous abortion has been questioned (Christiansen et al. 1990, 
Wilczynski 2006). Although the numbers were too small to reach a conclusion, 
recurrent spontaneous abortions were three times more common in women with 
extreme skewing (3/10) than in women with random patterns of XCI (3/30).  
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Table 3.16 Clinical characteristics and XCI status of PEE patients 
 
Patient DOB Diagnosis Pregnancy 
History 
GW of 
Disease 
GW of 
Delivery 
IUGR/ 
Birth Weight(gr) 
Sex of 
Child 
≥90 percent skewing 
04-176* 1977 HELLP G3, P1 24 30 -/1,200 F 
04-182* 1972 MP G9, P4 32 40 -/3,000 M 
04-187 1969 SP G6, P4 35 38 -/2,400 F 
04-190* 1980 SP G1, P1 29 29 +/850 M 
04-287 1970 SP G1, P1 30 30 -/1,550 M 
04-291 1966 SP G6, P5 35 37 -/2,350 F 
04-298* 1980 SP G1, P1 39 39 -/3,000 F 
04-378 1962 MP G3, P3 40 40 -/3,350 M 
06-237 1972 MP G3, P3 35 38 +/2,500 M 
06-241 1968 MP G6, P6 36 38 -/3,650 F 
80-89 percent skewing 
04-192* 1979 SP G1, P1 29 33 +/1,500 M 
04-368 1981 SP G1, P1 26 41 -/2,400 F 
04-372 1969 SP G3, P3 36 39 -/2,800 M 
04-376 1970 MP G4, P3 36 40 -/3,500 M 
04-401 1982 SP G2, P1 34 36 -/2,450 M 
06-242 1978 MP G1, P1 36 38.5 -/3,600 M 
70-79 percent skewing 
04-186 1985 SP G1, P1 32 33 +/1,100 F 
04-284* 1975 HELLP G4, P3 32 33 -/2,100 M 
04-289* 1975 SP G2, P2 38 38 +/2,450 M 
04-365 1982 SP G1, P1 32 36 -/2,500 M 
06-238 1980 SP G1, P1 26 34 +/1,000 F 
06-239 1979 SP G3, P2 18 20 ?/500 (ex) F 
60-69 percent skewing 
04-178 1985 SP G1, P1 34 35 -/2,050 M 
04-181 1977 HELLP G2, P2 33 33 +/1,600 M 
04-184 1967 MP G6, P4 39 40 ?/3,300 F 
04-285 1960 SP G3, P1 16 20 -/400 M 
04-288 1972 SP G1, P1 23 34 +/1,250 F 
04-364 1964 SP G6, P5 24 25 ?/900 F 
04-370 1966 MP G3, P3 39 39 -/2,850 F 
04-374 1977 SP G1, P1 39 40 -/2,800 F 
04-402 1983 E G1, P1 38 38 -/3,000 M 
04-403 1969 SP G4, P4 34 34 ?/1,800 F 
06-236 1973 MP G1, P1 36 38 -/3,300 M 
06-245 1973 MP G3, P3 32 37 +/2,350 (ex) F 
06-246 1984 SP G1, P1 26 34 +/1,150 F 
50-59 percent skewing 
04-180 1976 MP G4, P4 34 35 -/2,100 F 
04-188 1975 SP G2, P2 31 32 -/1,800 M 
04-189 1977 SP G1, P1 27 33 -/1,400 M 
04-292 1966 SP G1, P1 32 37 -/2,000 F 
04-293 1970 SP G3, P3 32 32 -/1,350 F 
04-367 1974 SP G3, P3 33 33 -/2,000 F 
04-373 1972 SP G1, P1 36 39 -/2,800 M 
04-405 1971 E G4, P2 34 34 -/1,700 F 
06-234 1971 SP G1, P1 30 38 +/1,900 M 
06-235 1982 SP G1, P1 24 28 +/850 (ex) F 
06-244 1982 MP G1, P1 37 39 -/3,300 M 
 
DOB: date of birth, GW: gestational week, IUGR: intra-uterine growth retardation, M: male. F: 
female, MP: mild pre-eclampsia, SP: severe pre-eclampsia, E: eclampsia, HELLP: hemolytic anemia-
elevated liver enzymes and low platelet count syndrome G: gravida, P: para 
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3.2. PEDIATRIC SAMPLES 
 
 
3.2.1. PCR-based X inactivation study of peripheral blood of Turkish pediatric 
control samples 
 
XCI was found to be informative in 124 of 183 controls (67.8%). Skewed XCI was 
observed in 12 of 124 informative controls (9.7%) and extremely skewed XCI was 
observed in only 4 of 124 control individuals (3.2%). Extremely skewed XCI is a 
very rare event in the newborn individuals. Our results displayed consistency with 
the previously published results (Amos-Landgraf et al. 2006). 
 
 
 
3.2.2. PCR-based X inactivation study of peripheral blood of Turkish juvenile 
idiopathic arthritis patients 
 
81 children diagnosed with JIA were genotyped for XCI pattern. 62 of them display 
informative XCI (76.5%). Extremely skewed XCI was observed in 8 of the 62 
informative patients (12.9%). The same pattern was observed in only 4 of 124 
informative pediatric controls (P=0.002; odds ratio=4.4 (95%CI: 1.3-15.4). Skewed 
XCI was observed in 14 of 62 informative patients (22.6%) and only in 12 of 124-
control group (9.7%) (P=0.02; odds ratio=2.7 (95%CI: 1.2-6.3). The gel image of 
representative JIA samples is exhibited on Figure 3.15. The overall XCI pattern of 
JIA samples and control group children are summarized in Table 3.17. Skewed and 
extremely skewed pattern difference between JIA patients and control individuals 
were statistically significant. To the best of our knowledge this is the first study that 
investigates XCI pattern in the blood cells of the pediatric samples.  
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Figure 3.15 Gel image of XCI patterns of 6 JIA patients. Polymerase chain reaction products from 
the androgen receptor methylation assay demonstrate X chromosome inactivation patterns in samples 
06-7 (allele ratio: not informative), 06-8 (90%:10%), 06-9 (71%:29%), 06-12 (76%:24%), 06-13 
(95%:5%), and 06-14 (95%:5%). For each sample, DNA was either undigested (-) or digested (+) 
with the methylation-sensitive restriction enzyme Hpa II. Marker (M; pUC mix 8 [331-bp and 242-
bp]) fragment is visible. 
 
 
 
Table 3.17 Proportion of JIA patients and controls with skewed XCI 
 
Degree of skewing (%) No. (%) observed with skewing 
 JIA patients (n=62) Controls (n=124) 
90+   8 (12.9) 4 (3.2) 
80-89   6 (9.7) 8 (6.5) 
70-79 13 (21.0) 28 (22.6) 
60-69 18 (29.0) 37 (29.8) 
50-59 17 (23.5) 47 (37.9) 
For comparison by χ2, P = 0.024 (>80% skewing); P = 0.022 (>90% skewing) 
 
 
The clinical characteristics about JIA patients were listed in Table 3.18. The 
information was used in order to construct a correlation between skewed XCI and 
any clinical state of the disease. The only attractive correlation was established 
between nonrandom XCI and the clinical classification of JIA. It was interesting that 
only one patient was polyarticular in the group with skewed XCI pattern (7.1%) 
whereas 12 in 48 patients with random XCI pattern were polyarticular (25.0%). 
Although the number of patients with skewed XCI was small, most probably 
skewed XCI may play a role more in the etiology of oligoarthritis JIA.   
             M     06-7             06-8            06-9             06-12           06-13          06-14             0      
Hpa II              -         +        -        +        -        +        -        +         -       +          -        + 
79 
 
Table 3.18 Clinical characteristics and XCI status of JIA patients 
 
 Code DoB OoD (y) 
Clinical 
Class 
Clinical 
Severity 
Affected 
Joint(s) Pregnancy History ANA RF Uveitis 
90+           
1 06-029 1996 3.5 O Active 3 A:3 + - - 
2 05-069 1990 11 O remission 4 G:3,P:3,A:0 - - - 
3 05-188 1989 7 O remission 2 G:3, P:3; A:0 + - + 
4 06-014 1993 14 O remission 2 G:2,P.1, A:1 - - - 
5 06-013 1983 16 EO Active 8 G:3, P:3; A:0 + - - 
6 06-016 2002 2 O remission 1  - - - 
7 06-030 1999 2 O Active 3  + - - 
8 06-008 1994 2 O remission 1  + - + 
80-89           
9 05-179 2000 3 P remission 6 G:5, P:3,A:2 + - + 
10 06-026 2001 2 O  Active 2  + - - 
11 07-1078 2004 3 O Active 1 G:4,P:3,ectopik:1 - - - 
12 05-064 1994 7 O Active 3 G:5,P:5,A:0 + - + 
13 06-020 2003 2 O remission 1 G:4, P:4, A:0 - - - 
14 07-1080 2003 3 P remission 5 G:3,P:3,A:0 - - - 
70-79           
15 05-170 1991 10 P remission 7  - - - 
16 07-1087 1998 9 O remission 2 G:3,P:2,anembryonic:1 -   
17 06-012 1986 10 O remission 1 P:2,G:2, A:0 - - - 
18 05-071 1995 1 P Active 10 G:2,P:2,A:0 - - - 
19 05-178 1996 8 P Active 10 G:5,P:5,A:0 - - - 
20 06-021 2002 2 O remission 1 G:3,P.3,A:0 - - - 
21 06-052 2002 2.5 O Active 2 A:2 + - - 
22 05-187 1990 10 O remission 2 G:3,P:2,A:1 - - - 
23 05-183 1999 5 O remission 1  + - - 
24 06-009 1996 7 O remission 2  + - - 
25 06-043 1998 2 O Active 2 A:2 + - - 
26 05-065 1990 2 P Active 10 G:4,P:3,DC:1,Ex:1 - + - 
27 05-063 1991 11 O remission 3  + - - 
60-69           
28 05-070 1994 5 P Active 13 G:2,P:2,A:0 - - - 
29 06-025 2000 4 O Active 2 G.1,P:1,A:0 + - - 
30 07-1079 1987 3 P Sekel 14 G:4,P:3,A:1 - - - 
31 05-601 2001 4 O remission 3 G:1,P:1,A:0 - - - 
32 05-173 2001 2 O remission 1 P:2,G:2, A:0 + - - 
33 05-182 1994 9 EO Active 7 G:5, P:2, DC:3 - - - 
34 06-024 1999 4 O remission 1 G:4,P.2,A:1,DC:1 + - + 
35 06-037 1996 4 O remission 3 A:2 + - + 
36 06-044 1991 7 O remission 2 A:1 - - - 
37 05-602 2003 2 O remission 1  + - - 
38 06-028 2001 1.5 O remission 2  + - - 
39 05-073 1995 4 P remission 7 G:2,P:2,A:0 + - + 
40 05-072 1988 1 P remission 10 G:3, P:3; A:0 - - - 
41 05-062 1984 11 O remission 3 G:4,P:4,A:0 - - - 
42 06-051 2000 3 O remission 2 A:1    
43 05-066 1998 3 O remission 1 G7,P6,A1 - - - 
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44 07-1084 1998 9 O remission 1 G:1,P:1,A:0 - - - 
45 07-1086 1995 10 O remission 2 G:2,P2,A0 + - - 
50-59           
46 05-168 1990 9 P Active 9  - - - 
47 06-034 1999 3 O remission 2     
48 05-167 2002 9 EO Active 8  - - - 
49 05-169 1987 4 P remission 6  - - - 
50 06-038 1998 3 O Active 2 A:1 - - - 
51 05-177 1992 10 P remission 5  - + - 
52 06-019 2000 4 O remission 1  - - - 
53 06-027 1999 7 O remission 2 G:3, P:3; A:0 + - - 
54 06-031 2000 2 O remission 2     
55 06-048 2002 1 O remission 2     
56 05-166 1980 13 P Active 12 G:2,P:2,A:0 - - - 
57 05-185 1998 6 O Active 2 G.2,P:2,A:0 + - + 
58 06-046 2005 1.5 O remission 2 A:1    
59 06-045 2002 2 O remission 2 A:1    
60 06-053 1998 2 O remission 1     
61 07-1081 2002 5 O remission 2 G:1;P:1 + - - 
62 07-1085 1998 9 O remission 1 G:3,P.3,A:0 + - - 
 
DoB: Date of birth, OoD: Onset of disease, y: year, O: oligoligoarticular, P: polyarticular, EO: 
extended oligoligoarticular, F: female, M: male G: number of pregnancies, P: para (pregnancies 
carried to term and delivered), A: spontaneous abortions, MTX: methotrexate, NSAID: non-steroidal 
anti-inflammatory drugs, PRED: prednisolone, IAS: intraarticular corticosteroids, SAZ: sulfasalazin, 
SAL: saline, +: present, -: absent. 
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3.2.3. PCR-based X inactivation study of peripheral blood of Turkish pediatric 
scleroderma patients 
 
9 of 14 pediatric scleroderma patients were informative (64.3%) for AR gene 
polymorphism. 2 of the 9 informative patients displayed extremely skewed XCI 
(22.2%). Skewed XCI was observed in 3 of the 9 informative patients (33.3%). The 
number of patients is very small to make a conclusion. However the incidence of 
pediatric SSc is too low, therefore it may take more time to reach a significant 
population size. A representative PAGE image of one patient is in Figure 3.16. The 
results were summarized in Table 3.19. 
 
 
 
                                          
 
Figure 3.16 Gel image of XCI patterns of one pediatric scleroderma patient. Polymerase chain 
reaction products from the androgen receptor methylation assay demonstrate X chromosome 
inactivation patterns in samples 07-1035 (allele ratio: 85%:15%). For the sample, DNA was either 
undigested (-) or digested (+) with the methylation-sensitive restriction enzyme Hpa II. Marker (M; 
pUC mix 8 [331-bp and 242-bp]) fragment is visible. 
 
 
Table 3.19 Proportion of pediatric SSc patients and controls with skewed XCI 
 
Degree of skewing (%) No. (%) observed with skewing 
 Pediatric SSc patients (n=9) Controls (n=124) 
90+ 2 (22.2) 4 (3.2) 
80-89 1 (11.1) 8 (6.5) 
70-79 1 (11.1) 28 (22.6) 
60-69 5 (55.5) 37 (29.8) 
50-59 0 (0.0) 47 (37.9) 
 
 
 
 
                M    07-1035      o 
Hpa II                -         + 
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3.3. CELL LINE SAMPLES 
 
 
3.3.1 PCR-based X inactivation study of cell line samples of British type I diabetes 
mellitus (TPO+) patients 
 
XCI status was found to be informative in 88.1% cases (312 in 354). Skewed XCI 
pattern was observed in 115 of 312 informative samples (36.9%). Extremely 
skewed XCI was observed in 88 samples (28.2%). PAGE image of T1D(TPO+) 
samples were displayed in Figure 3.17 and the overall results were summarized in 
Table 3.20.  
 
 
 
 
           
 
Figure 3.17 Gel image of XCI patterns of 6 cell lines of T1D(TPO+). Polymerase chain reaction 
products from the androgen receptor methylation assay demonstrate X chromosome inactivation 
patterns in samples 05-855 (allele ratio: 100%:0%), 05-856 (55%:45%), 05-857 (55%:45%), 05-858 
(50%:50%), 05-859 (95%:5%), and 05-860 (75%:25%). For each sample, DNA was either 
undigested (-) or digested (+) with the methylation-sensitive restriction enzyme Hpa II. Marker (M; 
pUC mix 8 [only 242-bp]) fragment is visible. 
 
 
 
 
 
 
 
 
                  M       05-855        05-856          05-857       05-858       05-859        05-860       o 
      Hpa II                  -        +         -       +          -       +        -        +       -        +        -        + 
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3.3.2 PCR-based X inactivation study of cell line samples of British type I diabetes 
mellitus (TPO-) patients 
 
XCI status was informative in 349 of 453 cell lines of T1D(TPO-) patients (77.0%). 
Extremely skewed XCI was observed in 84 of the 349 informative cell lines 
(24.1%). Skewed XCI was observed in 123 of 349 informative cell lines (35.2%). 
The gel image was represented in Figure 3.18, and the summarized results in Table 
3.20. 
 
         
 
     
      
 
Figure 3.18 Gel image of XCI patterns of 7 cell lines of T1D(TPO-). Polymerase chain reaction 
products from the androgen receptor methylation assay demonstrate X chromosome inactivation 
patterns in samples 06-480 (allele ratio: not informative), 06-481 (100%:0%), 06-482 (100%:0%), 
06-483 (100%:0%), 06-484 (63%:37%), 06-485 (85%:15%), and 06-486 (98%:2%). For each 
sample, DNA was either undigested (-) or digested (+) with the methylation-sensitive restriction 
enzyme Hpa II. Marker (M; pUC mix 8 [331-bp and 242-bp]) fragment is visible. 
 
 
 
 
3.3.3 PCR-based X inactivation study of cell line samples of British control 
(BBC1958) individuals 
 
British Birth Cohort 1958 samples were collected from the individuals that were 
born in 1958 in UK. 311 of 466 samples were informative in XCI status (66.8%). 65 
of 311 (20.9%) informative samples have extremely skewed XCI patterns whereas 
97 (31.2%) of them have skewed XCI patterns. A representative gel image of XCI 
results of BBC58 samples were displayed in Figure 3.19. All of the results of 3 
groups of British cell lines were summarized in Table 3.20. 
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Figure 3.19 Gel image of XCI patterns of 7 cell lines of BBC1958. Polymerase chain reaction 
products from the androgen receptor methylation assay demonstrate X chromosome inactivation 
patterns in samples 07-640 (allele ratio: not informative), 07-641 (100%:0%), 07-642 (100%:0%), 
07-643 (100%:0%), 07-644 (63%:37%), 07-645 (85%:15%), and 07-646 (98%:2%). For each 
sample, DNA was either undigested (-) or digested (+) with the methylation-sensitive restriction 
enzyme Hpa II. Marker (M; pUC mix 8 [331-bp and 242-bp]) fragment is visible. 
 
 
 
 
 
Table 3.20 Skewed XCI profiles in cell line DNA of British T1D (TPO+ and TPO-) 
patients and controls 
 
 
 
Degree of 
skewing 
(%) 
No. (%) observed with skewed 
T1D(TPO+) 
(n = 312) 
T1D(TPO-)  
(n = 349) 
Control (BBC58) 
(n=311) 
90+ 88 (28.2) 84 (24.1) 65 (20.9) 
80-89          27 (8.7) 39 (11.2) 32 (10.3) 
70-79 49 (15.7) 59 (16.9) 33 (10.6) 
60-69 52 (16.7) 50 (14.3) 51 (16.4) 
50-59 96 (30.8) 117(33.5) 130(41.8) 
 For comparison by χ2, P = 0.15 (>80% skewing); P = 0.04 (>90% skewing) for T1D(TPO+) 
samples and P = 0.28 (>80% skewing); P = 0.35 (>90% skewing) for T1D(TPO+) samples 
 
 
The difference in XCI status between cell lines of typeI diabetes mellitus patients 
and controls were stasitically not significant. It was an expected result bevause 
previous reports (Migeon et al. 1988) documented that lymphoblastoid cell lines 
were monoclonal. The XCI results of cell lines of all type I diabetes mellitus, 
BBC1958, and individuals of all Turkish controls were represented in Figure 3.20. 
There was still a significant difference in XCI patterns of Turkish control samples 
(for which DNA was isolated from peripheral blood) and BBC1958 control cohort 
(for which DNA was isolated from established cell lines). These results indicated 
that cell line samples were not ideal for XCI studies and expression studies.  
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Figure 3.20 Distribution of XCI in T1D, BBC1958 cell lines and Turkish control 
(DNA extracted from peripheral blood). 
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CHAPTER 4 
 
 
DISCUSSION 
  
 
All individuals are tolernant to their own ‘potential’ antigenic molecules. Self 
reactive lymphocytes are deleted or made unresponsive. Autoimmune disorders 
develop when self antigens escape from tolerance and are activated. The exact 
mechanisms of how these molecules escape from tolerance are not entirely known. 
However, a combination of genetic variants, environmental factors like pathogen 
exposure, pregnancy, smoking and diet are thought to have a role in the eiology of 
autoimmune diseases. 
 
One of the interesting features of autoimmune disorders is that they are mainly the 
problem of the female gender. Striking differences between the two sexes are 
observed both in systemic (i.e., scleroderma, Sjogren’s syndrome and systemic 
lupus erythamatosus), and in organ specific autoimmune diseases (i.e., autoimmune 
thyroid diseases). In other types of autoimmune disorders, like rheumatoid arthritis, 
multiple sclerosis and myasthenia gravis the female predominance is still apparent. 
There are certain diseases, such as type I diabetes mellitus, in which, subgroups 
characterized by distinct clinical manifestations may have a female preponderance. 
Hormonal status, pregnancy and sex chromosomes are the main differences between 
the two sexes. Steroid hormone differences between the two sexes make them a 
good candidate for the female predominance of autoimmunity. Even though both 
estrogens and androgens exist in females and males, their levels are different. This 
difference is a quantitative but not qualitative feature. In multiple sclerosis and 
rheumatoid arthritis, where female predominance holds, disease activity decreases 
during pregnancy, especially in the third trimester, where estrogen and progesterone 
levels are at peak (Nelson&Ostensen 1997, Confavreux et al 1998). However, 
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presence of pediatric forms of female prevalent autoimmune diseases raises 
questions on the validity of this subject. Pregnancy related microchimerism is 
another difference between the two sexes which may have role in female 
predisposition to autoimmunity. In fact, there are reports that display increased fetal 
cells in maternal blood and skin lesions of women with scleroderma (Artlett et al. 
1998, Nelson et al. 1998). However, these reports cannot explain alone why the 
non-pregnant women and children under the age of puberty are subject to 
autoimmunity. The third difference is X-Chromosome inactivation (XCI), a 
physiological compensation for the X-linked dosage between the two sexes (Lyon, 
1961). XCI is an epigenetic event that occurs early in development leading to 
transcriptional silencing of one of the X chromosome pairs (Huynh&Lee 2005). The 
silencing process is random; therefore normal females are mosaic of two cell 
populations. Disturbances in the XCI patterns may result in inadequate training for 
X-encoded self antigens in the thymus (Stewart, 1998).  
The main goal of this study was to investigate the role of skewed XCI, especially in 
hematopoietic stem cells, in the pathogenesis of female predominant autoimmune 
disorders. The diseases that were investigated for this purpose represent both the 
systemic and the organ specific autoimmune disorders. Scleroderma (SSc), 
Sjogren’s syndrome (SICCA), juvenile idiopathic arthritis (JIA), and rheumatoid 
arthritis (JIA) are systemic, while autoimmune thyroid diseases (AITDs) and type I 
diabetes mellitus (T1D) are organ specific autoimmune disorders. 
 
We first demonstrated skewed XCI patterns in peripheral blood mononuclear cells 
of a significant proportion of women with SSc in the Turkish [64%, OR: 20.0 
(95%CI: 8.5-46.6); p<0.0001] and the US [34%, OR: 5.9 (95% CI 2.7-12.8); 
P<0.0001] populations. The effect is more pronounced for patterns of extremely 
skewed XCI in the Turkish SSc [49.1%, OR: 38.9 (95% CI 11.0-137.3); P<0.0001] 
and the US SSc [18.1%, OR: 3.8 (95% CI 1.9-7.6); P<0.0001] patients. Next, 
skewed XCI patterns was obsevred in peripheral blood mononuclear cells of a 
significant proportion of female subjects with AITDs in the Turkish [33.8%, OR: 
5.8 (95% CI 2.6-12.8; P<0.0001] and the Tunisian [26%, OR: 2.8 (95% CI 1.5-5.4; 
P=0.0022] population. Turkish AITDs patients displayed 19.3% (OR: 9.6 (95% CI 
2.7-34.3); P<0.0001) and Tunisian AITDs probands showed 14% [OR: 3.8 (95% CI 
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1.5-9.8); P=0.0046] extremely skewed XCI patterns in their blood cells. Third, a 
high proportion of skewed [34.2%, OR: 4.1 (95% CI 2.1-8.1); P<0.0001] and 
extremely skewed [22.4%, OR: 6.7 (95%CI 2.7-17.0); P<0.0001] XCI patterns was 
observed in a group of Tunisian RA patients. In thepediatric age groups, 
approximately 23% of JIA patients demonstrated skewed XCI patterns [OR: 2.7 
(95% CI 1.2-6.3); P=0.0024]. We showed extremely skewed XCI patterns in 
mononuclear blood cells of a significant proportion [12.9% OR: 4.4 (95% CI 1.3-
15.4); P=0.0022] of JIA patients. Lastly, in a high proportion of PEE patients, 
skewed XCI patterns was observed [34.7%, OR: 2.7 (95% CI 1.2-6.3); P=0.0024] in 
blood cells. With respect to the extremely skewed XCI ratios, the proportion is still 
high [21.7%, OR: 11.7 (95% CI 2.4-56.0); P=0.0005] in PEE patients. In Turkish 
female controls approximately 8% demonstrate skewed and 3% demonstrate 
extremely skewed XCI. Similar proportions were observed in the blood cells of 
pediatric control individuals (9.7% skewed and 3.2% extremely skewed). These 
ratios are in accordance with the XCI profiles of other diverse control populations 
from US (Chitnis et al. 2000, Amos-Landgraf et al.  2006). All of the results were 
summarized in Table 4.1. 
 
Skewed XCI is not a common finding in all female prevalent autoimmune disorders. 
For example, in SICCA, a statistically significant result was not observed (Table 
4.1). Likewise in primary billiary cirrhosis (PBC) a recent publication reports 
random patterns in blood cells (Miozzo et al. 2007). Lack of association is not an 
unexpected finding because initiation of autoimmunity in PBC is most probably due 
to molecular mimicry (Kaplan&Gershwin 2005). In light of known causes of 
SICCA, initiation of breakdown of self-tolerance could be other factors such as to 
viral infections (Kordossis et al. 1998, Haddad et al. 1992, Terada et al. 1994). We 
agree with the hypothesis that a subsequent event, such as environmental exposure 
to viral, chemical, or other agents, may trigger a cascade that results in certain types 
of autoimmune disorders. 
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Table 4.1 Summary of the results of XCI patterns of the autoimmune diseases analyzed in this study 
 
Disease 90+ 80-89 50-79 NI OR for 90+ skewing (95%CI and P) OR for 80+ skewing (95%CI and P) 
AITDs-TR (n=110) 16 (19.3) 12 (14.5) 55 (66.2) 27 (24.6) 9.6 (95% CI 2.7-34.3; P<0.0001) 5.8 (95% CI 2.6-12.8; P<0.0001) 
AITDs-SCN. (n=40)* 5 (16.0) 6 (18.8) 21 (66.0) 8 (20.0) 7.4 (95% CI 1.7-33.2; P=0.0215) 6.0 (95% CI 2.3-15.8; P<0.0001) 
AITDs-TUN (n=145) 14 (14.0) 12 (12.0) 74 (74.0) 45 (31.0) 3.8 (95% CI 1.5-9.8; P=0.0046) 2.8 (95% CI 1.5-5.4; P=0.0022) 
AITDs-TR&TUN (n=255) 30 (16.4)  24 (13.1) 129 (70.5) 72 (28.2) 4.6 (95% CI 2.0-10.5; P<0.0001) 3.3 (95% CI 1.9-5.9; P<0.0001) 
AITD-TR&SCN.&TUN(n=295) 35 (16.3) 30 (14.0) 150 (69.8) 80 (27.1) 4.5 (95% CI 2.0-10.5; P<0.0001) 3.4 (95% CI 2.0-6.0; P<0.0001) 
RA-TUN (n=106) 17 (22.4) 9 (11.8) 50 (65.8) 30 (28.3) 6.7 (95%CI 2.7-17.0; P<0.0001 4.1 (95% CI 2.1-8.1; P<0.0001) 
AKR-TUN (n=44) 0 (0) 3 (10.7) 25 (89.3) 16 (36.4) P=1.0 P=1.0 
SSc-TR (n=70) 27 (49.1) 8 (14.5) 20 (36.4) 15 (21.4) 38.9 (95% CI 11.0-137.3; P<0.0001) 20.0 (95% CI 8.5-46.6; P<0.0001) 
SSc-US (n=125) 17 (18.1) 15 (16.0) 62 (66.0) 31 (24.8) 3.8 (95% CI 1.9-7.6; P<0.0001) 5.9 (95% CI 2.7-12.8; P<0.0001) 
SSc-TR&US (n=195) 44 (29.5) 23 (15.4) 82 (55.1) 46 (23.6) 8.6 (95% CI 5.1-14.7; P<0.0001) 9.3(95% CI 4.5-19.2; P<0.0001) 
PEE-TR (n=67) 10 (21.7) 6 (13.0) 30 (65.2) 21 (31.3) 11.7 (95% CI 2.4-56.0; P=0.0005) 5.2 (95% CI 2.0-13.4; P=0.0006) 
JIA-TR (n=81) 8 (12.9) 6 (9.7) 48 (77.4) 19 (23.5) 4.4 (95% CI 1.3-15.4; P=0.0022) 2.7 (95% CI 1.2-6.3; P=0.0024) 
SICCA-TR (n=78) 3 (5.9) 5 (9.9) 43 (84.3) 27 (34.6) P=0.4 P=0.2 
C-Children-TR (n=92) 2 (2.8) 6 (8.3) 64 (88.9) 20 (21.7)   
C-Newborn-TR (n=91) 2 (3.8) 2 (3.8) 48 (92.3) 39 (42.9)   
C-Newborn-US (n=590)** 4 (0.7) 29 (4.9) 557 (94.4) ?? (?)   
C-Adult-TR (n=160) 3 (2.41) 7 (5.6) 114 (91.9) 36 (22.5)   
C-Adult-US (n=415)** 22 (5.3) 59 (14.2) 334 (80.5) ?? (?)   
C-Adult-TUN (n=97) 4 (8.7) 5 (10.9) 37 (80.4) 51 (52.6)   
 
UK: United Kingdom, TR: Turkey, SCN: Scandinavia, TUN: Tunisia, US: United States, T1D: Type 1 diabetes, AITDs: Autoimmune thyroid diseases, SSc: 
Scleroderma, RA: Rheumatoid arthritis, JRA: Juvenile rheumatoid arthritis, PEE: Pre-eclampsia, SICCA: Sjogren’ syndrome, CI: confidence interval, NI: not 
informative 
*     (Brix et al. 2005) 
**   (Amos-Landgraf et al.  2006) 
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Our results suggest that a significant proportion of female patients with autoimmune 
disorders have extremely skewed XCI. Skewing could be the result of a primary or 
a secondary event. The former is bias in the initial choice of which X chromosome 
is inactivated due to germline XIST (Xinactive- specific transcript) mutations 
(Puck&Willard 1998). The secondary causes are deleterious X-linked mutations, X 
chromosome rearrangements, aging, twinning, or monoclonal expansion of cells 
(Brown, 1999). We believe that deleterious X-linked mutations or X chromosome 
rearrangements and their differential expression patterns could provide a 
disadvantage to blood cells and lead to skewed XCI.  
 
In an attempt to determine whether skewed XCI is specific to blood or observed in 
other tissues as well, we collected samples from buccal mucosa, hair and affected 
tissues of a selected group of patients in the SSc and AITDs groups. In both groups, 
only those patients with extreme skewing were included. As shown in Figure 3.3 
and 3.6 extreme skeweing is not observed in the skin biopsy samples of SSc 
patients. Likewise, thyroid biopsy specimens of AITDs patients do not display a 
pronounced skewing of XCI. Again, differential expression patterns of X-linked 
mutations could account for this observation. These results suggest that the putative 
X-linked antigens may be presented to the extremely skewed immune system cells 
of these patients.  
 
X-linked lethal mutations, which would be compatible with life in females because 
of X-inactivation mosaicism, is an appealing causative mechanism in autoimmune 
diseases. If skewing is the result of X-linked mutations, these should be inherited 
from the maternal lineage unless they occur de novo during gametogenesis. 
Therefore, we analyzed the parental origin of the inactive X chromosome in 19 
patient-mother pairs in US SSc subjects. Of the 10 pairs with informative 
genotyping results, inactive X was found to be of maternal origin in eight pairs. This 
result is on the border of statistical significance (P=0.055). Assuming this result 
holds, we will be left with an interesting puzzle. Why are maternally inherited X 
chromosomes more likely to be inactivated in highly skewed patients? One 
possibility is that some X chromosomes confer a selective disadvantage to both the 
organism itself and the peripheral cells within the organism. This precise situation 
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has been documented in X-linked immunodeficiency, where heterozygous (female) 
carriers have high X-inactivation skew (because of natural selection within the 
organism), while affected males have a survival disadvantage (Puck&Willard 
1998). When an X-encoded genotype is selectively disadvantageous to cells, skew 
is an outcome. When an X-encoded genotype is selectively disadvantageous to an 
organism, preferential maternal inheritance is an outcome. Together, this leads us to 
the hypothesis that some highly skewed patients have an X chromosome that would 
confer a selective disadvantage on homozygotic women and on males. 
Another evidence for our hypothesis could be the increase in recurrent spontaneous 
abortions in the patients with extremely skewed XCI pattern in scleroderma, 
autoimmune thyroiditis and pre-eclampsia in this study. It has been documented that 
recurrent spontaneous abortion was associated with extremely skewed XCI (Lanasa 
et al. 1999, Sangha et al. 1999, Kim et al. 2004, Bagislar et al. 2006). Deleterious X 
chromosome mutations that are associated with cell-growth disadvantage could be 
tolerated in females due to the XCI process. Cell death occurs early in development 
if the mutation is carried on the active X chromosome and the XCI pattern becomes 
skewed. However in hemizygous males the putative mutations become a male lethal 
trait and may contribute to the etiology of recurrent spontaneous abortion. 
 
Maternally inherited skewed XCI profile accompanies the disease phenotype for our 
AITDs Family 1.We observed segregation between the disease and marker alleles 
with the DNA markers residing on Xp22 and Xp11q13 regions of the X-
chromosome in this family. Although there are publications that report examples of 
skewed XCI segregating with a trait (Pegoraro et al. 1997, Bicocchi et al. 2005), 
this is the first example in AITDs to the best of our knowledge. In a recent 
publication on a three generation kindred, extremely skewed XCI profile was 
documented in three female subjects who have hemophilia A (Bicocchi et al. 2005). 
The authors concluded that skewing in the family resulted from an abnormality in 
the initial choice process, because the inactive X was always of paternal origin in 
affected female subjects. This process prevented the X chromosome, which carried 
the mutant FVIII allele, from being an inactive X. The inactive X chromosome was 
of paternal origin in our Family 2 with two affected sisters. Extension of both the 
XCI and linkage studies to large cohorts with familial AITDs cases could prove to 
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be very rewarding in understanding the relation between skewed XCI and 
autoimmune thyroidites. 
 
Since scleroderma is the first disease in which pregnancy related microchimerism 
has been documented, we investigated a subset of Turkish and US SSc patients to 
see whether a correlation exist between skewed XCI and microchimerism. Neither 
maternal nor fetal microchimerism were found to be correlated with skewed X-
inactivation. In conclusion, the two types of female mosaicism, which are skewed 
X-inactivation and maternal/fetal microchimerism, appear to be independent risk 
factors in scleroderma. One possible explanation for these data is that mosaicism 
itself is an underlying cause of scleroderma and, by extension, female-prevalent 
autoimmune disease in general. 
 
The cause of autoimmune diseases could be the cause of the skewing, or the 
skewing of XCI could be the cause of autoimmunity. If the the secondary selection 
is the result of autoimmune reaction, the disease would cause the skewing. 
Alternatively, if the disease is at least partially caused by an X-encoded gene, the 
disease allele could increase or decrease the fitness of cells inactivating the wild 
type or mutant allele of this gene, leading to secondary selection for immune cells 
inactivating one or both X-chromosomes. This would mean that both the disease 
and the skewing is the result of the X-linked gene. We believe that escape from self 
tolerance could be the result of skewing because the degree of skewing is at the 
extreme profiles (>95%) in most patients. If the skewing was due to aging or result 
of an autoimmune reaction, we expect to observe more patients in the milder ranges 
(80:20 or 90:10).  
 
The location of these putative X-linked mutations is a key point. Our proposal is 
that they do not need to be at a certain gene or locus on the chromosome. On the 
contrary, any mutation that affects the viability of the cell could lead to skewed 
XCI. In addition, X/autosomal translocations which fall within and outside genes or 
other X chromosome aberrations could affect XCI ratios. Therefore, a variety of X 
chromosomal events including a single mutation in a very rich repertoire of genes 
could be critical for female predisposition to autoimmunity. This may also explain 
why despite the extensive linkage genome scans, X chromosome is not clearly 
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implicated in familial cases of autoimmune thyroid diseases, (Imrie et al. 2001) or 
why a major locus for autoimmunity proves to be so difficult to find in the genome 
(Wellcome Trust Case Control Consortium, 2007). “Loss of mosaicism” for X-
linked gene expression as the first step of the cellular events that lead to breakdown 
of self-tolerance in females may be considered at this point. 
 
Lymphoblastoid cell lines (LCL), which have been immortalized by infection with 
Epstein Barr Virus (EBV), are being actively and extensively used to examine the 
expression of specific genes and genome-wide expression profiles. In this study, 
using X chromosome inactivation (XCI) as a measure of the degree of clonality, we 
confirm and quantify widespread near monoclonality in two independent sets of 
control and T1D cell lines.Our results on British T1D and control lymphoblastoid 
cell line (LCL) pauciclonality, indicate that expression data from LCLs are not well 
reliable to detect correlations between SNPs and gene expression. When the 
expression of a gene is affected by methylation patterns or other epigenetic 
meiotically stable factors (Gimelbrant et al. 2007, Migeon et al. 1988), the 
expression measurement will not be representative of the in vivo cell population in 
LCLs. From the random inactivation of the same allele in the small number of 
clones that constitute the LCL strong allelic imbalance can result. This may result in 
increased false positive and false negative rates. In fact, by the random subsampling 
of a small number of clones in a LCL any gene expression measurement that is 
variable across cells in vivo can be significantly altered By this way, the power of 
genome-wide studies or specific gene studies to detect association between SNPs 
and expression traits may be affected by this additional measurement noise in LCLs. 
Consequently, we recommend where possible the use of bulk, non cell line, ex vivo 
cells when measuring gene expression, and in particular when focusing on allele-
specific expression. 
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CHAPTER V 
 
 
FUTURE PERSPECTIVES 
 
 
In this study we tested the hypothesis that disturbances in XCI may cause female 
preponderance in autoimmune disorders. This hypothesis depends on two events: 
First, an X-linked mutation leading to “loss of mosaicism”, and second 
“heterozygosity for allelic variants of the putative critical genes”. For the future, we 
developed a research strategy in which we are going to conduct a comprehensive 
genomic study by using high-density microarray analysis. All known 
nonsynonymous, synonymous and intronic SNPs on X chromosome were listed 
using NCBI and Ensembl databases. After elimination of redundant and non-
appropriate SNPs, 1618 nonsynonymous, 1091 synonymous, and 2802 intronic 
SNPs on X chromosome were included on the array. In addition, 166 SNPs from 
other autosomal chromosomes that are known to have association with certain 
autoimmune diseases were added. The exonic SNPs cover 783 genes and the 
intronic SNPs correspond to 160 genes. The array chips were produced and the 
experimental part was completed with 56 SSc, 82 AITDs, 48 PEE, 20 JIA, 2 
SICCA, 7 pediatric SSc, and 250 control samples (total 465 samples).  
In the analysis part of these experiments, the allelic frequency, their heterozygosity 
status and copy number variations will be searched. For each disease, the candidate 
alleles will be selected.  
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thyroiditis. Numbers in bold: Tunisian sode number of members, italic numbers: 
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Evidence from autoimmune thyroiditis of skewed
X-chromosome inactivation in female predisposition
to autoimmunity
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The etiologic factors in the development of autoimmune thyroid diseases (AITDs) are not fully understood.
We investigated the role of skewed X-chromosome inactivation (XCI) mosaicism in female predisposition
to AITDs. One hundred and ten female AITDs patients (81 Hashimoto’s thyroiditis (HT), 29 Graves’ disease
(GD)), and 160 female controls were analyzed for the androgen receptor locus by the HpaII/polymerase
chain reaction assay to assess XCI patterns in DNA extracted from peripheral blood cells. In addition,
thyroid biopsy, buccal mucosa, and hair follicle specimens were obtained from five patients whose blood
revealed an extremely skewed pattern of XCI, and the analysis was repeated. Skewed XCI was observed in
DNA from peripheral blood cells in 28 of 83 informative patients (34%) as compared with 10 of 124
informative controls (8%, Po0.0001). Extreme skewing was present in 16 patients (19%), but only in three
controls (2.4%, Po0.0001). The buccal mucosa, and although less marked, the thyroid specimens also
showed skewing. Analysis of two familial cases showed that only the affected individuals demonstrate
skewed XCI patterns. Based on these results, skewed XCI mosaicism may play a significant role in the
pathogenesis of AITDs.
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Introduction
Hashimoto’s thyroiditis (HD) and Graves’ disease (GD)
are autoimmune thyroid diseases associated with multiple
genetic factors. Although the pathogenesis is poorly
understood, a widely accepted model suggests an inherited
background, which predisposes the subjects to autoimmu-
nity. Additional intrinsic and extrinsic factors such as
hormones and the environment may ultimately trigger or
contribute to the development of the disease phenotype.1
Extensive linkage genome screens during the past decade
have resulted in the identification of several thyroid-
specific susceptibility genes and/or loci, but confirmation
through multiple population studies is still awaited for
the majority of these loci.1,2 A common feature of auto-
immune diseases, including autoimmune thyroid diseases
(AITDs), is an increased prevalence in women when
compared with men. The most striking sex differences are
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observed in AITDs, scleroderma, Sjo¨gren’s syndrome, and
systemic lupus erythematosus, which are diseases where
over 80% of the patients are females.3
It has been demonstrated that risk of autoimmunity
could be increased by a lack of exposure to self-antigens in
the thymus and the presence of autoreactive T cells.4 – 6
Disturbances in the X-chromosome inactivation (XCI)
process provide a potential mechanism whereby the lack
of exposure to self-antigens could occur,7,8 including
AITDs.9,10 X-chromosome inactivation is a physiologic
process that takes place in early female development and
results in the transcriptional silencing of one of the pair of
X chromosomes.11 As a result of this epigenetic regulation,
a random inactivation of the X chromosome inherited
from either parent occurs and normal female subjects
are thus a mosaic of two cell populations. It is therefore
an attractive hypothesis that skewed XCI could lead to
the escape of X-linked self-antigens from presentation in
the thymus or in other peripheral sites that are involved
in tolerance induction, inadequate thymic deletion, and
finally loss of T-cell tolerance. Indeed, we recently
observed skewed XCI in blood cells of women with
scleroderma.12
Based on our observation that an association exists
between skewed XCI and female predisposition to auto-
immunity, we hypothesized that skewed XCI may be
involved in the pathogenesis of AITDs, particularly in the
hematopoietic compartment. We observed extremely
skewed XCI in the blood samples of a significant propor-
tion of female patients with AITDs.
Methods
Patients and pedigree analysis
Caucasian women diagnosed with AITDs (n¼110), and
healthy female controls with no history of autoimmune
disease and cancer (n¼160) were included in the study.
Among the patients, 81 were diagnosed with HT and 29
with GD. The mean ages were 44.8714.1 (mean7SD) years
for AITDs (46714.2 years in the Hashimoto patients, and
40.6713.2 years in the Graves’ patients), and 46710 for
controls. The duration of the symptoms was 5.777.4 years
among the AITDs patients (5.777 years in the Hashimoto
patients and 678.5 years in the Graves’ patients). The
mean age of diagnosis was 39712 years. All of the patients
had attended the outpatient clinics of the Endocrinology
and Metabolic Diseases Department of Ankara University
School of Medicine for at least 1 year since the onset of
disease. Patients were randomly chosen for the study.
All clinical investigations described in this manuscript
were conducted in accordance with the guidelines in the
Declaration of Helsinki (http://www.wma.net). The ethics
review board of the participating institutions approved the
study protocol. Informed consent was obtained from all
subjects.
The diagnosis of HD was made by the existence of a firm
goitre in combination with elevated thyroid auto-anti-
bodies (thyroglobulin and/or thyroid peroxidase), a low
ultrasonographic echogenity of the gland, and demonstra-
tion of lymphocytic infiltration by fine-needle aspiration
biopsy and/or biochemical hypothyroidism. The diagnosis
of GD was based on biochemical hyperthyroidism, and a
diffuse symmetrical goitre in combination with positive
thyroid antibodies (thyroglobulin, thyroid peroxidase or
TSH receptor). In addition, thyroid ophthalmopathy and/
or diffuse hyperplasia on an isotope scan or ultrasonogra-
phy demonstrating homogenous echo texture may accom-
pany the clinical picture.
Following the XCI studies, a complete pedigree analysis
was carried out for 64 individuals informative for the AR
polymorphism with medical follow-up of reported AITDs
among family members when possible. Owing to emigra-
tion or unwillingness to contribute family information,
data could not be obtained from the remaining 19
participants. Family history of AITDs was determined by
reviewing the probands’ pedigree to determine the number
of relatives affected by these autoimmune diseases. Only
first- and second-degree relatives were counted. A positive
family history was noted if one additional AITD was
documented by medical review.
X-chromosome inactivation analysis
Genotyping of a highly polymorphic CAG repeat in the
androgen-receptor (AR) gene was performed to assess the
XCI patterns as described elsewhere.12,13 Densitometric
analysis of the alleles was performed at least twice for
each sample using the MultiAnalyst version 1.1 software. A
corrected ratio (CrR) was calculated by dividing the ratio of
the predigested sample (upper/lower allele) by the ratio of
the nonpredigested sample for normalization of the ratios
that were obtained from the densitometric analyses. The
use of CrR compensates for preferential amplification
of the shorter allele when the number of PCR cycles
increases.14 A skewed population is defined as a cell
population with greater than 80% expression of one of
the AR alleles. This corresponds to CrR values ofo0.33 or43.
Haplotype analysis
Human MapPairs Version 10 purchased from Research
Genetics (currently available by Invitrogen, CA, USA) was
used to screen the X chromosome. Site-specific PCR, 6%
polyacrylamide gel electrophoresis, and silver staining
techniques were used for genotyping the individuals. Gels
were manually pictured and genotyped. Cyrillic program
(version 2) was used to generate the haplotypes. A total of
27 X-chromosome-specific DNA markers from the Map-
Pairs Panel were genotyped. Map order and physical
positions (Mb) of the additional polymorphic DNA markers
were obtained from USCS genome browser (The University
of California Santa Cruz, CA, USA http://genome.ucsc.edu/).
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Statistical methods
The results from control and test groups in XCI studies
were compared by w2 test with Yate’s correction.
Results
PCR-based X-inactivation study of peripheral blood
XCI status was informative in 83 of the 110 AITDs patients
and in 124 of the 160 controls. Some heterozygous
individuals were considered uninformative since only
those whose alleles resolve adequately for densitometric
analyses were included in the study. Skewed XCI (480%
skewing) was observed in 28 of the 83 patients (34%), and
10 of the 124 controls (8%) (Po0.0001). When the data for
the two groups of AITDs patients was analyzed indepen-
dently, 23/67 (34.33%, Po0.0001) of the Hashimoto’s
patients and 5/16 (31.25%, P¼0.0167) of the Graves’
patients were found to display the skewed XCI in blood.
More importantly, extremely skewed XCI, defined as
490% inactivation of one allele, was present in 16 patients
(19%), and in only three controls (2.4%, Po0.0001) (see
Table 1). Extremely skewed XCI is a rare event in the
general population. It has been reported in only 1–2% of
women aged 20–40 years, and in 2–4% of women aged
55–72 years.15,16 The distribution of XCI skewing in the
general population is thought to be mainly due to chance
deviations from 50:50 as a result of the limited number of
embryonic cells present (4–20) at the time of XCI.17 Age
alone is unlikely to influence the strikingly bimodal data in
our AITDs patients (Figure 1). We did not observe a shift
towards the skewed range in older patients and controls.
PCR-based X-inactivation study of thyroid biopsy,
buccal mucosa, and hair follicle specimens
Thyroid biopsy, buccal mucosa, and hair follicle specimens
were obtained from five patients (04-121, 04-198, 04-214,
04-221, and 04-225). Their blood XCI profile displayed
almost exclusive representation of only one allele of the AR
polymorphism in their methylation-sensitive PCR assay,
which indicates extremely skewed XCI. Five randomly
selected patients showed skewing in the same direction for
all tissues, except hair follicle, that in the thyroid being less
marked than blood and buccal cells (Figure 2). Hair follicle
specimens had a random XCI pattern. The allele ratios are
given in Table 2.
Pregnancy history and pedigree analysis
Characteristics of the AITDs patients with skewed and
random XCI are shown in Table 3. Only those patients with
a complete pregnancy and family history are included in
this table. The pedigrees of many AITDs probands with
skewed XCI versus those with random XCI were interesting
in two aspects. First, recurrent spontaneous abortions
(defined as three or more pregnancy losses), which have
been shown to be associated with skewed XCI,16,18 occurred
in four of 25 (16%) of our AITDs probands with skewed
XCI. Conversely, a history of recurrent spontaneous abor-
tions was negative both in the patients with random XCI
and in the control group subjects (Po0.0199). Although the
etiology of recurrent abortions in thyroid autoimmunity
remains unknown, women who present with thyroid
antibodies in the first trimester of pregnancy have a two-
to four-fold increase in their miscarriage rates.19
Second, a positive family history, particularly in the
skewed group, was apparent (12/25, 48% in the skewed;
and 10/39, 25.6% in the random groups). We therefore
contacted all of the 12 probands in an attempt to extend
the X-chromosome inactivation studies to other family
members. Initially, a positive response was received from
three families, but blood samples could be obtained from
Table 1 Proportion of patients and controls with skewed
X-chromosome inactivation
Degree of
skewing (%) No. (%) observed with skewing
Autoimmune thyroiditis
(n¼83)
Control females
(n¼ 124)
90+ 16 (19.27) 3 (2.41)
80–89 12 (14.45) 7 (5.64)
70–79 6 (7.22) 22 (17.74)
60–69 16 (19.27) 29 (23.38)
50–59 33 (39.75) 63 (50.80)
For comparison by w2, Po0.0001 (480% skewing); Po0.0001 (90+%
skewing).
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Figure 1 Distribution of X-inactivation patterns according to age in
AITDs patients and control subjects.
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the family members of only two probands (04-445, Family
1; and 04-298, Family 2). An important observation
emerges from a study of these families: only the affected
individuals demonstrate skewed XCI patterns. For example,
XCI is extremely skewed in the affected sister and mother of
04-445 (Family 1), but random in the two unaffected sisters.
The inactive X chromosome here is of maternal origin. In
patient 04-298 (Family 2), skewing in the 80–89% range is
noted for her affected sister, but unfortunately her mother
was not informative for the AR polymorphism. Interest-
ingly, the inactive X chromosome appears to be of paternal
origin in Family 2 (Supplementary Figures 1 and 2).
Haplotype analysis
Because XCI segregates as a heritable trait associated with
the disease in two generations of Family 1, we performed
haplotype analysis by using polymorphic X-chromosomal
markers to determine possible segregation between the
Table 2 X-chromosome inactivation patterns in blood,
thyroid, buccal mucosa, and hair follicle specimens
Sample 04-121 04-198 04-214 04-221 04-225
Blood 94:6 91:9 84:16 92:8 91:9
Thyroid 72:28 79:21 76:24 74:26 64:36
Buccal 86:14 97:3 87:13 89:11 82:18
Hair 60:40 50:50 () 59:41 52:48
04-225
04-121
04-198
+- +- +-+
M Thy. biopsy Buccal Hair
04-214
04-221
Blood
-Hpa ll
Figure 2 X-inactivation analysis of androgen receptor locus. PCR
products of undigested () and HpaII-digested (þ ) DNA from
peripheral blood, thyroid biopsy, buccal, and hair follicle samples of
AITDs patients 04-121, 04-198, 04-214, 04-221, and 04-225 are
shown. Two alleles are seen in undigested samples, whereas a single
allele resulting from extremely skewed XCI is clearly visible in all
peripheral blood samples. Allele ratios are given in the text and in
Table 2. M: marker (pUC mix 8), 331 and 242 bp fragments are visible.
Table 3 Characteristics of the patients who are informative for X-chromosome inactivation status
Patient Birth date Disease onset Pregnancy history Sex and birth date of children Family history of first-degree relatives
90+% skewing
1 04-136a 1975 2004 G0,P0,A0 () ()
2 04-127b 1975 2003 G0,P0,A0 () ()
3 04-138b 1962 1980 G7,P0,A7 () Two sisters
4 04-298b 1979 2003 G1,P1,A0 F03 Mother, one sister
5 04-445b 1961 2000 G1,P1,A0 F88 Mother, one sister
6 04-198b,c 1935 2004 G2,P2,A0 M68,M72 ()
7 04-221b,c 1958 2000 G4,P2,A2 M91,F94 Two sisters
8 04-250b 1967 1996 G7,P2,A5 M89,M93 One son
9 04-226b,c 1963 2004 G3,P3,A0 M83,F88,M98 One sister
10 04-233a 1967 1990 G4,P3,A1 M88,F94,M01 ()
11 04-121b,c 1957 1988 G7,P4,A3 F78,M83,F91,F94 ()
12 04-205b 1927 2003 G6,P5,A1 M47,M50,F52,F53,M55 ()
13 04-225b,c 1936 1975 G6,P6,A0 F56,F58,F60,F62,M64,M66 One daughter
80–89% skewing
14 04-132b 1960 2002 G0,P0,A0 () Mother, one sister
15 04-223b 1956 1988 G0,P0,A0 () Mother, one sister
16 04-105a 1978 1999 G5,P1,A4 M98 ()
17 04-131b 1944 2002 G3,P2,A0 M69,M71 ()
18 04-120b 1956 1994 G3,P3,A0 F75,M77,F78 ()
19 04-107b 1948 1998 G4,P3,A1 F70,F72,F76 ()
20 04-98b 1956 2000 G8,P3,A1 F79,F81,F87 Two daughters
21 04-218b 1941 1991 G4,P3,A1 M61,F63,F67 ()
22 04-108b 1952 1999 G5,P3,A2 F77,F78,M83 ()
23 04-208b 1960 1999 G5,P3,A0 F83,F85,M88 Mother
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disease and marker alleles. Although the size of this family
is not large enough to prove linkage, it still provides
valuable information about the exclusion area on the X
chromosome. This helps to define a minimal critical region
on the X chromosome, which might be associated with
AITDs. Xp11-q13 (GATA144DO4, DXS7132, and AR) and
Xp22 DNA markers (DXS8022, DXS987, and DX9902)
showed concordance among the affected individuals
indicating positive segregation between the disease and
marker alleles. The haplotype structure is shown in
Figure 3. However, lod score20 analysis did not allow
formal acceptance of linkage to any loci mainly due to the
small size of the family.
Discussion
The autoimmune diseases include more than 70 chronic
disorders that affect approximately 5% of the population. A
reduction in sex ratio (male:female) is characteristic of
most such diseases, including AITDs.3 Even though the
Table 3 (Continued)
Patient Birth date Disease onset Pregnancy history Sex and birth date of children Family history of first-degree relatives
24 04-110a 1960 1998 G4,P4,A0 M80,M83,M85,F96 ()
25 04-214b,c 1921 1999 G9,P8,A1 F44,M45,F47,F48,M54,F56,F58,M60 One daughter
70–79% skewing
26 04-203b 1961 2004 G3,P1,A0 M82 ()
27 04-230b 1951 1999 G2,P2,A0 M77,M86 One son
28 04-213b 1947 1998 G7,P3,A0 F67,M68,M71 ()
29 04-228b 1953 2001 G3,P3,A0 M71,M73,M82 ()
30 04-137b 1932 1981 G5,P4,A0 F50,F53,M55,F59 ()
60–69% skewing
31 04-206a 1946 1964 G1,P0,A1 () ()
32 04-92b 1971 1998 G3,P1,A0 F96 Mother
33 04-240b 1975 2003 G2,P1,A0 M00 ()
34 04-139b 1959 2002 G1,P1,A0 M97 ()
35 04-257b 1973 2004 G3,P2,A1 M95,M01 ()
36 04-112b 1952 1999 G2,P2,A0 F72,F77 Mother
37 04-220a 1955 1998 G3,P2,A0 M74,M78 ()
38 04-103b 1962 1986 G6,P2,A1 F82,M92 ()
39 04-251b 1941 1984 G5,P3,A1 M60,M63,M65 Two sisters
40 04-99b 1961 1997 G6,P3,A2 F81,F85,F87 Mother, one sister
41 04-224a 1950 2001 G6,P5,A1 M69,M72,F73,M75,F78 ()
50–59% skewing
42 04-96b 1939 1996 G0,P0,A0 () ()
43 04-242b 1960 1999 G0,P0,A0 () ()
44 04-129b 1982 1998 G0,P0,A0 () Mother
45 04-196b 1956 1999 G6,P1,A0 F93 ()
46 04-231b 1964 2003 G1,P1,A0 M93 ()
47 04-201a 1971 2001 G2,P1,A1 F93 Mother
48 04-95b 1975 2004 G3,P2,A0 F98,M00 ()
49 04-239b 1951 2003 G3,P2,A0 M68,M75 ()
50 04-246b 1961 1996 G2,P2,A0 M78,F81 ()
51 04-200b 1954 1992 G5,P2,A0 M73,M75 Three sisters
52 04-237b 1970 2004 G2,P2,A0 M93,F97 ()
53 04-102b 1964 2003 G3,P2,A1 F95,F87 ()
54 04-204b 1949 2002 G4,P2,A0 F71,M73 ()
55 04-93a 1960 2003 G2,P2,A0 M91,F94 ()
56 04-116a 1960 2003 G4,P2,A0 F86,M89 One brother
57 04-197b 1961 1976 G6,P3,A2 M82,M84,M98 ()
58 04-229b 1938 1980 G3,P3,A0 M61,M63,F65 One sister
59 04-255b 1974 1993 G3,P3,A0 F92,M96,F01 ()
60 04-212a 1958 2002 G4,P3,A0 M76,F80,M84 ()
61 04-238b 1939 2002 G6,P4,A0 M61,M65,F67,M72 ()
62 04-117b 1944 2004 G6,P4,A0 M60,M64,F66,F67 ()
63 04-211a 1950 2002 G6,P6,A0 F66,F67,F72,M84,M85,M86 ()
64 04-243a 1937 1994 G12,P7,A1 M57,M59,F60,F62,M65,M67,F68 ()
G, number of pregnancies; P, para (pregnancies carried to term and delivered); A, spontaneous abortions.
aGraves’ disease.
bHashimoto’s thyroiditis.
cPatients from whom thyroid biopsy samples were obtained.
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female prevalence of autoimmune diseases has been
recognized for over a hundred years, candidate mecha-
nisms that could be important in pathogenesis have been
uncovered only during the past two decades. These include
genetic traits associated with autoimmunity,21 pregnancy-
related microchimerism,22 and disturbances in XCI mosai-
cism in female subjects.12 In this study, we demonstrate
skewed XCI patterns in peripheral blood mononuclear cells
of a significant proportion (34%) of female subjects with
AITDs. Approximately 8% of female control subjects
demonstrate skewed X-inactivation patternsX80:20, which
is consistent with previous estimates.16,18,23 The effect is
more pronounced at patterns of X-inactivation X90:10;
nearly 20% of AITDs patients show such skewing (Supple-
mentary Figure 3), compared with only a few percent of
female control subjects. Our results show that factors
associated with extremely skewed XCI could account for a
significant proportion of female patients with AITDs.
Skewed XCI is a result of primary or secondary causes.
The former is bias in the initial choice of which X
chromosome is inactivated due to germline XIST (X-
inactive-specific transcript) mutations.24 The secondary
causes are deleterious X-linked mutations, X chromosome
rearrangements, aging, twinning, or monoclonal expan-
sion of cells (for a review, see Brown25). We believe that
deleterious X-linked mutations or X chromosome rearran-
gements and their differential expression patterns could
provide a disadvantage to blood and buccal cells, and
possibly to thyroid cells in AITDs patients, and lead to
skewed XCI. This has been supported by our observation
that maternally inherited skewed XCI profile accompanies
the disease phenotype for our AITDs Family 1. We observed
segregation between the disease and marker alleles with
the DNA markers residing on the distal short arm and
pericentromeric regions of the X chromosome in this
family. Although examples of skewed X-inactivation
segregating with a trait have been reported previously,18,26
this is the first example in AITDs to the best of our
knowledge. In a recently published study on a three-
generation kindred, extreme skewing of X inactivation was
documented in three female subjects who have hemophilia
A.26 Since the inactive X was always of paternal origin
in affected female subjects, the authors concluded that
skewing in the family resulted from an abnormality in the
initial choice process. This prevented the X chromosome,
which carried the mutant FVIII allele, from being an
inactive X. In our Family 2 with two affected sisters, the
inactive X chromosome was of paternal origin like the
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Figure 3 Haplotype structure of Family 1. Patient 04-445 was
arbitrarily selected to construct the haplotype. Maternally inherited
haplotype was highlighted with solid black bar. Haplotypes of the
remaining sibs were compared with the reference individual (04-445),
and shared portions were also marked with solid bars. Noninforma-
tiveness in the crossover regions were demonstrated with thin bars.
The regions between the DNA markers DXS8051 and DXS8036 as well
as DXS8014 and AR regions on Xp22 and Xp11-q13 regions,
respectively, were not excluded since positive segregation between
the disease and marker alleles was observed.
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hemophilia A family. Extension of both the XCI and
linkage studies to large cohorts with familial AITDs cases
could prove to be very rewarding in understanding the
relation between skewed XCI and autoimmune thyroidites.
Studies that aim to delineate the medical consequences
of skewed X-inactivation have shown that clinical mani-
festation of X-linked disorders in female subjects could be
influenced by disturbances in the XCI process.27 In
addition, it has been hypothesized that skewed XCI could
be a factor that influences female predisposition to
autoimmunity.7,8 Now that we have demonstrated skewed
patterns of XCI in a significant proportion of female AITD
patients, deviation from the physiological range of XCI
mosaicism could be considered as a potential mechanism
contributing to disease pathogenesis. This is further
supported by the recently reported observation that female
twins with AITDs have a high frequency of skewed XCI.28
Although extremely skewed XCI is rare, it does not
always lead to the development of AITDs. A subsequent
event, such as environmental exposure to viral, chemical,
or other agents may trigger a cascade that results in AITDs.
In addition, the co-inheritance of genetic susceptibility
factors, such as functional variants in vital negative
regulatory molecules of the immune system,29,30 may
exacerbate the effects of skewed XCI and contribute to
the development of autoimmune diseases including AITDs.
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Abstract Pre-eclampsia is a disorder that aVects
approximately 5% of pregnancies. We tested the
hypothesis that skewed X-chromosome inactivation
(XCI) could be involved in the pathogenesis of pre-
eclampsia. Peripheral blood DNA was obtained from
67 pre-eclampsia patients and 130 control women.
Androgen receptor (AR) was analyzed by the HpaII/
polymerase chain reaction assay to assess XCI patterns
in DNA extracted from peripheral-blood cells. In addi-
tion, buccal cells were obtained from seven patients,
and the analysis repeated. Extremely skewed XCI was
observed in 10 of 46 informative patients (21.74%),
and in 2 of 86 informative controls (2.33%, P = 0.0005;
2 test). Our Wndings support a role for the X-chromo-
some in the pathogenesis of pre-eclampsia in a sub-
group of patients.
Introduction
Pre-eclampsia is a pregnancy-speciWc syndrome of
unknown etiology. It is the leading cause of maternal
and perinatal mortality, characterized by increased
blood pressure and proteinuria (Roberts and Cooper
2001; Broughton Pipkin 2001). The disease occurs only
in the presence of a placenta and resolves with the
removal of the placenta. Studies that aim to identify
susceptibility loci with signiWcant linkage to familial
cases of pre-eclampsia (OMIM 189800) resulted in
the identiWcation of four chromosome regions: 2p13
(Iceland) (Arngrimsson et al. 1999), 2p25 and 9p13
(Finland) (Laivuori et al. 2003), and 10q22 (The
Netherlands) (Lachmeijer et al. 2001; Oudejans et al.
2004). The Dutch pre-eclampsia locus shows maternal
segregation, and recently STOX1 (storkhead box 1;
also called C10orf24), was identiWed as a candidate
gene for this locus (van Dijk et al. 2005).
Maternal endothelial dysfunction and failure of the
tolerance system as evidenced by Th-1 type immunity
are early pathophysiological modiWcations in pre-
eclampsia (Saito and Sakai 2003). Failure of the toler-
ance system is associated with autoimmune diseases. A
negative selection system against potentially self-reac-
tive T-cells in the thymic medulla and cortex-medulla
junction is critically important in establishing T-cell
tolerance. The negative selection process is mediated
primarily by the dendritic cells, which participate in
antigen presentation (Speiser et al. 1989; Laufer et al.
1996). Lack of exposure to self-antigens in the thymus
and the presence of autoreactive T-cells have been
shown to increase the risk of autoimmunity (Klein
et al. 2000).
It was hypothesized that disturbed X-chromosome
inactivation (XCI) could be a mechanism whereby lack
of exposure to self-antigens may occur in females (Kast
1977; Stewart 1998). X-inactivation is an epigenetic
modiWcation in females that results in the transcriptional
inactivation of one of the pair of X-chromosomes at
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Hum Genet random (Lyon 1961). Normal females are thus mosaics
of two cell populations. Four recently published stud-
ies, one by a Japanese group on primary ovarian failure
(Sato et al. 2004), one by us on scleroderma (Ozbalkan
et al. 2005), and two on autoimmune thyroid diseases
(Brix et al. 2005; Ozcelik et al. 2006), raised the possi-
bility that skewed XCI could play an important role
in the pathogenesis of autoimmune diseases. Since
the disease may have an autoimmune component, we
hypothesized that skewed XCI could be involved in the
pathogenesis of pre-eclampsia as well.
We observed that the number of women with
extreme skewing of XCI is signiWcantly higher in the
pre-eclampsia group than in healthy control women
with no history of pre-eclampsia, autoimmune diseases
or cancer. The cause of skewed XCI mosaicism in auto-
immune diseases and pre-eclampsia is not yet known.
Possible mechanisms include skewing of XCI as cause
of the disease, or alternatively the cause of pre-eclamp-
sia could also be the cause of the skewing.
Materials and methods
Patients
Sixty-seven Caucasian women diagnosed with pre-
eclampsia, and 130 apparently healthy Caucasian
female controls were genotyped to determine whether
women with pre-eclampsia have a greater frequency
of extremely skewed XCI than control subjects. The
ethics review board of the participating institutions
approved study protocol. Pregnancy history, age, and
disease information accompanied by informed consent
was obtained from all subjects. In the control group
(124/130) women gave birth to at least one child, and
none had a history of pregnancy loss, autoimmune dis-
ease or cancer. The birth registry at the Etlik Maternity
and Women’s Health Teaching Hospital in Ankara was
used to contact the pre-eclamptic cases. All women in
the patient group had singleton deliveries. The mean
ages were 29.8 § 5.7 years (mean § SD; range = 21–
42 years old) for the cases, and 31.6 § 5.6 (range = 21–
47 years old) for the controls.
Pre-eclampsia was deWned as the development of
hypertension plus proteinuria within 7 days of each
other after the twentieth week of gestation in women
with no proteinuria at baseline. Hypertension and
severe hypertension were deWned as diastolic blood
pressures of at least 90 and 110 mm Hg, respectively,
occurring on at least two occasions, 4–168 h apart. Uri-
nary protein excretion of >300 mg in 24 h was indica-
tive of proteinuria. Pre-eclampsia was considered
severe in the presence of severe hypertension or severe
proteinuria, HELLP syndrome (haemolysis, elevated
liver enzymes, low platelets), or eclampsia. Those sub-
jects with a previous history of chronic hypertension,
renal disease or diabetes mellitus were excluded.
X-chromosome inactivation analysis
DNA was extracted from 10 ml venous blood samples
with NucleoSpin Blood kit (Macherey-Nagel, Düren,
Germany) according to the manufacturer’s protocol.
After ethanol precipitation, DNA was dissolved in dis-
tilled water and stored at 4°C.
Genotyping of a highly polymorphic CAG repeat in
the androgen-receptor (AR) gene was performed to
assess the XCI patterns (Allen et al. 1992). Patients
with ¸90% representation of one allele were classiWed
as extremely skewed XCI. The DNA was divided into
two identical aliquots, one of which was incubated
overnight at 37°C with methylation-sensitive restric-
tion enzyme HpaII (MBI Fermentas, Vilnius, Lithua-
nia) for the digestion of unmethylated (or active)
alleles. A second restriction enzyme, RsaI (MBI Fer-
mentas, Vilnius, Lithuania), which recognizes a four
base pair sequence not present in the ampliWed region
of the AR locus was also included in the reaction to
facilitate the HpaII digestion process. The other ali-
quot of the DNA was digested with RsaI alone as a
control. Male DNA with cytogenetically veriWed 46XY
karyotype was used as a control for incomplete diges-
tion.
After restriction enzyme digest, residual DNA was
ampliWed by using the primers 5-GTC CAA GAC
CTA CCG AGG AG-3 and 5-CCA GGA CCA GGT
AGC CTG TG-3. Amplicons were labeled by includ-
ing a radioactive nucleotide (-[33P] -dCTP) (NEN,
Perkin Elmer Life Sciences, Boston, Massachusetts) in
the polymerase chain reaction (PCR). PCR products
were separated on 8% denaturing 29:1 acrylamide/bis-
acrylamide gel for 5 h at 60 W. Gels were dried and
autoradiographed on MedicalWlm CP-BU (Agfa, Agfa-
Gevaert AG, Belgium). Densitometric analysis of the
alleles was performed at least twice for each sample
using the appropriate software (MultiAnalyst version
1.1; Bio-Rad, Hercules, California).
In addition, cold PCR followed by electrophoretic
separation of the alleles in 4% MetaPhor agarose
(FMC BioProducts, Rockland, Maine) for 4 h 30 min
at 80 V was carried out. Since the number of cycles
could be critically important for the outcome of densito-
metric analyses, samples were subjected to 25 and also
30 cycles of ampliWcation during the hot and the cold
PCR. Products were visualized by ethidium bromide123
Hum Genet staining, and densitometric analysis of the alleles was
performed at least twice for each sample using the
MultiAnalyst version 1.1software. A corrected ratio
(CrR) was calculated by dividing the ratio of the predi-
gested sample (upper/lower allele) by the ratio of the
non-predigested sample for normalization of the ratios
that were obtained from the densitometric analyses.
The use of CrR compensates for preferential ampliWca-
tion of the shorter allele when the number of PCR
cycles increases (Delforge et al. 1995). A skewed popu-
lation is deWned as a cell population with greater than
80% expression of one of the AR alleles. This corre-
sponds to CrR values of <0.33 or >3.
Statistical methods
The results from control and test groups were com-
pared by the Fisher’s exact test.
Results
XCI status was found to be informative in 69% of the
cases (46/67) and 66% of the controls (86/130). Only
those individuals whose alleles resolve adequately for
densitometric analysis were included in the study.
Extremely skewed XCI was present in ten (21.74%)
cases and two (2.33%) controls (P = 0.0005). It is well
established that extremely skewed XCI is a rare event
in a diverse group of control females (Busque et al.
1996; Naumova et al. 1996; Sharp et al. 2000; Amos-
Landgraf et al. 2006). When XCI values between 80
and 89% were also considered, skewed XCI was
observed in 16 of the 46 (34.78%) informative cases,
and 8 of the 86 (9.30%) controls (P = 0.0006) (Table 1).
DNA from buccal cells was analyzed in seven patients
with various degrees of skewing. They were chosen
randomly to assess whether the results from blood, a
mesodermal tissue, is comparable to other tissue types
such as buccal cells, which have an ectodermal origin.
Similar XCI patterns were observed (Table 2). Since it
would be of interest to identify diVerences in the preg-
nancy details between those of women with extreme
skewing, and women with normal X-inactivation, we
obtained clinical characteristics of the pre-eclampsia
patients informative for XCI status, and the controls
(Supplemental Tables 1, 2). Although the numbers are
too small to reach a conclusion, it is interesting that
recurrent spontaneous abortions is three times more
common in women with extreme skewing (3/10) than
in women with random patterns of XCI (3/30) (Supple-
mental Table 3). It is well established that the fre-
quency of skewed XCI is increased in recurrent
spontaneous abortions (Lanasa et al. 1999; Sangha
et al. 1999; Bagislar et al. 2006). Interestingly, a com-
mon genetic background for pre-eclampsia and recur-
rent spontaneous abortions has been questioned in the
medical literature (Christiansen et al. 1990).
Discussion
We observed skewed XCI patterns in peripheral-blood
mononuclear cells of a signiWcant proportion (35%) of
females with pre-eclampsia. Approximately 9% of
female control subjects demonstrated skewed XCI pat-
terns ¸80:20. The eVect is also pronounced at patterns
of XCI ¸90:10; nearly a quarter of pre-eclampsia
patients showed such skewing, compared with only 2%
of control subjects. Although skewed XCI patterns
¸80:20 could be as high as 19.5% (Amos-Landgraf
et al. 2006) or 21.6% (Naumova et al. 1996) in pheno-
typically normal females, skewing in the range of
¸90:10 or ¸95:5 is quite rare with only 3.6 and 1.7% of
the population, respectively (Amos-Landgraf et al.
2006). With respect to the relatively low percentage of
controls in the ¸80:20 range in our study, this result
may be a reXection of the pregnancy histories. An
overwhelming majority (124/130) had experienced a
normal pregnancy period with healthy deliveries.
Clinical manifestation of X-linked disorders in
females could be inXuenced as a consequence of distur-
bances in the XCI process (Lyon 2002). High fre-
quency of skewed XCI has also been observed in
Table 1 Proportion of the patients and controls with skewed
XCI
For comparison by 2, P = 0.0006 (>80% skewing); P = 0.0005
(¸90% skewing)
Degree of
skewing
(%)
No. (%) observed 
with skewing
Pre-eclampsia
patients 
(n = 46)
Control
females 
(n = 86)
90+ 10 (21.74) 2 (2.33)
80–89 6 (13.04) 6 (6.98)
70–79 6 (13.04) 15 (17.44)
60–69 13 (28.26) 20 (23.26)
50–59 11 (23.91) 43 (50.00)
Table 2 X-chromosome inactivation patterns in blood and buc-
cal mucosa specimens
Sample 04–176 04–182 04–190 04–298 04–192 04–284 04–289
Blood 91:90 93:70 90:10 98:20 83:17 71:29 70:30
Buccal 90:10 90:10 90:10 100:0 80:20 69:31 66:34123
Hum Genet recurrent spontaneous abortions (Lanasa et al. 1999;
Sangha et al. 1999), X-linked mental retardation (Plenge
et al. 2002), breast and ovarian cancers (Kristiansen
et al. 2002), and in mothers of homosexual men (Bock-
landt et al. 2006). In addition, it has been hypothesized
that skewed XCI could be a factor that inXuences
female predisposition to autoimmunity: recently
skewed XCI has been reported in three autoimmune
disorders, scleroderma (Ozbalkan et al. 2005), autoim-
mune thyroid diseases (Brix et al. 2005; Ozcelik et al.
2006), and premature ovarian failure (Sato et al 2004).
Skewed XCI could be the result of a bias in the ini-
tial choice of which X-chromosome is inactivated (pri-
mary cause), or selection against cells in which a given
X-chromosome has been inactivated (secondary cause)
[for review see Puck and Willard 1998; Brown 1999].
At present, we do not know the nature of the relation-
ship between XCI patterns and pre-eclampsia; except
that aging (a secondary cause) is highly unlikely to
be involved because of the relatively young ages of
the patients (mean age of diagnosis at 29.8 § 5.7 years
for all the patients, 30.3 § 6.2 years for patients with
skewed XCI, and 29.4 § 5.5 years for patients with ran-
dom XCI) (Fig. 1). However, two possibilities could be
considered: The cause of pre-eclampsia could also be
the cause of the skewing, or the skewing of XCI could
be the cause of pre-eclampsia. If the autoimmune reac-
tion is the cause of the secondary selection, the disease
would cause the skewing. Alternatively, if the disease is
at least partially caused by an X-chromosome gene, the
disease allele could increase or decrease the Wtness of
cells inactivating the wild type or mutant allele of this
gene, leading to secondary selection for immune cells
inactivating one or both X-chromosomes. This would
mean that the X-linked gene causes both the disease
and the skewing. Since both, pre-eclampsia and skewed
XCI may be heritable traits, the women with pre-
eclampsia and skewed XCI may share the same muta-
tion(s) in one or more X-linked genes. This implies
that it would be particularly important to establish if
any of the women who are included in the study were
related. However, they were neither related, nor were
they from the same geographical location.
Skewed XCI patterns are now demonstrated in a
signiWcant proportion of a subgroup of pre-eclampsia
patients. Therefore, disturbed XCI mosaicism could be
considered as a contributing factor to disease patho-
genesis. Further studies, such as haplotype analysis of
X-linked markers in mother-child pairs of pre-eclamp-
sia patients, and a search for X-chromosomal aberra-
tions in pre-eclampsia patients by microarray analysis
(Larrabee et al. 2004), could be critically important in
understanding the genetic etiology.
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ABSTRACT
Aims: This study aimed to identify the underlying genetic
defect of a large Turkish X linked nystagmus (NYS) family.
Methods: Both Xp11 and Xq26 loci were tested by
linkage analysis. The 12 exons and intron–exon junctions
of the FRMD7 gene were screened by direct sequencing.
X chromosome inactivation analysis was performed by
enzymatic predigestion of DNA with a methylation-
sensitive enzyme, followed by PCR of the polymorphic
CAG repeat of the androgen receptor gene.
Results: The family contained 162 individuals, among
whom 28 had NYS. Linkage analysis confirmed the Xq26
locus. A novel missense c.686C.G mutation, which
causes the substitution of a conserved arginine at amino
acid position 229 by glycine (p.R229G) in exon 8 of the
FRMD7 gene, was observed. This change was not
documented in 120 control individuals. The clinical
findings in a female who was homozygous for the
mutation were not different from those of affected
heterozygous females. Skewed X inactivation was
remarkable in the affected females of the family.
Conclusions: A novel p.R229G mutation in the FRMD7
gene causes the NYS phenotype, and skewed X
inactivation influences the manifestation of the disease in
X linked NYS females.
Congenital nystagmus (NYS) is an ocular oscilla-
tory movement disorder caused by a motor
instability that can manifest with or without
afferent visual system dysfunction. This entity is
defined both clinically and by electronystagmogra-
phy. Certain clinical features usually differentiate
congenital NYS from other oscillations. NYS may
be irregular, but is always conjugate and horizon-
tal, though very rarely vertical. There may be a
torsional component. Some patients with this
abnormality also show head oscillations, which
tend to increase when the patient attends to an
object, an effort that also increases the NYS.
Therefore, it seems probable that both the head
tremor and the ocular oscillations are the conse-
quence of a common disordered neural mechan-
ism.1
The underlying defect in congenital NYS
remains elusive. The Eye Movement
Abnormalities and Strabismus Working Group
proposed the term, infantile nystagmus syndrome,
for the NYS that is known as congenital NYS.
Although there is some controversy concerning
classification of NYS in infancy, it has been
suggested that NYS with an onset before 6 months
of age can be divided into three categories:2 (1)
congenital idiopathic NYS in which no visual or
associated neurological impairment can be found;
(2) sensory deficit NYS in which there is a visual
abnormality, such as ocular albinism, optic nerve
hypoplasia, congenital stationary night blindness
and blue cone monochromatism; (3) neurological
NYS, which is associated with a neurological
disorder. Category 1 is also called congenital motor
NYS, which is presumed to have a primary defect
in the part of the brain responsible for ocular motor
control.3
Congenital motor NYS is a genetically hetero-
geneous disorder. Autosomal dominant (MIM
164100), recessive (MIM 257400) and X linked
(MIM 310700) patterns of inheritance are
described for this disorder. X linked inheritance is
the most common form of NYS (NYS1). An
irregular dominant pattern of X linked inheritance
has been frequently reported, although some
pedigrees support X linked recessive inheritance.4
The penetrance is full in males and approximately
50% to 29% in females.5 6 Large intrafamilial
variance in waveforms can be observed. Two
distinct loci, one on the Xq26–q273 and the other
on the Xp11.47 regions have been reported as the
likely loci for X linked dominant NYS. The locus
on the long arm (Xq26) has been confirmed by
subsequent reports of various ethnic populations.8–
10 To the best of our knowledge, there are only two
reports supporting the Xp11.4 locus.7 11 The pat-
tern of inheritance and clinical profile of Xp11-
linked families are not different from Xq26-linked
pedigrees. X linked recessive NYS has also been
mapped to the Xq26 region, which harbours the X
linked dominant NYS locus.10 Recently, mutations
in the FRMD7 (FERM domain-containing 7) gene
have been reported as a molecular cause in Xq26-
linked families.6 Little is known about the function
of the FRMD7 gene; however, the restricted
expression pattern of this gene in the human
embryonic brain and developing neural retina
suggests a role in eye movement and gaze
stability.6
Herein, we report an extensive NYS pedigree,
including 162 individuals across six generations
from southeastern Turkey. The mode of inheri-
tance is clearly X linked, demonstrating a reduced
penetrance in female obligate gene carriers. Genetic
linkage analysis confirmed the Xq26–q27 locus,
and further mutation analysis identified a novel
p.R229G missense mutation in the FRMD7 gene
that causes this disorder. We also detected a
predisposition to skewed X inactivation in affected
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females, suggesting that the X inactivation mechanism might
have a role in manifestation of the disease in females.
METHODS
Clinical evaluation
The family was identified during fieldwork to study a large
craniosynostosis pedigree in Antakya, Turkey. The complete
pedigree structure contains over 427 individuals, including a
separate branch of congenital idiopathic NYS. Only the NYS
branch is included in this study, and the pedigree structure is
shown in fig 1. Pedigree formation was completed in the field by
NA, IV and SK. Neurological evaluation of 23 individuals was
conducted by YK, a neurologist and member of the family. The
recruitment criteria were NYS noted at birth or during the first
3 months of life, and no abnormalities of the ocular or neural
visual pathway. Visual acuity of all the patients was measured
by Snellen card. Eye movements were recorded by a video
camera in 16 patients. Video recordings were further reviewed
by a neuro-ophthalmologist (TK). Peripheral blood samples
were collected from 48 individuals with informed consent for
further molecular studies. The Hacettepe University Ethics
Committee approved the study (FON 02/6-13)
Genetic linkage analysis
The family was tested for linkage to two reported loci on
chromosome regions Xp117 and Xq26.3 Map order and physical
positions (Mb) of the polymorphic markers were obtained from
the University of California Santa Cruz (USCS), Genome
Bioinformatics Center (http://genome.ucsc.edu). Oligonucleotide
samples were purchased from MWG-Biotechnology (Ebersberg,
Germany). Site-specific PCR, 7% polyacrylamide gel electrophor-
esis and silver staining technique were used in genotyping the
individuals. Gels were manually pictured. The Cyrillic program
was used to generate haplotype and input files for linkage analysis.
Two-point linkage was performed with the MLINK component of
the LINKAGE package, assuming X linked dominant inheritance
with 0.36 penetrance in females. Mutant allele frequencies were
kept as 0.0001. Equal marker allele frequency of DNA markers was
assumed.
Mutation analysis
We designed primers to amplify all 12 protein-coding exons and
adjacent intronic sequences of the FMRD7 gene by PCR using
standard conditions (supplementary table). Due to its size, exon
12 was amplified in three overlapping fragments. Subsequent to
amplification, PCR fragments were purified, with QIAquick
spin columns (Qiagen), and directly sequenced using the
corresponding forward primers with the ABI PRISMH
BigDyeTM Terminator v2.0 cycle sequencing ready reaction kit
and an ABI PRISMH 3100 genetic analyser (Applied Biosystems).
We re-sequenced all identified mutations in independent
experiments, tested for co-segregation within the families, and
screened 120 Turkish control individuals for the c.686C.G
mutation by PCR and subsequent restriction digestion using
BccI (MBI Fermentas, Germany).
Evaluation of X chromosome inactivation (XCI)
Genotyping of a highly polymorphic CAG repeat in the
androgen-receptor (AR) gene was performed to assess the XCI
patterns.12 DNA was divided into two identical aliquots, one of
Figure 1 Complete pedigree structure of X linked idiopathic congenital NYS. Full shaded symbols indicate the NYS phenotype. Quarter shaded
symbols demonstrate individuals with craniosynostosis. The craniosynostosis branch (relatives of individuals 150, 151 and 51) was not included in this
study.
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which was incubated overnight at 37uC with the methylation-
sensitive restriction enzyme HpaII (MBI Fermentas, Vilnius,
Lithuania), for the digestion of unmethylated (or active) alleles.
A second restriction enzyme, RsaI (MBI Fermentas, Vilnius,
Lithuania), which recognises a four-base-pair sequence not
present in the amplified region of the AR locus, was also
included in the reaction to facilitate the HpaII digestion process.
Male DNA with a cytogenetically verified 46,XY karyotype was
used as the control for complete digestion. The other half of the
DNA was treated similarly, but without HpaII. After restric-
tion-enzyme digestion, residual DNA was amplified using the
primers 59-GTC CAA GAC CTA CCG AGG AG-39 and 59-CCA
GGA CCA GGT AGC CTG TG-39. PCR products were
separated on 10% denaturing 29:1 acrylamide-bisacrylamide
gel for 5 h at 20 W. Gels were stained with ethidium bromide
and visualised under UV light. Densitometric analysis of the
alleles was performed at least twice for each sample using the
appropriate software (MultiAnalyst v1.1; Bio-Rad, Hercules,
CA). A corrected ratio (CrR) was calculated by dividing the ratio
of the predigested sample (upper/lower allele) by the ratio of the
non-predigested sample for normalisation of the ratios that
were obtained from the densitometric analyses. The use of a CrR
compensates for preferential amplification of the shorter allele
when the number of PCR cycles increases.13 A skewed population
is defined as a cell population with.80% expression of one of the
AR alleles. This corresponds to CrR values of ,0.25 or .4.0.
Table 1 Examination findings of the family members
PID Gender DOB Nystagmus Head oscillations DM type II Obesity Other findings
23 F 1939 Pendular + – – –
24 M 1929 Pendular + + + Asthma, corneal opacity on the left, hypertension
32 M 1961 Pendular + jerk + + + Diabetic neuropathy, cataract, hypertension
38 M 1950 Pendular – + + Diabetic neuropathy, amyloid lichenosis
40 M 1945 Pendular + + + –
42 M 1943 Pendular + + + Diabetic neuropathy, psoriasis, hypertension
46 M 1939 Pendular + + + Diabetic neuropathy, ptosis on the left
48 M 1930 Pendular + + + Diabetic neuropathy, hypertension, ptosis on the right
65 F 1981 Pendular + jerk + – – –
66 F 1982 Pendular + jerk – – – Strabismus
93 F 1980 Pendular – – – –
105 M 1986 Pendular + jerk + – + Febrile convulsion
108 M 1985 Pendular + – – –
112 M 1998 Pendular – – – –
121 F 1971 Pendular + – + –
131 F 1965 Pendular + – – –
133 F 1969 Pendular – – – –
136 M 1968 Pendular + – + –
138 M 1993 Pendular – – – –
139 M 1993 Pendular – – – –
36 M 1957 – – + + –
39 F 1951 – – – + –
43 F 1951 – – – + –
53 F 1959 – – + + Psoriasis, hypertension
54 F 1960 – – – + –
69 M 1978 – – – + –
79 M 1971 – – – + –
80 M 1974 – – – + –
81 M 1976 – – – + –
82 M 1989 – – – + –
87 F 1970 – – – + –
91 M 1969 – – – + –
94 M 1989 – – – + Allergic conjuctivitis
95 M 1976 – – – + –
107 F 1983 – – – + –
115 M 1975 – – – + –
116 M 1979 – – – + –
117 M 1980 – – – + Asthma bronchiale
118 F 1970 – – – + –
119 F 1978 – – – + Asthma bronchiale
120 F 1984 – – – + –
122 F 1986 – – – + –
123 M 1967 – – – + –
124 M 1968 – – – + –
125 M 1969 – – – + –
126 M 1960 – – – + –
134 M 1968 – – – + –
DM, diabetes mellitus; DOB, date of birth; PID, Personal Identification Number presented in fig 1.
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RESULTS
Clinical presentation and formal genetics of the family
The most striking findings of this pedigree were, 1, NYS and, 2,
obesity and type 2 diabetes in some family members (table 1).
Other findings included craniosynostosis and allergic com-
plaints, such as bronchial asthma. In all, 20 patients had
rhythmic pendular type NYS, with varying frequencies and
amplitudes. Video recordings of 16 individuals supported the
clinical observations. On lateral gaze, four individuals had
horizontal jerk NYS, whereas six patients had spontaneous head
oscillations, and 13 had oscillations during fixation (table 1).
Visual acuity among the patients varied from 20/20 to 20/100.
Direct ophthalmoscopic findings were unremarkable. In all,
seven NYS patients had diabetes, and 10 were obese. Among the
non-NYS family members, 27 were obese (two of them with
diabetes) (table 1) suggesting independent segregation of the
two disorders (NYS and obesity and/or type 2 diabetes) in the
same family. Regarding the NYS phenotype, male-to-male
transmission was not observed. This finding supported X linked
inheritance. There were 33 obligate gene carrier females in this
family, and only 12 of them developed NYS (fig 1); therefore,
the penetrance of the NYS phenotype in females was estimated
to be approximately 36% for this family.
Linkage studies
The family was tested for a linkage to both Xp11.4-p11.37 and
Xq26–q273 loci. The NYS phenotype was previously mapped
between the DNA markers DXS8015 and DXS1003 on the
Xp11.4 locus. The DNA markers DXS6810, GATA144D04 and
DXS7132 were used in this study, and the physical positions of
these markers are: DXS8015 (39.44 Mb)-DXS6810, (42.57 Mb)-
GATA144D04 and (44.67 Mb)-DXS1003 (46.19 Mb)-DXS7132
(64.33 Mb). Four NYS patients were recombinant for the entire
region (data not shown). Negative LOD scores were also
obtained. The excluded region was 6–7 cM for each DNA
marker (table 2).
Significant LOD scores were obtained for the entire region,
with a maximum of 4.04 at h= 0 cM for the DNA marker
DXS8094 (table 2) in the Xq26–q27 region (fig 2). A single
cross-over event in an NYS patient (person 40) positioned the
disease gene telomeric to the DNA marker DXS8068. We also
observed the first homozygote female case of the NYS
phenotype (fig 1, person 133). No phenotypic differences were
observed among the females, in terms of homozygote and
heterozygote states (table 1).
Mutation results
We sequenced all 12 coding exons of the recently described X
linked NYS gene FRMD7, which was located in the critical
region in two affected male individuals of the family, and
identified the c.686C.G mutation in exon 8 of the gene (fig 3A).
The mutation co-segregated with the disease in the family
(fig 3B) and was not observed in 120 healthy individuals of the
same ethnic background. The novel c.686C.G mutation
predicted a substitution of a conserved arginine at amino acid
position 229 in the functionally important FERM-C domain of
the protein by glycine (p.R229G). Interestingly, three other
missense mutations in the FERM-C domain of FRMD7 have
been described in the original gene identification paper6 (fig 3C),
suggesting an important role for this domain in the pathogen-
esis of congenital NYS.
X chromosome inactivation results
Since at least seven females in the pedigree had NYS, we
analysed the XCI patterns to verify if skewed XCI could be
responsible for the clinical manifestation of the disease. Skewed
patterns with ratios of 81:19 per cent in individual 65, 85:15 per
cent in 121, and 80:20 per cent in 131 and 133 was apparent,
while individual 23 was not informative, and only individuals
93 and 66 displayed random XCI with ratios of 57:43 per cent
and 62:38 percent, respectively. Among the non-NYS females,
XCI status was analysed in 18 individuals. With the exception
of individual 35, who had a skewed XCI (93:7) pattern, and four
more non-informative females (individuals 41, 43, 54 and 86), all
women displayed random XCI profiles (table 3). Skewed X
inactivation was significantly increased in the NYS females
when compared with the non-NYS females in the family (odds
ratio was 26:1; 95% CI = 1.83 to 367.7).
Table 2 Two point LOD scores with the DNA markers selected from Xp11 and Xq26 regions
Recombination fraction (h) cM
Marker 0.00 0.01 0.05 0.10 0.20 Exclusion (cM)
Xp11
DXS6810 2‘ 25.35 22.64 21.54 20.58 7
GATA144D03 2‘ 25.19 22.50 21.43 20.52 6
DXS7132 2‘ 25.32 22.62 21.53 20.57 7
Xq26
GATA172D05 2‘ 21.78 20.53 20.11 0.12 2
GATA165B12 2‘ 0.54 1.07 1.16 1.00 2
DXS1047 2‘ 1.08 1.58 1.62 1.37 2
DXS8068 2‘ 0.38 0.93 1.03 0.91 2
DXS8072 3.74 3.68 3.44 3.12 2.45 2
DXS8071 0.82 0.80 0.72 0.62 0.43 2
DXS1187 3.37 3.32 3.10 2.81 2.21 2
DXS8033 3.68 3.62 3.38 3.07 2.41 2
DXS8094 4.04 3.98 3.72 3.38 2.65 2
DXS1062 2.55 2.51 2.33 2.09 1.59 2
DXS1192 0.48 0.47 0.43 0.38 0.29 2
DXS984 3.74 3.68 3.44 3.12 2.45 2
GATA31E08 3.37 3.32 3.10 2.81 2.21 2
Exclusion area = recombination fraction (cM) at which the LOD score was (22. Significant LOD scores were obtained with the DNA markers from the Xq26 region.
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DISCUSSION
In this study, we described a large family with X linked
congenital NYS. The disorder was completely penetrant in
males; however, reduced penetrance was observed in females.
Various penetrance rates, ranging from 54% to 29%, are
suggested to be due to family size.3 5 6 Our study also supported
36% penetrance in females. This extremely low penetrance rate
in females might challenge the mode of inheritance estimations.
For genetic counselling purposes, it might be difficult to
distinguish X linked recessive and dominant patterns in small
family trees. Genetic linkage analysis provided strong evidence
of linkage to the previously established locus on Xq26–27,
which is the major locus for X linked NYS (NYS1). A
recombination event in a single affected male positioned the
disease gene telomeric to the DNA marker DXS8068 (fig 2).
Combining these data with previous studies, the 8 Mb region
residing between DNA markers DXS8068 and DXS1211
containing the recently reported FRMD7 gene6 was critical for
this family.
We identified the novel p.R229G missense mutation in the
FRMD7 gene in the study family. The following points support
the disease-causing nature of this mutation: (i) p.R229G co-
segregated with the disease in this family; (ii) our control
studies excluded p.R229G as a non-synonymous polymorphism
Figure 2 Haplotype structure between the NYS phenotype and the DNA markers selected from Xq26. The order and the physical locations (Mb) of the
DNA markers are shown to the upper left. A single recombination event in affected individual 40 positioned the disease gene telomeric to DXS8068
containing the FRMD7 gene (130.93 Mb).
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Figure 3 Identification of a novel missense mutation in the FRMD7 gene. (A) Representative sequence chromatograms of the identified c.686C.G
(p.R229G) mutation in an affected male (mutant), a carrier female (carrier) and an unaffected male (wild-type). (B) Co-segregation of the mutation in the
family. Results of BccI restriction fragment analysis presenting an undigested 234 bp PCR-fragment in affected male individuals, a fully digested PCR
fragment in unaffected males (two fragments 131 bp and 101 bp in size), and one undigested and one digested allele in carrier females (three
fragments 234 bp, 131 bp and 101 bp in size). A non-digested sample, labelled as C, was included as a control (C) schematic view of conserved
FRMD7 domains and locations of described mutations located in the FERM-C domain.
Table 3 Distribution of skewed x-inactivation between nystagmus and normal members of the family
PID DNA no. Status Skewing degree
Skewed
1 35 N42 Normal 93:7
2 121 N46 Affected 85:15
3 65 N31 Affected 81:19
4 131 N40 Affected 80:20
5 133 N21 Affected 80:20
Random
1 33 N18 Normal 72:28
2 45 N11 Normal 71:29
3 107 N28 Normal 71:29
4 72 N41 Normal 69:31
5 15 N30 Normal 67:33
6 11 N37 Normal 67:33
7 53 N27 Normal 63:37
8 66 N16 Affected 62:38
9 93 N26 Affected 57:43
10 118 N13 Normal 56:44
12 99 N10 Normal 54:46
13 122 N14 Normal 54:46
14 119 N43 Normal 53:47
15 120 N12 Normal 51:49
16 Spouse of 129 N7 normal 50:50
PID reflects personal identification numbers on fig 1. A total of five individuals (fig 1, individuals 23, 41, 43, 54 and 86) were not
informative. The disease status of non-informative individuals was normal except person 23.
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in the Turkish population; (iii) the mutation is located in the
FERM-C domain in the surrounding of previously described
missense mutations in families with congenital NYS.6 14
The functional role of FRMD7 remains to be elucidated. The
FRMD7 transcript is abundantly expressed in most tissues, and
a localised and restricted expression was found to be involved in
embryonic development in regions affecting motor control of
eye development.6 Homologies of the B41 and FERM-C domains
of FRMD7 to other proteins, such as FARP1 and FARP2, which
are involved in neurite branching of cortical neurons, led to the
hypothesis that FRMD7 could also be involved in the develop-
ment of similar neuronal pathways.
Skewed X inactivation has consistently been suggested as a
mechanism that may influence the penetrance of X linked NYS
in females;3 7 8 9 however, except for only one study,7 an X
inactivation pattern was not previously studied in NYS families.
No correlation between X inactivation patterns and the NYS
phenotype was observed in this sole study.7 Nevertheless, NYS
in the family used in that study was linked to the Xp11 region
rather than the major NYS locus on Xq26–q27. Our Xq26-linked
NYS family implies that skewed XCI could be a factor that
influences the clinical manifestation of NYS in females. It is well
established that skewed XCI is a rare event in a diverse group of
control females.15 16 In agreement with this prior observation,
we only observed skewed X inactivation in a single healthy
spouse (individual 35). None of the obligate gene carrier females
and none of the remaining healthy spouses demonstrated
skewed X inactivation (table 3); however, increased suscept-
ibility to skewed X inactivation was apparent in the clinically
affected females. On the other hand, we observed random X
inactivation in two affected females, individuals 66 and 93, with
XCI scores of 62:38 and 57:43, respectively. This finding may be
a reflection of tissue mosaicism, which has been clearly shown
in women.16 To the best of our knowledge, inactivation status
of the FRMD7 gene has not been studied. Further investigations
of the X inactivation status of FRMD7 might help contribute to
an understanding of the irregular pattern of inheritance of
NYS1.
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Mutations in the very low-density lipoprotein
receptor VLDLR cause cerebellar hypoplasia
and quadrupedal locomotion in humans
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Quadrupedal gait in humans, also known as Unertan syndrome, is
a rare phenotype associated with dysarthric speech, mental retar-
dation, and varying degrees of cerebrocerebellar hypoplasia. Four
large consanguineous kindreds from Turkey manifest this pheno-
type. In two families (A and D), shared homozygosity among
affected relatives mapped the trait to a 1.3-Mb region of chromo-
some 9p24. This genomic region includes the VLDLR gene, which
encodes the very low-density lipoprotein receptor, a component of
the reelin signaling pathway involved in neuroblast migration in
the cerebral cortex and cerebellum. Sequence analysis of VLDLR
revealed nonsense mutation R257X in family A and single-
nucleotide deletion c2339delT in family D. Both these mutations
are predicted to lead to truncated proteins lacking transmembrane
and signaling domains. In two other families (B and C), the
phenotype is not linked to chromosome 9p. Our data indicate that
mutations in VLDLR impair cerebrocerebellar function, conferring
in these families a dramatic influence on gait, and that hereditary
disorders associated with quadrupedal gait in humans are genet-
ically heterogeneous.
genetics " Unertan syndrome
Obligatory bipedal locomotion and upright posture of mod-ern humans are unique among living primates. Studies of
fossil hominids have contributed significantly to modern under-
standing of the evolution of posture and locomotion (1–5), but
little is known about the underlying molecular pathways for
development of these traits. Evaluation of changes in brain
activity during voluntary walking in normal subjects suggests that
the cerebral cortices controlling motor functions, visual cortex,
basal ganglia, and the cerebellum might be involved in bipedal
locomotor activities (6). The cerebellum is particularly impor-
tant for movement control and plays a critical role in balance and
locomotion (7).
Neurodevelopmental disorders associated with cerebellar hy-
poplasias are rare and often accompanied by additional neuro-
pathology. These clinical phenotypes vary from predominantly
cerebellar syndromes to sensorimotor neuropathology, ophthal-
mological disturbances, involuntary movements, seizures, cog-
nitive dysfunction, skeletal abnormalities, and cutaneous disor-
ders, among others (8). Quadrupedal locomotion was first
reported when Tan (9, 10) described a large consanguineous
family exhibiting Unertan syndrome, an autosomal recessive
neurodevelopmental condition with cerebellar and cortical hy-
poplasia accompanied by mental retardation, primitive and
dysarthric speech, and, most notably, quadrupedal locomotion.
Subsequent homozygosity mapping indicated that the phenotype
of this family was linked to chromosome 17p (11). Thereafter,
three additional families from Turkey (12–14) and another from
Brazil (15) with similar phenotypes have been described, and
video recordings illustrating the quadrupedal gait have been
made (10–12). Here, we report that VLDLR is the gene respon-
sible for the syndrome in two of these four Turkish families and
report additional genemapping studies that indicate the disorder
to be highly genetically heterogeneous.
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Fig. 1. Phenotypic (A) and cranial radiologic (B) presentation of quadrupe-
dal gait in families A and D. (A) Affected brothers VI:20 and VI:18 and cousin
VI:25 in family A (Upper) and the proband II:2 in family D (Lower) display
palmigrate walking. This is different from quadrupedal knuckle-walking of
the great apes (2). The handsmake contactwith the ground at the ulnar palm,
and consequently this area is heavily callused as exemplified by VI:20. Stra-
bismus was observed in all affected individuals. (B) Coronal and midsagittal
MRI sections of VI:20, demonstrating vermial hypoplasia, with the inferior
vermial portion being completely absent. Inferior cerebellar hypoplasia and a
moderate simplification of the cerebral cortical gyri are noted. The brainstem
and the pons are particularly small (Left and Center). Similar findings are
observed for II:2 (Right).
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Results
The proband of Family A (12) is a 37-year-old male with habitual
quadrupedal gait (Fig. 1A Upper Left and Fig. 2A, VI:20). He did
not make the transition to bipedality during his childhood
despite the efforts of his healthy parents. He has dysarthric
speech with a limited vocabulary, truncal ataxia, and profound
mental retardation. He was not aware of place or of the year,
month, or day. His MRI brain scan revealed inferior cerebellar
and vermial hypoplasia, with the inferior vermial portion being
completely absent. Whereas corpus callosum appeared normal,
a moderate simplification of the cerebral cortical gyri accom-
panied by a particularly small brainstem and the pons was
observed (Fig. 1 B Left andCenter). Subsequently, we studied the
proband’s affected brother and cousin (Fig. 1AUpper Center and
Fig. 2. Homozygosity mapping of cerebellar hypoplasia and quadrupedal locomotion to chromosome 9p24 (A) and identification of the VLDLR c769C 3 T
mutation in family A (B) and of theVLDLR c2339delTmutation in family D (C). (A) Pedigree of family A; filled symbols represent the affected individuals. Squares
indicatemales, and circles indicate females. Blackbars represent thehaplotype coinheritedwith thequadrupedal phenotype in the family. Recombinationevents
in individuals VI:16 (obligate carrier) and VII:4 (normal sibling) positioned the disease gene between markers rs7847373 and rs10968723. Physical positions and
pairwise lod scores for each marker are shown on the upper left. Zmax represents the maximum lod score obtained at !! 0.00 cM. (B and C) Sequences of critical
regions of VLDLR for wild-type and homozygous mutant genotypes.
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Upper Right and Fig. 2A, VI:18 and VI:25) and other branches
of the family living in nearby villages in southeastern Turkey. All
affected individuals were offspring of consanguineous marriages
(Fig. 2A). With the exception of one female (VII:1), who was an
occasional biped with ataxic gait, all affected persons in family
A had quadrupedal locomotion.
The proband of family D (14) is a 38-year-old male (Fig. 1A
Lower Left and Center). Like all other quadrupedal individuals
in these families, he did not make the transition to bipedality
during his early childhood. He is profoundly retarded and
exhibits dysarthric speech along with truncal ataxia. His MRI
brain scan images are consistent with moderate cerebral cortical
simplification and inferior cerebellar and vermial hypoplasia
(Fig. 1BRight). The 65-year-old aunt and 63-year-old uncle of the
proband are both mentally retarded and continue to walk on
their wrists and feet despite their advanced ages. The family is
consanguineous; all relatives were raised in neighboring villages
on the western tip of the Anatolian peninsula.
All patients in these four families had significant developmen-
tal delay noted in infancy (Table 1). They sat unsupported
between 9 and 18months, and began to crawl on hands and knees
or feet. Whereas normal infants make the transition to bipedal
walking in a short period, the affected individuals continued to
move on their palms and feet and never walked upright. All
patients had severe truncal ataxia affecting their walking pat-
terns. They can stand from a sitting position and maintain the
upright position with flexed hips and knees. However, they
virtually never initiate bipedal walking on their own and instead
ambulate efficiently in a quadrupedal fashion. All patients had
hyperactive lower leg and vivid upper extremity reflexes. Normal
tone and power were observed in motor examination. All
affected persons were mentally retarded to the degree that
consciousness of place, time, or other experience appeared to be
absent. However, no autistic features were expressed. The
affected individuals all had good interpersonal skills, were
friendly and curious to visitors, and followed very simple ques-
tions and commands. Additional clinical information on families
A and D is provided in supporting information (SI) Table 2.
To identify the chromosomal locale of the gene or genes
responsible for this phenotype, we carried out genome-wide
linkage analysis and homozygosity mapping in families A–C (see
Materials and Methods below). Although the families lived in
isolated villages 200–300 km apart and reported no ancestral
relationship, the rarity of the quadrupedal gait in humans led us
to expect a single locus shared by affected individuals in all
families. Instead, the trait mapped to three different chromo-
somal locales. In family A, linkage analysis and homozygosity
mapping positioned the critical gene on chromosome 9p24
between rs7847373 and rs10968723 in a 1.032-Mb region (Fig.
2A and SI Fig. 4). In family B, the trait mapped to chromosome
17p13, confirming a previous study (11). In family C, highly
negative logarithm of odds (lod) scores were obtained for both
chromosomes 9p24 and 17p13 (SI Figs. 5 and 6); gene mapping
in this family is ongoing. In family D, polymorphic markers from
the critical intervals of chromosomes 9p24 and 17p13 were
genotyped, and homozygosity was detected with markers on
9p24. Together, these results indicate that the syndrome includ-
ing quadrupedal gait, dysarthric speech, mental retardation, and
cerebrocerebellar hypoplasia is genetically heterogeneous.
The chromosome 9p24 region linked to the trait in families A
and D includes VLDLR, the very low-density lipoprotein recep-
tor. We hypothesized that a gene involved in neural develop-
ment, cell positioning in brain, and cerebellar maturation could
be involved in the pathogenesis of quadrupedal gait. In addition,
cerebellar hypoplasia with cerebral gyral simplification was
shown to be associated with a genomic deletion that includes
VLDLR (16). We therefore considered VLDLR (17) to be a
prime positional candidate for our phenotype and sequenced the
gene in genomic DNA from probands of the four families (SI
Table 3). The VLDLR sequence of affected members of family
A was homozygous for a nonsense mutation in exon 5 (c769C3
T; R257X) (Fig. 2B). The VLDLR sequence of the proband of
family D was homozygous for a single-nucleotide deletion in
exon 17 resulting in a stop codon (c2339delT; I780TfsX3) (Fig.
2C). VLDLR sequences excluded the possibility of compound
heterozygosity in families B and C (SI Fig. 7). In families A and
D, homozygosity for the VLDLR mutations was perfectly coin-
herited with quadrupedal gait (SI Figs. 8 and 9). Both mutations
were absent from 100 unaffected individuals who live in the same
local areas of southeastern and western Turkey as families A and
D (SI Fig. 10).
Table 1. Physical, radiological, and genetic characteristics of the Turkish families in this study and of Hutterite family DES-H (27)
Characteristic Family A Family B Family C Family D DES-H
Chromosomal location 9p24 17p Not 9p or 17p 9p24 9p24
Gene and mutation VLDLR
(c769C3 T)
Unknown Unknown VLDLR
(c2339delT)
Deletion including VLDLR
and LOC401491
Gait Quadrupedal Quadrupedal Quadrupedal Quadrupedal Bipedal
Speech Dysarthric Dysarthric Dysarthric Dysarthric Dysarthric
Hypotonia Absent Absent Absent Absent Present
Barany caloric nystagmus Normal Cvs defect Pvs defect Not done Not done
Mental retardation Profound Severe to profound Profound Profound Moderate to profound
Ambulation Delayed Delayed Delayed Delayed Delayed
Truncal ataxia Severe Severe Severe Severe Severe
Lower leg reflexes Hyperactive Hyperactive Hyperactive Hyperactive Hyperactive
Upper extremity reflexes Vivid Vivid Vivid Vivid Vivid
Tremor Very rare Mild Present Absent Present
Pes-planus Present Present Present Present Present
Seizures Very rare Rare Rare Absent Observed in 40% of cases
Strabismus Present Present Present Present Present
Inferior cerebellum Hypoplasia Hypoplasia Mild hypoplasia Hypoplasia Hypoplasia
Inferior vermis Absent Absent Normal Absent Absent
Cortical gyri Mild simplification Mild simplification Mild simplification Mild simplification Mild simplification
Corpus callosum Normal Reduced Normal Normal Normal
Cvs, central vestibular system; Pvs, peripheral vestibular system.
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VLDLR!R257X is in the ligand-binding domain, and
VLDLR!I780TfsX3 is in the O-linked sugar domain of the
VLDLR protein (Fig. 3 A and B). Mutant VLDLR transcripts
were expressed in endothelial cells from blood of affected
individuals (Fig. 3C), and in these cells, levels of mutant and
wild-type transcript expression appeared approximately equal
(Fig. 3D; please also see SI Text). Because the stop codons of
both mutations are located in the extracellular domain of
VLDLR (Fig. 3B), the encoded mutant proteins could not be
inserted into the membrane and could not function as receptors
for reelin.
We propose VLDLR-associated Quadrupedal Locomotion
(VLDLR-QL) or Unertan Syndrome Type 1 to describe the
phenotype of families A and D.
Discussion
The identification of these VLDLR mutations provides molec-
ular insight into the pathogenesis of neurodevelopmental move-
ment disorders and expands the scope of diseases caused by
mutations in components of the reelin pathway (18). Reelin is a
secreted glycoprotein that regulates neuronal positioning in
cortical brain structures and the migration of neurons along the
radial glial fiber network by binding to lipoprotein receptors
VLDLR and APOER2 and the adapter protein DAB1 (19). In
the cerebellum, reelin regulates Purkinje cell alignment (20),
which is necessary for the formation of a well defined cortical
plate through which postmitotic granual cells migrate to form the
internal granular layer (21). Homozygous mutations in the reelin
gene (RELN) cause the Norman–Roberts type lissencephaly
syndrome, associated with severe abnormalities of the cerebel-
lum, hippocampus, and brainstem (OMIM 257320) (22). Muta-
tion of Reln in the mouse results in the reeler phenotype and
disrupts neuronal migration in several brain regions and gives
rise to functional deficits such as ataxic gait and trembling (23).
In contrast, mice deficient forVldlr appear neurologically normal
(24), but the cerebellae of these mice are small, with reduced
foliation and heterotopic Purkinje cells (17).
In humans, homozygosity for either of two VLDLR truncating
mutations leads to cerebrocerebellar hypoplasia, specifically
vermial hypoplasia, accompanied by mental retardation, dysar-
thric speech, and quadrupedal gait. In the Hutterite population
of North America, homozygosity for a 199-kb deletion encom-
passing the VLDLR gene leads to a form of Disequilibrium
Syndrome (DES-H, OMIM 224050), characterized by nonpro-
gressive cerebellar hypoplasia with moderate-to-profound men-
tal retardation, cerebral gyral simplification, truncal ataxia, and
delayed ambulation (16). The designation Disequilibrium Syn-
drome was originally given to cerebral palsy characterized by a
variety of congenital abnormalities, including mental retarda-
tion, disturbed equilibrium, severely retarded motor develop-
ment, muscular hypotonia, and perceptual abnormalities (25,
26). Neither DES-H nor other disequilibrium syndromes have
been reported to include quadrupedal gait. The movement of
most DES-H patients was so severely affected that independent
walking was not possible. Those who could walk had a wide-
based, nontandem gait (27).
The neurological phenotypes in the Turkish families and in the
Hutterite families appear similar, with the most striking differ-
ence being the consistent adoption of efficient quadrupedal
locomotion by the affected Turkish individuals (Table 1). In our
view, the movement disorder described for the Hutterite patients
may be a more profound deficit, with the patients perhaps
lacking the motor skills for quadrupedal locomotion. The 199-kb
deletion in DES-H encompasses the entire VLDLR gene and
part of a hypothetical gene. LOC401491, the hypothetical gene,
is an apparently noncoding RNA that shares a CpG island and
likely promoter with VLDLR, and is represented by multiple
alternative transcripts expressed in brain. It has been suggested
that the DES-H phenotype could be the result of deletion of
VLDLR or both VLDLR and the neighboring gene (16).
Fig. 3. Functional domains of VLDLR with positions of the mutations relative to the exons (A), domains (B), and the analysis of VLDLR transcript (C and D).
(A) The gene consists of 19 exons. Arrows indicate the locations of the mutations. (B) VLDLR consists of ligand-binding type repeat (LBTR), epidermal growth
factor repeat (EGFR) I–III, YWTD "-propeller (YWTD), O-linked sugar domain (OLSD), transmembrane domain (TD), and cytoplasmic domain (CD) (34)
(www.expasy.org/uniprot/P98155). (C) Restriction-based analysiswithHphI revealed thepresenceof only themutant (347bp) andboth themutant andwild type
(396 and 347 bp; please note that the 49-bp fragment is not visible) VLDLR transcripts in patient VI:20 and carrier V:18 (both from family A), respectively. M is
a DNA size marker. (D) Quantitative RT-PCR analysis of VLDLR transcript from peripheral blood samples of all probands in families A and D and controls was
performed. Relative expression ratios were normalized according to the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and the
endothelial marker KDR (kinase insert domain receptor). "Ct values were calculated from duplicate samples and were converted to linear scale (35). Control
denotes ‘‘VLDLR expression in controls,’’ VLDLR-GAPDH denotes ‘‘VLDLR expression in patients normalized to GAPDH,’’ and finally VLDLR-KDR denotes ‘‘VLDLR
expression in patients normalized to KDR.’’
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It has been suggested that in the Turkish families, lack of
access to proper medical care exacerbated the effects of cere-
bellar hypoplasia, leading to quadrupedality. Although it may be
true that family B lacked proper medical care, families A and D
had consistent access to medical attention, and both families
actively sought a correction of quadrupedal locomotion in their
affected children. An unaffected individual in family A is a
physician who was actively involved in the medical interventions.
In family D, the proband’s mother sought a definitive diagnosis
and correction of the proband’s quadrupedal locomotion from
private medical practices and from two major academic medical
centers. The parents in family A discouraged quadrupedal
walking of their affected children, but without success. We
conclude that social factors were highly unlikely to contribute to
the quadrupedal locomotion of the affected individuals.
In conclusion, we suggest that VLDLR-deficiency in the brain
at a key stage of development leads to abnormal formation of the
neural structures that are critical for gait. Given the heteroge-
neity of causes of quadrupedal gait, identification of the genes in
families B and C promises to offer insights into neurodevelop-
mental mechanisms mediating gait in humans.
Materials and Methods
Study Subjects. Parents of patients and other unaffected individuals gave
consent to the study by signing the informed consent forms prepared accord-
ing to the guidelines of the Ministry of Health in Turkey. The Ethics Commit-
tees of Baskent and Cukurova Universities approved the study (decision
KA07/47, 02.04.2007 and 21/3, 08.11.2005, respectively).
Genome-Wide Linkage Analysis. Linkage analysis was performed by SNP geno-
typingwith the commercial release of the GeneChip 250K (NspI digest) or 10K
Affymetrix arrays as described (28). In addition, genotype datawere analyzed
by hand to identify regions of homozygosity. The parametric component of
theMerlin package v1.01 was used for the multipoint linkage analysis assum-
ing autosomal recessivemodeof inheritancewith full penetrance (29, 30). The
analysis was carried out along a grid of locations equally spaced at 1 cM.
Haplotype analysis was performed on chromosomal regions with positive lod
scores (Fig. 2A and SI Figs. 4–6). Pairwise linkage was analyzed by using the
MLINK component of the LINKAGE program (FASTLINK, version 3) (31–33).
Markers D17S1298 (3.51 Mb) and D9S1779 (0.4 Mb), D9S1871 (3.7 Mb) were
used to test for homozygosity to chromosomes 17p13 and 9p24, respectively.
Mutation Search. Sequencing primers were designed for each VLDLR exon by
using Primer3, BLAST, and the sequence of NC!000009. DNA from all of the
probands was sequenced in both directions by using standard methods. The
mutations in exons 5 (c769C 3 T) and 17 (c2339delT) were detected in all
affected (homozygous) and carrier (heterozygous) individuals of families A
and D, respectively. The c769C3 T mutation creates a restriction site for the
enzyme HphI (5#-GGTGA(N)82 3#), and the c2339delT mutation abolishes a
restriction site for the enzyme MboI (5#-G2 ATC-3#). Assays using these
restriction enzymes were developed to test for the mutations in all four
families and in 200 healthy controls from the Turkish population. Restriction
based mutation and quantitative RT-PCR analyses of VLDLR transcript in
patients and controls was also performed (please see SI Text relating to Fig. 3
C and D).
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